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Executive summary  
 
Systematic reviews and meta-analysis are the most appropriate and preferred study designs to inform 
clinical decision-making. Patients, clinicians, researchers and policymakers rely on this type of design 
since it aggregates several studies at the same time, increasing internal and external validity. 
Furthermore meta-analyses can increase statistical validity, reaching higher levels of power and 
precision as compared to single studies. This often means better understanding the magnitude of the 
treatment effect, and identifying the best intervention in pairwise or network (multiple) comparisons. 
Despite these advantages, meta-analyses also have limitations and shortcomings. Power and precision 
depend on several elements, such as size of studies, number of events, sample variability and 
underlying heterogeneity. These elements are precondition and cannot be modified by reviewers. If 
one or more of these elements are problematic, the meta-analysis will replicate the same problem, 
despite the severity of the problem might be diminished by the co-presence of multiple studies. For 
instance meta-analyses including several small studies will be prone to several biases, eg, small study 
effect and publication biases. Moreover actual studies often explore modest intervention effects, 
which are difficult to be identified: even limited perturbations of study data can result in biases that 
can hide or inflate intervention effects, sabotaging the decision-making process of health 
professionals. 
Against this background, we first wondered if RCTs included in systematic reviews and meta-analysis 
are adequately reported in terms of power and relevance/conclusiveness of findings. Secondly we 
explored how detect and assess underpowered, inconclusive and imprecise meta-analyses, using and 
comparing two modern approaches - Trial Sequential Analysis and the GRADE (Grading of 
Recommendations Assessment, Development and Evaluation). Third, we explored new meta-analytic 
techniques to contrast multiple interventions through direct and indirect evidence, in an extreme 
attempt to solve major limitations of a priori literature and lack of head to head trials.  
In order to answer these research questions, we moved from the unit of analysis of systematic reviews, 
the randomized controlled trial, to the methods to cumulate evidence. Inadequate reporting, 
underpowered meta-analyses and conflicting direct and indirect evidence beyond head-to-head 
comparisons can alter the clinical decision-making process unless proper assessment, analysis and 
critical interpretation are put in place. 
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My dissertation is organized in three main Sections:  
- Section 1: We focused on how sample size calculations were reported in RCTs exploring the 
efficacy of low back pain rehabilitation interventions and, among those adequately reported, how 
findings were interpreted in terms of statistical significance and clinical relevance. 
- Section 2: We explored Trial Sequential Analysis and the GRADE approach in several medical 
areas. We compared the agreement of the approaches in evaluating the overall quality of evidence. 
- Section 3. We finally combined direct and indirect evidence on a sample of RCTs assessing 
rehabilitation interventions for low back pain through a network meta-analysis. 
This dissertation focuses on innovative advanced methods used in evidence synthesis science. These 
methods are a partial answers to the need for precise and reliable results, standard and transparent 
methods to assess the body of the evidence, and comparisons of multiple interventions in addition of 
pair-wise comparisons.  
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Background and Rationale   
 
The systematic review and its role  
Clear and comprehensive summaries of medical literature information is needed to inform health 
professionals and policy makers about the best available treatments (Sackett, Rosenberg et al. 1996). 
Systematic reviews (SRs) and meta-analysis of randomized controlled trials (RCTs) are recognized 
by the scientific community to be the gold standard in demonstrating the efficacy of an intervention 
(Cook, Hislop et al. 2015). Systematic reviews have gained momentum in the medical field thanks to 
their efficiency in keeping up-to-date the accumulation of the evidence and to be a key document for 
clinical practice guideline developers that used them as a starting point for guideline production, 
identifying those treatments that insure the best payback of researches (Grimshaw, Eccles et al. 2012).  
The Cochrane Collaboration defines a systematic review as “an attempts to collect all empirical 
evidence that fits pre-specified eligibility criteria in order to answer a specific research question” 
(Higgins JPT and Green S 2011) using systematic methods to select, critically assess and provide 
synthesis of characteristics and findings of the studies included in the reviews (Oxman and Guyatt 
1993). Indeed, a systematic review provides a qualitative, and possibly a quantitative, synthesis of 
the evidence. Other definitions consistently mention key elements central to systematic reviews:  
searching for evidence, appraising its quality and synthetizing the results across studies (Moher, 
Tetzlaff et al. 2007). 
A qualitative synthesis is based on a comprehensive assessment of the methodological quality of trials 
included in the review, i.e. the study’s internal validity related to whether it answers its research 
question ‘correctly’, free from bias. Whereas, the quantitative synthesis is obtained by combining 
information from all relevant studies: a meta-analysis, a key element of most systematic reviews, is 
the statistical synthesis of the results of independent studies pooling the effect sizes of each study 
(Higgins JPT and Green S 2011).  
Decision makers, clinicians, and patients have high expectations, i.e. results unbiased and consistent 
among reports (Whiting, Savovic et al. 2016). However, the inconsistent quality of systematic reviews 
and meta-analyses of RCTs that are published in the literature has been previously documented (Shea, 
Grimshaw et al. 2007, Gagnier and Kellam 2013, Tunis, McInnes et al. 2013, Gianola, Castellini et 
al. 2016). SRs are not immune to methodological flaws and can reach invalid and discordant 
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conclusions, indeed. Major flows can be related to: (i) the quality of the included RCTs since the 
quality of a SR is strongly related to it, with primary studies at high risk of bias; then, (ii) different 
methods can be applied to same data, reaching contrasting conclusions: the statistical methods used 
generate quantitative synthesis can be underpowered, imprecise, unreliable without providing a 
conclusive evidence on a wide range of interventions comparisons.   
Thus, even though SRs and RCTs are usually considered high quality study designs, the body of the 
evidence could be generally of low or very low quality so that insufficient definitive conclusions 
could be reached and reported (Buchbinder, Maher et al. 2015).  
 
Quantitative synthesis of the evidence in a SR: the meta-analysis  
The meta-analysis of RCTs is considered the best approach to identify the actual benefit of a health 
intervention. This statistical method have several advantages (Higgins JPT and Green S 2011): 
To increase power. Power is the chance of detecting a real effect as statistically significant if it exists. 
Many individual studies are too small to detect small effects, but when several are combined there is 
a higher chance of detecting an effect. 
• To improve precision of the effect of an intervention: when several studies are combined to 
detect a small effect, the chance of detecting it increases. 
• To detect intervention effects when controversies arise from conflicting studies or to generate 
new hypotheses.  
A meta-analysis can also take into consideration the risk of bias of each single study, or across studies, 
and random errors limiting and balancing their affection on results.  
Neverthless, like any tool, it can be misued and it might not guarantee valid and reliable results. 
Indeed, ‘The best available evidence’ may not be synonymous with ‘sufficient evidence’ or ‘strong 
evidence’. 
 
Issues in meta-analysis: power, precision of findings and multiple comparisons 
Even if when systematic reviews and meta-analysis are methodologically great, most may still be not 
informative: “weak or insufficient evidence” is a common conclusion which makes the review not 
informative on what the best interventions is (Ioannidis 2016). Indeed, a meta-analysis is not 
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infallible: it has limitations, which have to be cautiously considered when interpreting the clinical 
findings.  
It has been showed in literature that the majority of published Cochrane meta-analyses including 
RCTs might be underpowered (Brok, Thorlund et al. 2009, Thorlund, Imberger et al. 2011, Imberger, 
Gluud et al. 2015). Much attention should be paid to potentially overestimated or underestimated 
conclusions. When a meta-analysis has not enough statistical power to detect an effect, the lack of 
power and precision can amplify the chances of random error, leading neutral or negative (non-
positive) findings (Brok, Huusom et al. 2012). Trial Sequential Analysis (TSA) is a frequentist 
methodology which can handle the risk of overestimating or underestimating clinical findings: it 
combines the calculation of a required information size for a meta-analysis and an adjusted threshold 
for a statistically significant treatment effect (Thorlund K, Wetterslev J et al. 2011). The information 
size required for more reliable and conclusive meta-analysis results may be assumed to be at least as 
large as the sample size of a single well-powered randomised clinical trial to detect or reject an 
anticipated intervention effect. TSA’ conclusions have the potential to be more reliable than those 
using traditional meta-analysis techniques. The calculation of the information size and the adjusted 
significance thresholds can indeed eliminate early false positive findings due to imprecision and 
repeated significance testing in meta-analyses. Methods as TSA emphasize the fact that an accurate 
and critic assessment, both qualitative and quantitative, of the body of the evidence has become 
fundamental in clinical research. It has been progressively important to reliably provide the extent of 
the confidence (the uncertainty) of the benefit or harm of the effect of an intervention. A good clinical 
decision requires accurate estimation of uncertainty as much as we would like to reach a definitive 
conclusion. Therefore, communicate greater error more accurately than to infer less error inaccurately 
seems a better solution. Trial Sequential Analysis is useful to handle this uncertainty.  
Another approach has become internationally and widely adopted for conveying the uncertainty 
associated with findings and conclusions: The Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) system. The GRADE system is an international standard to 
assess the strength of body of the evidence, informing transparently and explicitly the confidence that 
researchers have on the results. (Guyatt, Oxman et al. 2011). GRADE uses a framework of 
information about risk of bias, imprecision, inconsistency, indirectness and publication bias. 
Particularly, they define the issue of imprecision for SRs as the confidence in the estimate of the 
overall effect (Guyatt, Oxman et al. 2011). Imprecision also encompasses the size or importance of 
an effect, and it is influenced by the magnitude of the sample size or the number of events. The 
assessment of this domain is complex since it requires to balance the magnitude of the effect derived 
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from meta-analysis results, the achievement of an optimal information size and the clinical relevance 
of the effect.  
Both TSA and the GRADE approach, with the imprecision domain assessment, aim to define 
uncertainty of the evidence: clinicians and researchers need to find the most accurate method to be 
confident in clinical findings. 
An additional key limitation of a meta-analysis is that it can compare only two treatments at a time, 
yielding only partially information that clinicians, patients and policy-makers need. Since usually 
more than two treatment options are available in a real clinical setting for certain conditions, a meta-
analysis can offer just a part of the possible wealth of treatment options and might be not supportive 
for an optimal clinical decision-making. In the last decade, a new meta-analytic technique called 
network meta-analysis (NMA) has been developed to assess the effectiveness of several interventions 
and offer the synthesis of the evidence across a network of randomized trials. The advantage of this 
statistical method over standard pairwise meta-analysis is that it enables indirect comparisons of 
multiple interventions that have not been studied in a head-to-head fashion. The interest for this 
technique has been increased across researchers and over the time. The PRISMA Statement for 
Reporting of Systematic Reviews published an extension incorporating the guideline for reporting 
Network Meta-analyses of Health Care Interventions (Hutton, Salanti et al. 2015).  
Over the last 20 years, the literature describing methods used to quantitatively summarize the 
evidence has rapidly expanded with the above-mentioned innovative techniques in order to overcome 
meta-analysis limitations. This emphasises an endless need to find and provide the best and the most 
reliable available evidence for the clinical decision making process and the health care planning.  
  
RCT as unit of analysis: power and relevance of findings 
A randomized controlled trial is the unit of analysis for reviews and meta-analyses addressing the 
efficacy of an intervention. Meta-analysis can include one or more RCTs relatively small and not 
powered enough to detect a modest intervention effect. Small RCTs tend to show greater intervention 
effects than larger studies leading to the so-called ‘small-study effects’. Usually, meta-analysis with 
findings from small studies are more prone to publication bias (Schork 2003). Hypothetically, a meta-
analysis should include adequately powered studies, both to get rid of publication bias and to 
discourage future researchers from conducting small studies (Turner, Bird et al. 2013). 
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It has been demonstrated that most meta-analyses published by Cochrane reviews are made up by 
underpowered studies: Turner et al reported that the 70% of 14,886 meta-analyses across different 
medical field included underpowered studies and trials’ power was low across all areas (Turner, Bird 
et al. 2013).  Thus, the robustness of the conclusions of a meta-analysis should be assessed with 
careful interpretation of trials results.  
A review can draw conclusions about the efficacy and effectiveness of an intervention only collecting 
data and results from RCTs expected to be reliable and valid. The relevance of findings and quality 
of conduct in clinical trials can be judged almost only on the basis of what is reported in the published 
version of the article (Simera, Altman et al. 2008). Therefore, investigating the extent of good or poor 
reporting to evaluate the quality of trial conduction is essential to understand its validity and avoid 
distortions during evidence synthesis.   
Unfortunately, not all published manuscripts provide the essential and necessary information that 
allow readers, researchers and clinicians to assess the methodological quality of studies and interpret 
the findings (Hopewell, Dutton et al. 2010, Hoffmann, Erueti et al. 2013). It has been demonstrated 
that, despite the existence of reporting guidelines for 21 years, there is still a suboptimal uptake and 
a not correct usage of reporting guidelines (Jin, Sanger et al. 2018). An inadequate reporting is linked 
to poorly conducted research and clinical findings resulted from methodologically flawed randomized 
trials are more likely to comprise biased or misleading estimates of treatment effects (Schulz, 
Chalmers et al. 1995, Simera, Altman et al. 2008).  
The assessment of RCTs validity is an essential component when included in a review because it 
should influence the analysis, interpretation and conclusions of the review itself and be an unreliable 
unit of analysis for a meta-analysis.   
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Research questions 
Based on this background, I have focused my PhD program on three research questions, moving from 
the unit of the analysis of the SR, i.e. the RCT, to the methods to pool the evidence, i.e. meta-analyses 
and modern techniques. The research questions are:   
1. Are RCTs included in systematic reviews and meta-analysis adequately reported in terms 
of power and relevance of findings? 
Trials failing to detect a real difference between treatment effects may inflate the results of 
meta-analyses, obfuscating the clinical decision-making process. The possible lack of good 
quality in reporting of RCTs makes me unsure about not only the quality with which 
researchers report details in the published manuscripts but also whether authors perform an 
adequate sample size calculation at protocol stage. I wondered if RCTs included in Cochrane 
review are adequately powered and reported reliable results. Otherwise, if not, how can the 
estimates in the meta-analysis be adequate and precise? 
(First year of my PhD program) 
 
2. Which is the likelihood of meta-analysis to be underpowered, inconclusive and imprecise? 
Meta-analysis underpowered and imprecise exist. The TSA can handle the risk of 
overestimating or underestimating clinical finding. Moreover, the GRADE approach assess 
imprecision as part of the quality of the evidence. 
The TSA and the GRADE approach both take into consideration the imprecision domain in 
systematic reviews. Consequently, I ended up investigating how TSA can yield a different 
interpretation of this domain in meta-analysis results compared with those obtained by the 
GRADE system. 
(Second year of my PhD program) 
 
3. Is it possible to simultaneously compare multiple interventions in a systematic review? 
Head-to-head comparisons limits the relevance of findings generated by a systematic review. 
Network meta-analyses allow to better understand potentials of modern evidence syntheses 
applied to the medical field.  
(Third year of my PhD program)  
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Organization of the dissertation 
This dissertation is organized into two section: 
Section 1: Research question 1.  
We focused on a particular quality aspect: how sample size calculations were reported in RCTs 
published in low back pain rehabilitation and, among those adequately reported, how findings were 
interpreted in terms of statistical significance and clinical relevance. 
Section 2: Research questions 2  
We investigated key topics as uncertainty and imprecision in meta-analysis. We explored the Trial 
Sequential Analysis and the GRADE system in medical field. Thus, we showed how the above-
mentioned techniques are implemented in a modern evidence synthesis generation. 
Section 3. Research question 3.  
How to combine direct and indirect evidence on a sample of RCTs in rehabilitation field through a 
network meta-analysis was deepened. 
A general conclusion follows in the last section. 
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SECTION 1.  
Are RCTs included in systematic reviews and meta -
analysis  adequately reported in terms of power and 
relevance of  findings?  
 
Background 
Because of my background as physiotherapist, I addressed my first research question on RCTs 
published in the field of rehabilitation of mechanical low back pain where several gaps in conduction 
and reporting exist.  
In many countries mechanical low back pain is one of the most common causes of disability and lost 
work days and it is ranked as the greatest contributor to global disability (years lived with disability) 
(Hoy, March et al. 2014, March, Smith et al. 2014). Mechanical low back pain imposes significant 
economic and social burdens. Although several interventions are used to treat mechanical low back 
pain, including medicines and rest, rehabilitation plays a central role. Therefore, many researchers 
have devoted time and effort to examining the efficacy and safety of various rehabilitation 
interventions aimed at decreasing the impact of this condition.  
Although the number of reports of RCTs in rehabilitation has been increasing (Castellini, Gianola et 
al. 2016), most studies are empiric based on clinical observations with small sample sizes and 
inadequate reporting of essential information (Abdul Latif, Daud Amadera et al. 2011).  
We demonstrated that dimensions as description of interventions or adequate reporting of the 
outcomes are poorly reported across RCTs included in Cochrane systematic reviews published on 
LPB rehabilitation (Gianola, Castellini et al. 2016, Gianola, Frigerio et al. 2016). Based on this 
background, other dimensions should be assessed to correctly interpret the magnitude and accuracy 
of the effect of an intervention and guarantee its validity and generalizability: patients and sample 
size, statistical significance and clinical relevance.  
Over the last decade, several initiatives have promoted the accurate, complete, and transparent 
reporting of clinical studies to support research reproducibility and usefulness (Simera, Altman et al. 
2008). The CONSORT (Consolidated Standards of Reporting Trials) Statement has been properly 
introduced in 1996 to promote the reporting of findings of randomized controlled trials. It offers a 
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standard minimum set of reporting items, as the population included in the RCT, the characteristics 
of the intervention, the performed comparison, the chosen outcome measure, the sample size 
calculation (Kessler 2002, Boutron, Moher et al. 2008). Unfortunately, not all published manuscripts 
provide the essential and necessary information that allow readers, researchers and clinicians to assess 
the methodological quality of studies and interpret the findings (Hopewell, Dutton et al. 2010, 
Hoffmann, Erueti et al. 2013). It has been highlighted that inadequate reporting is linked to poorly 
conducted research and clinical findings resulted from methodologically flawed randomized trials are 
more likely to comprise biased or misleading estimates of treatment effects (Schulz, Chalmers et al. 
1995, Simera, Altman et al. 2008). As a consequence, investigating the extent of good or poor 
reporting is essential to evaluate the quality of trial conduction whose results can inflate the findings 
of a systematic review.  
The quality of the reporting of the following domains were judged: description of the interventions, 
outcomes assessment, reporting of sample size calculation and reporting of statistical significance 
and clinical relevance. I have selected RCTs on the efficacy of interventions for low back pain (a non-
pharmacologically intervention), where the reporting and description of the above-mentioned 
domains are considered fundamental.  
I have participated at the conduction and publishing of two manuscripts on the reporting of description 
of intervention and outcomes (Gianola, Castellini et al. 2016, Gianola, Frigerio et al. 2016). Overall, 
it has been confirmed a lack of quality of reporting of these domains.   
I found very interesting investigating how sample size calculation is stated and described in RCTs 
besides, how results are interpreted in terms of statistical significance and clinical relevance. Sample 
size calculation is essential to demonstrate that a trial is adequately designed to detect a likely real 
effect or association, if such exists, in a given population. To understand the validity of a RCT, the 
assumptions made in the power analysis should be reported in a transparent fashion.  
 
Reporting of power and sample size calculation  
Well-designed, properly executed RCTs provide the most reliable evidence on the effectiveness of 
health care interventions (Calvert, Blazeby et al. 2013). The validity of an RCT depends on several 
key factors that should be adequately reported: the sample size calculation is one of them. Sample 
size is related to statistical power, which derives from b error or type II error (Schulz and Grimes 
2005, McKeown A 2015): it represents the likelihood of failure to reject the null hypothesis when, in 
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fact, it should be rejected. The investigator’s aim is to minimize this type of error by increasing the 
sample size. Sample size calculation is essential in study design because a low-power study may fail 
to yield significant results and detect relevant clinical effects. Its description is fundamental in any 
published report so that readers can base their assessment on what is reported rather than rely on 
assumptions about how the study authors arrived at their results. However, sample size calculation is 
not always adequately reported (Ayeni, Dickson et al. 2012, Koletsi, Pandis et al. 2014, Rutterford, 
Taljaard et al. 2014). To ensure quality in trial conduction, the Consolidated Standards of Reporting 
Trials (CONSORT) 2010 statement recommends that authors provide a clear description of sample 
size calculation methods and assumptions as follows: the estimated outcomes in each group 
(minimum important treatment effect or effect size), the level of significance (a or type I error), the 
statistical power (b or type II error), and, for continuous outcomes, the assumed SD of the 
measurements (Antes 2010, Moher, Hopewell et al. 2010). In addition, the CONSORT guidelines 
recommend reporting the primary outcome using which important differences between 2 groups are 
determined. Authors should therefore decide and state a priori the fixed values for parameter 
assumptions. Although the number of reports of RCTs in rehabilitation has been increasing 
(Castellini, Gianola et al. 2016), most studies are based on clinical observations with small sample 
sizes and inadequate reporting of essential information (Abdul Latif, Daud Amadera et al. 2011).  
 
Reporting of statistical significance and clinical relevance  
As we already stated above, to understand the validity of RCT’s findings, the assumptions made in 
the power analysis should be reported in a transparent fashion. We wondered if among those trials 
adequately reporting the sample size calculation, their findings were interpreted taking into 
consideration the clinical relevance required in the calculation.  
Randomized controlled trials (RCTs) aim to show differences in an outcome measurement between 
two or more groups of patients undergoing different interventions (Hoffmann, Thomas et al. 2014). 
Authors of RCTs usually report findings in term of statistical significance (i.e., with a p-value < 0.05 
the intervention is more effective than the comparison). However, the p-value indicates the chance of 
the observed effect, does not consider the magnitude of benefits (or harm) and indeed the clinical 
relevance. This is defined as the estimate of the smallest treatment effect between groups that people 
would consider important and is often called minimally important difference (MID)(Beaton, 
Bombardier et al. 2000).  
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In rehabilitation, RCTs are often based on small sample sizes (Abdul Latif, Daud Amadera et al. 
2011) and most outcomes are patient-reported associated with small clinical changes (e.g., pain 
reduction from moderate to low). Recognizing small but clinically relevant effects requires clinical 
trials with large sample sizes. This scenario leads to two problems. First, when a small trial in 
rehabilitation achieves statistical significance, false positive outcomes may occur. Second, it should 
not be assumed that trial results which are statistically significant are also clinically relevant (Freiman, 
Chalmers et al. 1978). Even if the pre-specified value of success for the primary outcome has been 
met for the difference in treatment effects (usually a p-value of less than 0.05), it does not necessarily 
imply that the difference matters to patients (Wright 1996, van der Roer, Ostelo et al. 2006). For 
example, a recent re-analysis of data of a published Cochrane review on Multidisciplinary 
Biopsychosocial Rehabilitation (MBR) for LBP showed how findings were highly significant but 
irrelevant in practice. Across studies, pain was reduced by less than one-third of 1 MID unit on a 
numerical rating scale (0.27 MID units, confidence interval 0.07–0.48) (Gianola, Andreano et al. 
2018). A MID of 2 points out of 10 is usually considered meaningful (Ostelo, Deyo et al. 2008).  
 
Aim 
The purpose of the this section is to systematically assess the quality of reporting of power and sample 
size calculation in RCTs included in the Cochrane Systematic Reviews comparing mechanical LBP 
interventions.  
Moreover, among those trials adequately reporting the elements of the sample size calculation, we 
assessed whether treatment effects of RCTs for LBP are both statistically significant and clinically 
relevant. We also investigated if trials were powered to achieve clinically relevant outcomes assessing 
the risk of possible false-negative results (i.e., missing an effect that is actually there). 
We wanted to demonstrate that RCTs not adequately reported can reflect serious implications on 
research results as in meta-analysis.  
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Chapter 1. Improving Power and Sample Size Calculation in Rehabilitation Trial 
Reports: A Methodological Assessment 
 
Published as: Improving Power and Sample Size Calculation in Rehabilitation Trial Reports: A 
Methodological Assessment. Castellini G, Gianola S, Bonovas S, Moja L. 
Arch Phys Med Rehabil. 2016 Jul;97(7):1195-201. 
 
Abstract 
Objective: To systematically assess the reporting of sample size calculation in randomized controlled 
trials (RCTs) on rehabilitation interventions for mechanical low back pain. 
Data Sources: The Cochrane Database of Systematic Reviews was searched through February 2015.  
Study Selection: We conducted an electronic database search for RCTs published from January 1, 
1968 to February 28, 2015 and included in the Cochrane Systematic Reviews. 
Data Extraction: Two investigators independently used an ad hoc 6-item checklist derived from the 
Consolidated Standards of Reporting Trials (CONSORT) 2010 statement recommendations to extract 
data on sample size calculation. The primary outcome was the proportion of RCTs that reported 
sample size calculation; the secondary outcome was the completeness of sample size analysis 
reporting. We also evaluated improvement in reporting of sample size calculation over time. 
Data Synthesis: Sample size calculation was reported in 80 (36.0%) of the 222 eligible RCTs 
included in 14 Cochrane Systematic Reviews. Only 13 (16.3%) of these RCT reports gave a complete 
description, and about half reported ≥4 of the 6 elements of sample size calculation (median, 4; 
interquartile range, 3-5). Completeness of reporting of sample size calculation improved from 1968 
to 2013; since 2005, the number of RCTs reporting sample size calculation has increased compared 
with the number of RCTs not reporting it.  
Conclusions: Despite improvement, reporting of sample size calculation and power analysis remains 
inadequate, limiting the reader’s ability to assess the quality and accuracy of rehabilitation studies. 
 
Archives of Physical Medicine and Rehabilitation 2016;97:1195-201 
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Method  
 
Search strategy 
We conducted an electronic database search for systematic reviews published between 1968 and 
February 2015 limited to the Cochrane Database of Systematic Reviews. Search terms back pain and 
rehabilitation were run in “title, abstract, keywords” search tab in advanced search strategy. We 
included a systematic review if the title or the abstract presented mechanical low back pain as the 
disease target and the intervention was rehabilitative, as defined by the National Library of Medicine. 
We did not take into account interventions other than therapeutic rehabilitation (i.e. prevention) or 
involving population subgroups (i.e. pregnancy). From the eligible systematic reviews, we extracted 
all included trials with a randomized study design and published in English, Italian, Spanish, or 
French. After removing duplicates of RCTs, 2 researchers (G.C., S.G.) independently screened the 
title and abstract of all potentially eligible RCTs. Disagreements were resolved by consensus. 
 
Data extraction 
We extracted the general characteristics of RCTs: year of publication, number of authors, first 
author’s geographic region (Europe, North and South America, Asia, Australia), journal that 
published the study, and funding source. We developed an ad hoc checklist derived from the 
CONSORT checklist to extract data on sample size calculation. The checklist was uploaded on 
DistillerSR, a web-based database for data management. We examined whether the RCT report 
included a power of the sample size calculation was compliant with CONSORT guidelines. Following 
the CONSORT checklist(Moher, Hopewell et al. 2010), we assessed the description for reporting of 
6 sample size calculation elements: (1) type I or alpha error; (2) type II or beta error, or power; (3) 
assumption of the expected treatment effect of the intervention (ie, the difference between group 
means as effect size or minimal important difference and relative risk); and (4) the assumed variability 
expressed as an SD, a variance, or an intraclass correlation coefficient. We also looked for (5) the 
outcome on which sample size calculation was based and (6) whether there was an adjustment to 
accommodate attrition rate. In addition, we extracted from the Methods section the sample size 
planned (ie, as resulted from the sample size calculation procedure) and from the Results section the 
actual number of participants randomized (N) according to the CONSORT flow diagram. If there was 
no statement or CONSORT flow diagram reporting the number of patients randomized, we extracted 
it from implicit information (ie, “enrolled” or “included”). When articles reported the sample size 
20 
 
calculation, we examined whether there was a discrepancy between the sample size planned and the 
number of participants randomized. Moreover, we asked whether sample size reporting might be 
affected by the funding status of the RCT. Data extraction was performed independently by 2 
reviewers (G.C., S.G.). Disagreements were resolved by consensus. 
 
Statistical methods 
Descriptive statistics are presented as median (interquartile range) or number (percentage), when 
appropriate. The nonparametric Wilcoxon matched-pair signed-rank test and the chi-square test were 
used for statistical evaluations. For hypothesis testing, a probability value of <.05 was considered 
statistically significant. All statistical tests were 2-sided. Stata statistical software was used for all 
statistical analyses. 
 
Results  
Study selection 
We identified 14 relevant Cochrane systematic reviews in the Cochrane Library(Heymans, van Tulder 
et al. 2004, Urrutia, Burton et al. 2004, Hayden, van Tulder et al. 2005, Clarke, van Tulder et al. 2007, 
Furlan, Imamura et al. 2008, Khadilkar, Odebiyi et al. 2008, Yousefi-Nooraie, Schonstein et al. 2008, 
Henschke, Ostelo et al. 2010, Rubinstein, van Middelkoop et al. 2011, Rubinstein, Terwee et al. 2013, 
Wegner, Widyahening et al. 2013, Ebadi, Henschke et al. 2014, Kamper, Apeldoorn et al. 2014). 
Sixty of 301 RCTs included in these 14 systematic reviews were excluded because they were 
duplicates or multiple publications of the same RCT; 7 (2.3%) were excluded because their full text 
could not be retrieved; and 12 (3.9%) were excluded because they did not satisfy the language 
criterion. A total of 222 RCTs (73.7%) was included in our review (fig 1). 
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Figure 1. Flow diagram.  
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General characteristics 
The 222 eligible RCT reports were published in 78 journals. Most were published in Spine (22.5%, 
n=50), followed by Journal of Manipulative and Physiological Therapeutics (4.5%, n=10), Pain, 
British Medical Journal, and Archives of Physical Medicine and Rehabilitation (4.1%, n=9), and 
Clinical Journal of Pain (3.6%, n=8). Some 32 countries were indicated as countries of publication, 
with the top 3 countries being the United States (18.9%, n=42), the United Kingdom (13.1%, n=29), 
and the Netherlands (9.9%, n=22); most studies were published (59.5%, n=132) by European 
researchers. The period of RCT publication was from 1968 to 2013. The characteristics of the RCTs 
are reported in table 1. 
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Sample size calculation 
Reporting 
Only 80 (36.0%) of the 222 RCTs reported sample size calculation. However, there was a significant 
improvement in reporting of sample size calculation over time (fig 2). We found that 13.3% (11 of 
83) of trials published on or before 1996 reported sample size calculation compared with 49.6% (69 
of 139) of trials published on or after 1997 (Ӽ21= 29.85; P<.001). Furthermore, we found an 
association between reporting of a funding source and reporting of sample size calculation. In 
particular, 48.8% (61 of 125) of the trials reporting a funding source were also reporting a sample 
size calculation as compared with only 19.6% (19 of 97) of the trials not reporting a funding source 
(Ӽ21= 20.22; P<.001). This association was strong in the post-CONSORT era, with 61.4% (54 of 88) 
of the trials reporting a funding source also reporting a sample size calculation versus 29.4% (15 of 
51) of the RCTs not reporting a funding source (Ӽ21=13.19; P<.001). However, it was not significant 
in the pre-CONSORT era (18.9% vs 8.7%; Ӽ21=1.86; P=.17), but data were scarce. 
 
Figure 2. Trend of improvement in reporting of sample size calculation over time.  
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Complete description of sample size calculation 
Thirteen (16.3%) of the 80 RCTs reporting sample size calculation gave an adequate description of 
the a priori sample size calculation, with all 6 elements provided in compliance with CONSORT 
guidelines. Half of the RCTs reported at least 4 of 6 elements (fig 3). Of the 6 CONSORT elements 
required for sample size calculation, the 3 most frequently reported were power (91.3%, n=73), 
assumption of the expected treatment effect of the intervention (86.3%, n=69), and alpha or type I 
error (85.0%, n=68). Adjustment to accommodate attrition rate was the least frequently reported 
element (32.5%, n=26).  
 
Figure 3. Completeness of sample size calculation description.  
 
Characteristics of each element reported 
Each element could be expressed in a different way; table 2 present common expressions for 
elements. Power was usually defined as 1-beta (82.5%, n=66). The minimal important difference was 
the assumed value for the detection of the treatment effect most often reported in the 80 trials (46.3%, 
n=37). Concerning the outcome on which the calculation was based, all RCTs evaluated continuous 
outcomes: disability was the one most often reported (42.5%, n=34), followed by pain (22.5%, n=18). 
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Discrepancy between the sample size planned and the sample size randomized 
The sample size planned was reported in 72 of 80 RCTs. In the remaining 8 (10.0%) RCTs that 
reported the sample size calculation, the number of participants planned was not stated. The median 
number of participants needed to prove sufficient power was 120 (interquartile range, 17-2000), 
whereas the median number of participants randomized among these 72 
RCTs was 133 (interquartile range, 21-741). The number of participants randomized was lower than 
the number of participants planned in 17 RCTs (23.6%), equal in 13 (18.0%), and higher in 42 
(58.4%); figure 4 showed the discrepancy between the sample size planned and the number of 
participants randomized when the number obtained by the sample size calculation increased. 
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Figure 4. discrepancy between the sample size planned and the sample size randomized.  
 
Discussion 
Reporting of sample size calculation in RCTs on low back pain rehabilitation is often incomplete. We 
found that numerous RCTs published between the 1960s and the present failed to report a priori 
sample size calculation, barring readers from understanding whether calculation was done and 
whether it was done correctly. Among the RCTs reporting a priori sample size calculation, only a 
minority gave a complete description of the elements used. Nevertheless, the reporting of sample size 
calculation and its elements has increased over years; since 2005, more RCTs report sample size 
calculation than those that do not. Moreover, our results showed that the publication of the 
CONSORT statement has increased authors’ awareness of high-quality reporting as compared to that 
in the pre-CONSORT era. Despite this, assessing the quality of the reporting does not necessarily 
reflect the quality of the underlying research: it is fundamental, distinguishing between “what 
researchers do” and “what researchers report.” For instance, the assessment of risk of bias in a RCT 
leads to ambiguity between the quality of reporting and the quality of the research (Higgins JPT and 
Green S 2011). Our findings are consistent with a previous review of the general medical literature 
that described poor compliance by authors with CONSORT guidelines. Similarly, a review of 
physical medicine and rehabilitation trials published between 1998 and 2008 found that reporting had 
27 
 
somewhat improved, with only slightly more than half of the articles (57.3%) published in 2008 
reporting sample size analysis (Abdul Latif, Daud Amadera et al. 2011). Conducting responsible 
research entails complete accurate reporting in a transparent fashion according to international 
guidelines. To ensure high quality in conducting a clinical trial, it is not sufficient to state the sample 
size without giving a description of how it was calculated. More than half of the RCTs with a priori 
sample size analysis included in our review reported fewer than 4 of the 6 elements required for 
replication of calculations. A recent review (ACTTION systematic review) found that half of the 
published analgesic clinical trials gave an incomplete description of sample size calculation 
(McKeown A 2015). 
Sample size calculation is usually based on a single outcome, chosen as a primary measure: specifying 
it helps researchers to clarify the initial basis upon which an RCT is built, besides simplifying 
interpretation, judgment, and use of findings (Cook, Hislop et al. 2015). We noted that more than half 
of the RCTs stated the primary endpoint, similar to the rates reported in a previous review in physical 
medicine trials (Abdul Latif, Daud Amadera et al. 2011). In the literature, disability and pain are the 
most frequently investigated outcomes in low back pain rehabilitation: several authors have 
recommended including these measurements in the back-specific core outcome sets because they are 
most relevant to patients, health care practitioners, regulators, industry representatives, and 
policymakers (Froud, Patterson et al. 2014). They were also the elective outcome measures most often 
used in RCTs according to our and recent review that found a low frequency of reporting outcome 
and intervention descriptions, reflecting a multidimensional lack of quality in rehabilitation RCTs 
(Gianola, Castellini et al. 2016).  
Among the RCTs in which a power analysis was performed, 72 reported the sample size planned. In 
2 out of 3 of these RCTs, the sample size randomized was larger than the sample size planned, and 
in a small proportion (30%) the sample size randomized was smaller than the sample size planned. 
Although authors are always encouraged to include more than the minimum number of participants 
to compensate for loss to follow-up, over recruitment to account for attrition is unjustifiable both 
economically and ethically - economically unsound because of the high costs of clinical trials and 
ethically questionable because of potential harm to patients. Except for trials on rare diseases or early-
phase trials, underpowered studies are unethical because they may fail to yield significant results, are 
more likely to be inconclusive, and produce more false negatives (Maggard, O'Connell et al. 2003, 
Charles, Giraudeau et al. 2009, Calvert, Blazeby et al. 2013). However, trials with an overly large 
sample size may waste resources in terms of patients, time, and funding beside offering significant 
but not clinically relevant results. Authors should aim to achieve robust research findings by 
28 
 
calculating an adequate sample size by using time and resources in the best cost-effective manner 
(Fitzner and Heckinger 2010) and in collaboration with experienced biostatisticians and 
methodologist researchers (Ioannidis, Greenland et al. 2014).  
Our results show that funding status affects the quality of reporting. Building a sustainable funding 
scheme for clinical comparative research in areas less explored, that is, the “orphan areas” such as 
anesthesiology or orthopedics, is critical to support evidence-based practice in medical research 
(2010). Funding is fundamental to obtain more resources in terms of personnel and to make the 
research process more efficient. Economic support is important in both pharmacological research and 
research areas where public health needs are changing. For example, rehabilitation for low back pain 
has increased its importance in both primary care, where rehabilitation as intervention plays a central 
role in low back pain management, and research (Castellini, Gianola et al. 2016); therefore, evidence-
based rehabilitation has grown. When the aim is to translate results from research to practice, it is 
essential to focus on how the evidence is generated. RCT reports should provide essential information 
so that readers can make better decisions in clinical practice, especially in the rehabilitation of low 
back pain, an increasingly common health problem with a substantial community and financial 
burden(Maniadakis and Gray 2000, March, Smith et al. 2014).  
Future studies should assess the quality of reporting of other essential elements for clinicians in 
rehabilitation. For instance, an adequate and satisfied description of the experimental intervention 
should be crucial, as well as the description of the target population and the outcome selection. Maybe 
a multidimensional lack of reporting of information exists, reflecting difficulties in transferring the 
research’s results in clinical practice. 
 
Study limitations 
This study focused only on the reporting of sample size calculation and its elements as described in 
the Methods section of RCTs. It would have been interesting to compare the final publication with 
the published protocol to explore whether the absence of some elements was limited to the research 
article or were included in the research protocol. This was not possible because our sample comprised 
a wide range of RCTs published from 1968 to 2013.  
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Conclusions 
Sample size calculation is essential to demonstrate that a trial is adequately designed to detect a likely 
real effect or association, if such exists, in a given population(Fitzner and Heckinger 2010). Although 
some elements are difficult to define, the assumptions made in the calculation should be reported in 
a transparent fashion. The CONSORT statement provides a standard guidance for authors to prepare 
reports of trial findings and to facilitate their complete and transparent reporting. In addition, the 
SPIRIT (Standard Protocol Items: Recommendation for Interventional Trials) initiative has recently 
strengthened the purpose to improve transparency in the trial protocols (Chan, Tetzlaff et al. 2015). 
Furthermore, Cook et al(Cook, Hislop et al. 2015) have just created a more extensive set of elements 
for adequate reporting of this process in trial protocols and results, also providing justifications for 
the assumption of sample size calculation. Just as researchers should be encouraged to use these 
guidelines so, too, journal editors and peer reviewers should impose stricter criteria for adequate and 
transparent reporting. In addition, the sharing of software could help to simplify sample size 
calculation. Improving the methodological quality of RCTs, and all types of trials, will go some way 
to ensure the validity of results, reproducibility of research, and dissemination of results from research 
to practice. 
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Chapter 2. Rehabilitation interventions in randomized controlled trials for low 
back pain: proof of statistical significance often is not relevant 
 
Published as: Rehabilitation interventions in randomized controlled trials for low back pain: proof of 
statistical significance often is not relevant. Gianola S, Castellini G, Corbetta D, Moja L. 
Health and Quality of Life Outcomes; 17; July 2019 
 
Abstract 
 
Objective: We aimed to assess if treatment effects of randomized controlled trials (RCTs) for low 
back pain (LBP) are statistically significant and clinically relevant, and if RCTs were powered to 
achieve clinically relevant differences on continuous outcomes. 
Methods: We searched for all RCTs included in Cochrane Systematic Reviews focusing on the 
efficacy of rehabilitation interventions for LBP and published until April 2017. RCTs having sample 
size calculation and a planned minimal important difference were considered. In the primary analysis, 
we calculated the proportion of RCTs classified as “statistically significant and clinically relevant”, 
“statistically significant but not clinically relevant”, “not statistically significant but clinically 
relevant”, and “not statistically significant and not clinically relevant”. Then, we investigated how 
many times the mismatch between statistical significance and clinical relevance was due to 
inadequate power. 
Results: From 20 eligible SRs including 101 RCTs, we identified 42 RCTs encompassing 81 
intervention comparisons. Overall, 60% (25 RCTs) were statistically significant while only 36% (15 
RCTs) were both statistically and clinically significant. Most trials (38%) did not discuss the clinical 
relevance of treatment effects when results did not reached statistical significance. Among trials with 
non-statistically significant findings, 60% did not reach the planned sample size, therefore being at 
risk to not detect an effect that is actually there (type II error).  
Conclusions: Only a minority of positive RCT findings was both statistically significant and 
clinically relevant. Scarce diligence or frank omissions of important tactic elements of RCTs, such as 
clinical relevance, and power, decrease the reliability of study findings to current practice. 
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Methods 
This is a retrospective cohort study, building on a previous published research.15 We updated the 
search strategy, adopted the same eligibility criteria and re-run the same selection process. Here, 
methods are briefly reported.  
 
Literature search  
We moved from Cochrane Systematic Reviews (SRs) for selecting trials since they are usually 
considered of high quality, and adopt extensive search strategies. For the identification of Cochrane 
SRs on LBP, we updated the previous search strategy to April 2017.15 
 
RCTs eligibility criteria 
From the eligible Cochrane SRs, we extracted all trials. We considered a trial eligible if it met all the 
following criteria: (i) was a RCT; (ii) identified a primary outcome and determined the sample size 
on the basis of the primary outcome; (iii) considered continuous outcomes (e.g., pain, disability) 
leaving out any binary outcomes (e.g., fall or not fall); (iv) identified a priori planned MID for the 
primary outcome measure in the sample size calculation; and (v) the language of publication was 
English or Italian.  
 
Data collection  
We developed an ad hoc data extraction form. For each trial, we collected general information (e.g., 
country and year of publication) and specific information. Specific information included: the primary 
continuous outcome (e.g., pain), scales used for the outcome assessment (e.g., numeric pain rating 
scale), details on measurement scoring (e.g., 0-10 points), planned sample size, planned MID, any 
bibliographic reference and/or explanation of the rationale for the choice of the MID (e.g. 
anchor/distribution or other methods), follow-ups, number of randomized patients, number of patients 
at any follow up. When the time of follow-up analysis was not specified in the sample size calculation, 
we arbitrarily selected the follow-up time point closest to the end of the intervention.  
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In addition, we classified the type of intervention as “active treatment” or “inert treatment”, the 
second used when the expected responses could not be attributed to the investigated interventions 
(e.g. lack of biological plausibility of an effect). More precisely, we considered the interventions such 
as manipulation as “active treatment”, while placebo or sham control treatments as “inert treatment”. 
Referring to estimates of effect sizes, we noted the mean difference (MD) of the primary outcome 
and its 95% confidence intervals (CIs), or any other available data to estimate the effect size and its 
imprecision (e.g. standard errors).  
Determination of statistical significance. For every comparison between the intervention and control, 
we dichotomized the statistical significance as ‘achieved’ or ‘not achieved’ according to the pre-
specified significance level (i.e., when pre-specified significance level was less than 5%, p<0.05, 
statistical significance was classified as ‘achieved’). 
Determination of the clinical relevance. Between-group differences were compared with the planned 
MID reported in the sample size calculation, determining if the effect size reached clinical relevance. 
We classified clinical relevance as ‘achieved’ if the point estimate of the MD was equal or greater 
than the a priori planned MID, and ‘not achieved’ in the other case.  
Determination of study powered. We defined a study as “powered” if the sample size was equal or 
greater than the sample size originally planned. 
Finally, we screened all RCTs to determine how often authors discussed trial’ findings related to the 
clinical relevance. We revised all full-text sections and we classified each trial according to the 
attempt to interpret differences as clinically relevant as “clinical relevance discussed” or “clinical 
relevance not discussed”. Two reviewers conducted the screening independently and a third author 
was consulted in case of disagreements. 
 
Data analysis 
We reported data of continuous variables by medians and interquartile range (IQR), and data of 
categorical variables by frequencies and relative percentages. We computed the number of RCTs 
falling in each of the following four categories: “statistically significant and clinically relevant”, 
“statistically significant but not clinically relevant”, “not statistically significant but clinically 
relevant”, and “not statistically significant and not clinically relevant”. Whenever multiple arm 
comparisons were presented, in a primary analysis, we considered the whole trial as statistically 
33 
 
significant if at least one comparison was statistically significant. In a secondary analysis, we 
considered each multiple arm comparison as independent.  
 
Results 
Study selection 
We identified sixty-three Cochrane SRs. After the selection process, 20 SRs were considered for the 
identification of eligible trials. One hundred-five RCTs were eligible from the included Cochrane 
SRs but only 42 (40%) met the inclusion criteria and were finally included in our study. The study 
selection process is shown in Figure 1. 
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Trial’s characteristics 
The 42 included RCTs were published in 19 journals. Most of these were published in Spine (n=13, 
31%), in The British Medical Journal (n=5, 12%), and in the Clinical Journal of Pain (n=5, 12%). 
Thirteen countries were designated as publishing countries, of which the most frequent are United 
States (n=11 RCTs, 26%), United Kingdom (n=9 RCTs, 21%), Norway and the Netherlands (n=4 
RCTs, 10%). The publication period runs from 1996 to 2014 (median = 2006; IQR = 2003 - 2008). 
Most RCTs reported the funding source (81%). One-fifth of the studies was multi-arm and 29% of 
trials calculated the sample size based on a composite outcome. One-third of trials (32%) investigated 
comparisons against an inert intervention. All general characteristics are reported in Table 1. 
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Table 1. General characteristics.  
 
n° of RCT  
(n=42) 
% 
N° of countries (n=14)     
  United states 11 26 
  United Kingdom 9 21 
  Norway 4 10 
  Netherland 4 10 
  Brazil 3 7 
  Australia 3 7 
  Finland 2 5 
  Spain 1 2 
  Sweden 1 2 
  Switzerland 1 2 
  Italy 1 2 
  Thailand 1 2 
  Taiwan 1 2 
N° of journals (n=19)     
Most frequent journals     
  Spine 13 31 
  Clinical Journal of Pain 5 12 
  British Medical Journal 5 12 
  Journal of Manipulative and Physiological Therapeutics 3 7 
N° of reported funding  34 81 
Multi-arm trials 8 19 
 n° of comparisons 
(n=81) 
% 
Comparisons   
 active treatment versus active treatment 55 68 
 active treatment versus inert treatment 26 32 
 
Clinical relevance characteristics 
The majority of the included studies (n=37, 88%) reported MID as an absolute value, while the 
remaining studies reported it as a percentage of improvement over the baseline. Only a half of the 
included studies (n=20, 48%) referenced the source used to calculated the MID. Eliminating 
duplicates, 16 different method sources were found and examined. Of these, 6 were anchor-based, 
one distribution-based, one based on consensus (e.g. expert panel), three cited other articles, three 
were not clearly described and information was not found in two studies.  
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Is the effect always clinically relevant?  
Table 2 shows the main findings for statically significant and clinically relevant results. We found 
that almost a half of trials (n=16, 40%) were “not statistically significant and not clinically relevant” 
and more than a half (n=25, 59%) were statistically significant. Out of these 25, 15 trials (36% of all 
included trials) were both “statistically significant and clinically relevant” and 10 trials, (24 % of all 
included trials) were “statistically significant but not clinically relevant”. One trial was classified as 
“not statistically significant but clinically relevant”. 
Considering all comparisons of multiple arm trials (n=81) the four scenarios were similar to those 
reported in table 2. However, among statistical positive findings (scenario A and B, n=42 out of 81), 
a consistent part of the comparisons were against an inert treatment (40%) as compared to active 
head-to-head comparisons (60%).  
 
Table 2. Statistically significance and clinically relevance on continuous outcomes of LBP. Δ is the 
MID. Negative values means improvement (for example, greater pain reduction in the treatment vs. 
control group).  
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Scenario N° of trials (%) 
(total=42) 
N° of comparisons 
(%) (total=81) 
 
A) statistically significant and clinically relevant 
 
 
15 (36%) 
 
 
20 (25%) 
 
B) statistically significant but not clinically relevant 
 
 
10 (24%) 
 
 
22 (27%) 
 
C) not statistically significant but clinically relevant  
 
 
1 (2%) 
 
 
1 (1%) 
 
D) not statistically significant and not clinically 
relevant  
 
 
16 (38%) 
 
 
38 (47%) 
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Is the clinical relevance always discussed? 
Eighteen out of 42 trials (43%) did not report or discuss the clinical relevance of their results, even 
when clinical relevance was demonstrated (5%). Table 3 lists most frequent types of omissions and 
embellishments characterising reporting of results when clinical relevance was not reached and 
considered. Full omission for the primary outcome was the main strategy (11 trials). 
 
Table 3. Types of omissions and embellishments in reporting RCT findings when clinical relevance 
was not reached and considered (n = 42) 
* The Total refers to 16 trials that not discussed the clinical relevance. 
**Composite outcomes. 
 
Were non-statistically significant interventions powered? 
Four studies did not report the number obtained in the sample size calculation. For the other 38 
studies, the median of the sample sizes planned a priori was 125 subjects, while the median of the 
actual enrolled sample sizes was 133 subjects. Nevertheless, 14 trials out of 38 (37%) reached the 
planned sample size, while remaining were low-powered. Sixteen out of 38 trials (42%) do not 
achieve the statistical significance but less than half of these (n=6, 40%) have an adequate and 
powered sample size (Table 4, scenarios C and D).  
 
Clinical Relevance discussion Strategy for specific reporting No. (%)  
Clinical relevance discussed  24 (57) 
Clinical relevance not discussed  18 (43) 
                                 not reached   16 (39) 
Full omission for the primary outcome 7 (44) * 
Full omission for all primary outcomes used in the 
sample size calculation**  
4 (25) * 
Clinical relevance discussed only as within-group 
improvements 
4 (25) * 
Clinical relevance discussed at follow-ups not 
declared in the sample size calculation  
1(6) * 
                       reached   2 (5) * 
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Table 4. Statistical and clinical effects according to planned a priori sample size achievement. 
Scenario per n° of trials (total=38*) 
 
N° of 
powered 
trials (%) 
N° of 
unpowered 
trials (%) 
A) statistically significant and clinically relevant (n=14) 7 (50)  7 (50) 
B) statistically significant but not clinically relevant (n=8) 1 (12) 7 (87) 
C) not statistically significant but clinically relevant (n=1) 0 1 (100) 
D) not statistically significant and not clinically relevant (n=15) 6 (40) 9 (60) 
Totals  14 (37) 24 (63) 
* The total number of trials is 38 because four studies did not report the patients number obtained 
from the sample size calculation (1 study belongs to scenario A, 2 belong to scenario B and 1 study 
belongs to scenario D).  
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Discussion 
Based on the RCTs included in our retrospective cohort, we found a poor reporting of rehabilitation 
interventions for LBP in terms of validity and clinical relevance. In fact, only a half of the trials 
reported the source reference of the adopted planned MID as measure of validity of the clinical 
relevance and, among studies achieving statistically significant results (n=25/42), only 60% 
(n=15/25) achieved the planned clinical relevance. This means that 1 out of 2 studies reaching a 
statistically significant difference favoring a treatment has results that cannot be truly relevant for 
stakeholders, clinicians and patients. This result could also be overestimate because the 29% of trials 
reported the sample size based on composite outcomes at risk of falling in type I error. Less than a 
half of RCTs in our sample (43%) did not discuss their findings from a clinical perspective, mainly 
by omitting information, particularly when the clinical relevance was not reached. Finally, we found 
that in trials reaching statistically significant and clinically relevant results the majority of multi-arm 
comparisons were against inert treatments. All these findings support the hypothesis that the efficacy 
of rehabilitation interventions for LBP tend to be overestimated, or potentially underestimated if we 
considered that 63% trials with not statistically significant and not clinically relevant results did not 
have an adequate and powered sample size.  
Our results are coherent with the literature where the reporting of results in terms of clinical relevance 
is sparsely used across trials.(Hoffmann, Thomas et al. 2014) We confirm the preliminary results 
published by Van Tulder et al. focused on exercise therapy for chronic LBP reporting that less than 
half of studies (39%) with positive conclusions shown clinically important differences(van Tulder, 
Malmivaara et al. 2007). A general poor reporting of clinical relevance is also present across 
pharmacological interventions with a discussion of results in clinical terms ranging from 24% to 46% 
of the samples. (Pocock, Geller et al. 1987, Moher, Dulberg et al. 1994, Chan, Man-Son-Hing et al. 
2001, Molnar, Man-Son-Hing et al. 2009, Hoffmann, Thomas et al. 2014) 
When results of trials do not achieve a statistically significant and/or a clinically relevant difference 
among treatments, authors tends to discuss and shape the impression of their results for readers. In 
scientific writing, this is called “to spin” the scientific report(Junger 1995). In our sample of RCTs, 
the most frequently adopted strategy to spin the report was the under-reporting of the clinical 
relevance of  statistically significant results. One possible reason at the basis of this phenomenon can 
be found in the publication process of biomedical research that tends to favor the publication of 
positive results.(Chalmers and Matthews 2006) To some extent, similarly for statistical significance, 
it can happen that reports of RCTs with clinically relevant results are published more often than those 
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with not-clinically relevant results.(Rising, Bacchetti et al. 2008, Turner, Matthews et al. 2008),(Chan, 
Hrobjartsson et al. 2004, Chan and Altman 2005, Al-Marzouki, Roberts et al. 2008, Dwan, Altman 
et al. 2008, Song, Parekh et al. 2010) 
Clinical relevance can influence not only the statistically significant results but also the non-
statistically ones. In fact, the aim to detect a MID between the intervention and control group 
determines the power of study in the sample size calculation. A study conducted in 2008 in the field 
of physical medicine and rehabilitation reported that, of the 82 articles reviewed, 57% reported 
sample size calculation and 13% of them without sufﬁcient information about the parameters required 
for a priori calculation.(Abdul Latif, Daud Amadera et al. 2011) In a more recent published study on 
low back pain rehabilitation we denounced a low frequency of trials reporting all elements needed 
for sample size calculation.(Castellini, Gianola et al. 2016) Anyway, also taking into account all trials 
with all the elements for sample size calculation, we now found a very low percentage of powered 
trials that clinically interpreted their findings on the light of the planned clinical relevance. This issue 
encompass other healthcare professions than the physical rehabilitation in the evidence based care: a 
large proportion of the existing trials are poorly designed and underpowered.(Geha, Moseley et al. 
2013) The potential weakness in small-size “negative” clinical trials was already reported and pointed 
out fifty year ago.(Freiman, Chalmers et al. 1978) In a planning phase of a clinical trial, scientific 
ethics committees should be more rigid on the sample size definition requiring its “a priori” 
calculation and its complete reporting. Ethics committees should mandatory require researchers to 
provide the preliminary data or a referenced study assessing the MID of the outcome used for the 
determination of the sample size calculation. This is expected to happen also for pilot studies, even if 
exposed to unexplored knowledge. The size of a pilot study should be calculated in relation to the 
desired level of confidence for the SD and the chosen power and significance level of analysis in the 
main study. At high level of confidence, a pilot study of at least n=50 is advisable in many 
circumstances.(Sim and Lewis 2012)  The same process should be followed during the editorial 
assessment of a scientific report before its publication. We also suggest researchers to select a single 
primary endpoint for formal statistical inference otherwise involving several outcomes conventional 
significance testing can seriously inflate the overall type I error rate.(Pocock, Geller et al. 1987) 
Finally, an accurate replication of the sample size should be done, prior to the approval of 
experimental study, in order to avoid approximated, wrong and unfounded assumptions.  
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Implication for clinical practice 
A very low proportion of trials research (2.6%) reflects the priorities of patients and clinicians 
showing an important mismatch between wishes of patients and evaluations of researchers.(Crowe, 
Fenton et al. 2015) Treatments efficacy should be useful in terms clinical relevance. This would allow 
a better informing patients strategy on the possible benefits and harms of the intervention, as well as 
their size or likelihood, costs, and inconveniences of the intervention for a tailored therapy. The 
shared decision-making approach should encompass the patient’s preferences and values into the 
discussion in a perspective evidence based health-care.(Sackett, Rosenberg et al. 1996) A treatment 
leading to non-relevant results for patients is often an unsuccessful treatment, resulting in frustration, 
discontinuation of therapies and waste of resources. An approach focused on the achievement clinical 
relevance of a treatment will increase awareness of condition and the participation of each patient in 
the managing of their benefit-harm trade-off tailored, limiting the burden of physical rehabilitation 
conditions for obsolete or harmful or discontinued treatments. 
 
Implication for research  
We call for more adherence to reporting of planned sample size including the clinical relevance with 
the clinical interpretation of the effects. Without the complete information, the reader is unable to 
fully interpret the results of a study.(Hoffmann, Thomas et al. 2014) On one hand, authors have to 
report all elements used for sample size calculation, including the clinical relevance. Furthermore, 
they have the duty to interpret observed effects on the light of this threshold coherently. Otherwise, 
sample size calculation does not make any sense. On the other hand, editors and reviewers have to 
enforce authors to provide sufficient details about clinical relevance and sample size calculation 
(sample planned, randomized and reached) for the primary outcome.  
This would prevent an unusable treatment for its non-interpretable effects and leading to promote 
treatments clinically relevant. Then, the actual guidelines for the reporting of patient-reported 
outcome in RCTs, endorsed through the initiatives of the Consort Statement,(Boutron, Moher et al. 
2008, Calvert, Blazeby et al. 2013) promote the discussion (item 22) of a minimal important change 
in the interpretation of patient-reported outcome results. Actually, clinical relevance is not explicitly 
contemplated in the planning, the current item 7 only describe “how sample size was planned”. The 
reporting of patient-reported outcome in RCTs must consider to expand the item regarding the sample 
size definition introducing a dedicate section for the declared a priori clinical relevance and reporting 
of its validity (e.g., by citation of references). This approach can avoid too positive results improving 
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the assessment of the imprecision of quality of evidence and standardizing the process. If findings are 
statistically significant but not clinically important, the quality of evidence in the meta-analyses will 
potentially change the conclusions.(Guyatt, Oxman et al. 2011) 
 
Strength and limitations 
The major strength of this study is to assess the clinical relevance of results assuming the MID 
declared in the sample size of each study and not a standardized MID as already previously 
investigated.(van Tulder, Malmivaara et al. 2007) However, some limitations are present. The sample 
of trials only included non-pharmacological LBP interventions and our findings may not be extended 
to other trials published on different interventions (e.g., pharmacological interventions). Moreover, 
we did not assess the risk of bias in each trial that could have been correlated the quality of study to 
the interpretation of results. 
 
Conclusions 
Authors’ conclusions are usually too positive and the clinical relevance is not yet fully considered as 
a valid measure reported in the sample size, and in the interpretation of findings of RCTs in LBP 
rehabilitation. If authors of trials reported adequately the a priori sample size and commented their 
results in term of clinical relevance, the threshold for efficacy could identify the true effect. We also 
called for powered trials, particularly optimizing the sample size recruitment and for more attention 
in interpretations of findings from a clinical perspective. Even if studies with larger sample sizes are 
more onerous in terms of both time and money, they can give results that are more reliable if 
adequately powered and precise. Sample size calculation must be performed before conducting a trial 
in order to ensure to have a sufficiently large sample size to be able to draw meaningful conclusions. 
Without a complete, corrected and powered sample size, the common justification of “not enough 
power to detect a significant efficacy of the intervention” is always justifiable for negative studies.  
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General Conclusion  
It has been showed that the amount of research on low back pain has been increasing over the years 
(Castellini, Gianola et al. 2016). However, it seems that limited efforts were directed to improve its 
quality and validity. Indeed, a high prevalence of poor reporting in RCTs in low back pain 
rehabilitation was found in our research publications. This results in publishing research not reliable 
and inaccurate, with a production of wasteful research and consequent useless treatments in clinical 
practice and results not transferable to clinical practice.  
When a literature synthesis is needed to provide evidence about the effectiveness of an intervention, 
the RCT is the unit of analysis from which researchers, clinicians and stakeholders should start to   
look for it. Nevertheless, a valid and reliable RCT is essential to provide reliable evidence synthesis.  
When an RCT demonstrate to fail to report essential elements, as we showed, results of systematic 
reviews and meta-analysis should be cautiously critically considered and interpreted.  
 
45 
 
SECTION 2  
Which is the likelihood of a meta-analysis to be 
underpowered, inconclusive and imprecise?  
 
Background  
Even though a meta-analysis is often considered the best approach to quantitatively synthetize the 
evidence, in this section we are going to show methods useful to optimize meta-analyses results and 
overcome its limitation. In particular, (a) the likelihood to be underpowered, not conclusive and 
imprecise and (b) the limit to provide just head-to-head comparisons. 
 
Underpowered and imprecise meta-analysis 
Random errors frequently cause erroneous estimation of treatment effect when meta-analyses are 
small (Thorlund, Imberger et al. 2011). The lack of statistical power and precision can amplify the 
random error in a meta-analysis, leading neutral or negative (non-positive) findings. The TSA is a 
frequentist methodology which can handle the risk of overestimating or underestimating clinical 
findings: it combines the calculation of a required information size (RIS) for a meta-analysis and an 
adjusted threshold for a statistically significant treatment effect. TSA’ conclusions have the potential 
to be more reliable than those using traditional meta-analysis techniques. Methods as TSA emphasize 
the fact that an accurate and critic assessment, both qualitative and quantitative, of the body of the 
evidence has become fundamental in clinical research.  
During my first year I have deepened the TSA methodology spending a period at the Copenhagen 
Trial Unit, between April 2016 and September 2016. During this working experience and studying 
the TSA methodology, I came across a publication by Jakobsen and colleagues which suggested to 
include the TSA as a supplement of imprecision assessment of the GRADE system (Jakobsen, 
Wetterslev et al. 2014).   
The GRADE system is an international standard to assess the strength of body of the evidence, 
informing transparently and explicitly the confidence that researchers have on the results. (Balshem, 
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Helfand et al. 2011). GRADE uses a framework of information about risk of bias, imprecision, 
inconsistency, indirectness and publication bias. Particularly, it defines the issue of imprecision for 
SRs as the confidence in the estimate of the overall effect (Guyatt, Oxman et al. 2011). Imprecision 
also encompasses the size or importance of an effect, and it is influenced by the magnitude of the 
sample size or the number of events.  
I have with interest read the article by Jacobsen et al. on how the TSA and the GRADE assessment 
take both into consideration the imprecision domain in systematic reviews. Therefore, I have 
investigated how TSA can yield a different interpretation of this domain in meta-analysis results 
compared with those obtained by the GRADE system. Imprecision is a matter of interest in clinical 
decision making process. How much be confident in systematic reviews and trials results is what 
influence a clinician in his clinical decision making process.  
 
Multi comparisons of interventions in a meta-analysis 
A meta-analysis usually compares two interventions at a time, being of limited use since it provides 
only a partial view of the whole picture of treatment options for a given condition. Clinicians are 
always asked to provide the best evidence-based available treatment to their patients. A new meta-
analysis technique, called network meta-analysis (or multiple treatments meta-analysis or mixed-
treatment comparison), has been developed to assess the efficacy of several interventions and 
synthesize evidence across a network of randomized trials. I ended up with a case example on the 
effectiveness of interventions in low back pain rehabilitation developed in collaboration with a group 
of researchers.  
 
Aim  
In chapter 1, the TSA method was explained in theory and case example of its application were 
performed. Then, in chapter 2, we focused on imprecision domain of meta-analyses’ results and we 
compared the imprecision assessment of the GRADE approach to that obtained by a TSA application.   
Secondly, in chapter 3, we studied and applied the network meta-analysis in low back pain 
rehabilitation field. Indeed, a meta-analysis usually offers a comparison between 2 interventions at a 
time, limiting the ability of clinicians, researchers and stakeholders to choose the best intervention 
among all the available for a specific condition, which is often the case in real clinical practice.  
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Chapter 1. Trial Sequential Analysis 
The meta-analysis is an essential tool to detect intervention effects when controversies arises from 
conflicting studies. This statistical method can increase the power of results: when several studies are 
combined to detect a small effect, the chance of detecting it increases. A meta-analysis can also 
improve the precision of the intervention effect’ estimate since a great amount of information is 
collected (Higgins JPT and Green S 2011). However, it is not an infallible tool.  
 
Underpowered meta-analysis 
RCTs that fail to detect a real difference between treatment effects due to risks of biases may inflate 
the results of a meta-analysis. Our recent review of RCTs published in low back pain rehabilitation 
field showed that 64% of RCTs did not report transparently the power analysis (Castellini, Gianola 
et al. 2016). This has increased concerns not only about the quality with which researchers report 
details in the published manuscripts but also whether authors perform an adequate sample size 
calculation at protocol stage. Turner et al. found that, using the conventional power analysis and 
testing for a relative risk reduction of 30%, the 78% of Cochrane meta-analysis with a dichotomous 
outcome have a power <80% and the 50% have a power <27%. We can assume that the majority of 
published Cochrane meta-analyses might be underpowered and much attention should be paid to their 
overestimated conclusions (Turner, Bird et al. 2013, Imberger, Gluud et al. 2015, Imberger, Thorlund 
et al. 2016).  
From simulation studies we know that random errors frequently cause erroneous estimation of 
treatment effect when meta-analyses are small (Thorlund, Imberger et al. 2011). The lack of statistical 
power and precision can amplify the random error in a meta-analysis, leading neutral or negative 
(non-positive) findings. Recently, Imberger et colleagues demonstrated that in a sample of 50 meta-
analyses investigated an anesthesiology intervention, only the 12% (95% CI, 5%–25%) had a power 
≥ 80% (Imberger, Gluud et al. 2015). The same research group performed a further analysis where 
they showed that meta-analyses that surpassed their optimal information size had sufficient protection 
against overestimation of intervention effects (Thorlund, Imberger et al. 2011). Furthermore, in a 
sample of 22 cardiovascular meta-analyses reported to be conclusive, the 55% (n=12) were found to 
contain insufficient data to detect a 25% risk reduction (AlBalawi, McAlister et al. 2013).  
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Consequently, as in a single randomized controlled trial a sample size calculation is needed to 
guarantee a sufficient number of patients in order to have reliable results in detecting an effect that is 
closer to the ‘true’ one, a similar goal is needed for a meta-analysis.  
 
Random error 
If meta-analyses are small, they are likely to be updated in the future. The Cochrane Collaboration 
requires a regular updating of analyses in order to reflect the most currently research (Garner, 
Hopewell et al. 2016). This frequent updating lead to overestimate or underestimate the results since 
the type I error increase without being handled. The risk of random error increases more than 5% if 
accumulated data are analyzed during multiple up-dates (19). The more statistical tests are performed 
due to the accumulation of additional data, the higher is the probability of having a false positive or 
false negative result. This phenomenon is commonly identified as ‘multiplicity due to repeated 
significance testing’(Thorlund K, Wetterslev J et al. 2011). This increased error is analogous to the 
risk of error present when interim analyses are done in a single trial. In a single trial, adjustments are 
required for the increased random error caused by sparse data and repetitive testing. Monitoring 
boundaries are also commonly used to control the risk of random error at desired levels and to allow 
us to make inferential conclusions in the interim analysis (Bassler, Montori et al. 2008).  As well, in 
a meta-analysis such procedure should be performed. As a matter of fact, several studies have 
confirmed that meta-analyses have false negative or false positive results. In cardiovascular meta-
analyses, for instance, Albalawi et al. found that 17% of the statistically significant meta-analyses 
were false positives and 64% of those non statistical significant meta-analyses were potential false 
negatives (AlBalawi, McAlister et al. 2013). As well, Brok et al. declared that 19 out of 39 apparent 
conclusive Cochrane neonatal meta-analyses become inconclusive when the statistical analyses take 
into account the risk of random error due to repetitive testing (Brok, Thorlund et al. 2009). 
Despite the existing literature on this topic, recommendations about how taking into account the 
random error are not included neither in the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) Statement nor in the Cochrane Users Handbook (AlBalawi, McAlister et 
al. 2013). To handle the random error a technique has been suggested by Gluud C. et colleagues at 
the Copenhagen Trial Unit: The Trial Sequential Analysis (TSA) (Thorlund K, Wetterslev J et al. 
2011). This frequentistic method aim to reduce the uncertainty intrinsic in meta-analyses results, 
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providing a technique able to handle the type I and II error, combining the calculation of the required 
information size with the adjustment of the statistical threshold.  
 
The Trial Sequential Analysis – method  
The Trial Sequential Analysis (TSA) is a statistical technique developed to handle the random error 
and prevent premature statements of superiority of the experimental or control intervention or avoid 
probably falsely declarations of absence of effect in case of having too few data. TSA has two goals: 
(a) measure and account for the strength of the available evidence and (b) control the risk of type I 
error. The strength of the evidence is measured by defining a required information size while the 
control of the type I error is reached altering the way in which statistical significance is measured. 
Thus, TSA introduces the concept of the required information size (RIS) for a meta-analysis with 
adjusting the threshold for declaring the statistical significance. This technique can be viewed as more 
conservative than the conventional meta-analysis and it has been recently used in several systematic 
reviews (Bjelakovic, Gluud et al. 2014, Lee, Chan et al. 2015, Wetterslev, Meyhoff et al. 2015).  
 
The required information size for a conclusive meta-analysis 
The calculation of the required information size is similar to the sample size calculation in a single 
trial, which typically requires the expected proportion of patient with the outcome in the control group 
(or a standard deviation in case of continuous outcome), the expected relative risk reduction of the 
experimental intervention or the anticipated intervention effect (the minimum effect worthwhile for 
the patient), and the desired maximum risk of both type I error and type II error. The formula for the 
required information size is the following:  
 
Where δ is the a priori estimate of the mean difference among the two groups and σ2 is the associated 
variance. Whereas, the value of Z referred to the desired level of type I and II error.  
Heterogeneity adjustment 
A meta-analysis includes likely heterogeneity due to the included trial populations, interventions, and 
methods therefore, it is not realistic to consider homogeneous the included trials in a meta-analysis 
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(Thorlund K, Wetterslev J et al. 2011, Thorlund, Imberger et al. 2012). A meta-analysis has usually 
more variation in population and interventions, compared with a single trial. Therefore, since 
increased variation can decrease the precision of results, information size must incorporate all sources 
of that variation, including heterogeneity. It seems so reasonable that meta-analysis’ sample size 
needs to be adjusted in order to allow for the variance introduced by this heterogeneity: this is 
achieved increasing the size of the sample.  One approach for incorporating heterogeneity in 
information size is to adopt a heterogeneity -adjustment factor and multiply the information size by 
it.  
In the fixed effect model is assumed that all included trials can be view as duplicates of the same trial. 
On the other hand, in the random effect model it is assumed that all included trials come from a 
distribution of several possible trials. The variance in a random effects model is always higher and 
greater than that in the fixed model. Therefore, the heterogeneity-adjustment factor must account for 
the increase in variation that a meta-analysis incurs from going from the fixed-effect assumption to 
the random-effects assumption. An accurate adjustment can be achieved by making the heterogeneity 
adjustment factor equal to the ratio of the total variance in a random-effects model meta-analysis and 
the total variance in a fixed-effect model. The heterogeneity-adjustment factor is therefore always 
equal to or greater than 1.  
In order to adjusted the size of the sample for the amount of heterogeneity expressed by I2, the RIS 
obtained through the formula above is multiplied for 1/(1-I2).  
However, when the trial weights are not equal, using I2 will lead to an underestimation of the 
adjustment factor, and so, an underestimation of the required information size (Wetterslev, Thorlund 
et al. 2009).  
In this case, we can define a measure of diversity (D2) as the quantity which satisfies the equation:  
 
Where vR and vF represent the variances (inverse of trials’ weights) in the random and fixed models 
respectively, τ2 is the between trial variance and σ2D is the typical moment based sampling error within 
the trials. D2 can be defined as the percentage of the total variance (sum of between trial variance and 
sampling error) in a random effects model, contributed by the between trial variance. Using D2 in 
calculating the required information size in any random effects model meta-analyses seems less 
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biased than the I2 in simulation study (Wetterslev, Thorlund et al. 2009). Therefore, the required 
information size is adjusted taking into consideration this measure of diversity. 
 
The alpha-spending function and trial sequential monitoring boundaries 
The standards for testing statistical significance in meta-analyses should be, at least, equal to those of 
an RCT. Updating meta-analyses is similar to interim analyses of an RCT. In an RCT is mandatory 
to perform an interim analysis when it could be unethical to keep recruiting patients if one of the 
groups investigated (experimental or the control group) is superior to the others. When calculating 
the sample size, it should be decided the level of statistical significance we want to use as threshold 
to test when sample size has been reached. At this point, only when the size of the sample has been 
fulfilled, a two-sided p-value of less than 0.05 (test statistic z-value of ± 1.96) can be accepted as 
statistical level. There is a general consensus about the fact that the sequential testing as in an interim 
analysis increase the risk of type I error more than 5% if not handled, resulting even in a type I error 
from 10% to 30%. Therefore, the statistical level should be more conservative and restricted (less 
than the nominal p value of 0.05) before the a priori estimated sample size has been reached. Such 
adjustments can be performed through the use of sequential monitoring boundaries that function as a 
threshold for the employed test statistic. Sequential monitoring boundaries demand a conservative 
interpretation when data are sparse in a single trial, but become increasingly tolerant as more data 
accumulate and get closer to the RIS. Similar boundaries are used for cumulative meta-analysis 
updates and they are referred as trial sequential monitoring boundaries.  
The methods for adjusting the significance threshold in TSA are based on the Lan and DeMets 
approach (Thorlund K, Wetterslev J et al. 2011). Their method referred to the alpha spending 
function, which is a monotonically increasing function that can assign a maximum type I error risk at 
each significance testing according to the accrued information. As the accrued information increases, 
the size of the acceptable type I error also increases. The alpha spending function is defined from 0 
to 1, where 0 represents no patients randomized and 1 where the required information size has been 
reached. At any point between 0 and 1, the alpha spending function is equal to how much type of I 
error has been acceptable. This results in conservative boundaries when limited amount of 
information has been accumulated, i.e. early stages, and more lenient boundaries when more and 
more data are gathered. The alpha – spending function Lan DeMets provides strongly conservative p 
value closer to 0.01 at early stages of accumulated data and more lenient p values (closer to 0.05) 
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when the sample size gest closer to the required information size. Therefore, each z value of the 
monitoring boundaries corresponds to the maximal allowed cumulative type I error for that number 
of participants.  
In conclusion, the trial sequential monitoring boundaries applied on the TSA have the aim to maintain 
the overall risk of type I error ≤ 5% independently of how many times the hypothesis is repeated. The 
complex calculations for trial sequential monitoring boundaries are all automated via easy-to-use free 
software (2011), and can be performed by clinicians and clinical researchers with basic training in 
statistics. 
 
The cumulative test statistic (Z-curve) 
Once the information size is calculated, the studies are added one at a time in a chronological order 
and the results are summarized as a new study is added. At each stage the conclusiveness of the 
evidence is analyzed and provided as a z score producing a curve which is commonly named as the 
Z-curve. This statistic is given by the log of the pooled intervention effect divided by its standard 
error, and is commonly referred to as the Z-statistic or the Z-value. Under the assumption that the two 
investigated interventions do not differ (the null hypothesis) the Z-value will approximately follow a 
standard normal distribution (a normal distribution with mean 0 and standard deviation 1). The larger 
the absolute value of an observed Z-value, the stronger is the statistical evidence that the two 
investigated interventions do differ and so the less is the probability that the data come from 
population where the null hypothesis is true. The cumulative z-score estimate the random error and 
is interrelated with the trial sequential monitoring boundaries.  
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Figure 1 showed how TSA is displayed:  
 
Figure 1. Trial Sequential Analysis (taken by Imberger et al. 2016, (Imberger, Thorlund et al. 2016)) 
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To better clarify how a TSA can result, four examples with the relative interpretation are extracted 
by Brok et. al (Brok, Thorlund et al. 2009):  
 
The red line corresponds to the trial sequential monitoring boundaries, the blue line is the cumulative 
z-score over the time, the dotted black horizontal line is the conventional statistic of p = 0.05 and the 
dotted black vertical line represents the required information size.  The trial sequential monitoring 
boundaries (red) needs to be crossed by the cumulative z-curve in order to obtain reliable evidence. 
Following the explanation of the four scenarios:  
A. Non conclusive evidence: the number of participants has not reached the required 
information size yet and the z-cumulative curve has not crossed the trial sequential 
monitoring boundaries.  
B. Evidence for at least 25% relative risk reduction: the number of participants has not reached 
the information size, but the cumulative Z-curve crossed the monitoring boundary. 
C. Evidence for at least 25% relative risk reduction: the number of participants reached the 
information size and the cumulative Z-curve crossed the monitoring boundary.  
D. Evidence of less than 25% relative risk reduction: The cumulative Z-curve has not crossed 
the monitoring boundary before reaching the information size.  
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In summary, when the cumulative Z-curve (the series of Z-statistics after each consecutive trial) 
crosses the trial sequential monitoring boundary for benefit and the RIS, a sufficient level of evidence 
has been reached and no further trials may be needed to demonstrate the superiority of the 
intervention. However, if the RIS has not been crossed yet even though the monitoring boundary for 
benefit is crossed, there is sufficient certainty that the effect is beneficial for the patients but further 
trials are needed to amplify the confidence in the conclusion. On the contrary, if the cumulative Z-
curve does not cross any of the trial sequential monitoring boundaries, insufficient evidence to reach 
a conclusion can be declared and additional trials may be needed.  
 
Adjusted confidence interval following trial sequential analysis 
Having considering the adjustment of the overall type I error in significance test, some considerations 
should be done also on the construction of confidence intervals. If a meta-analysis is subjected to 
repeated statistical evaluation, it produces also a series of confidence intervals over the time and the 
probability that all of these confidence intervals will contain the ‘true’ overall effect is certainly less 
than 95%. Therefore, when a meta-analysis is subjected to repeated statistical evaluation, there is an 
exaggerated risk that the ‘naïve’ confidence intervals will yield spurious inferences.  
The confidence interval can be adjusted as the statistical significance testing by replacing the 
threshold of the conventional statistical significance with the value obtained with the statistical 
monitoring boundaries.  
 
The futility test or beta-spending function 
The TSA software allows us to even assess when an intervention unlikely have an effect as large as 
the anticipated one (Thorlund K, Wetterslev J et al. 2011, Jakobsen, Wetterslev et al. 2014). In other 
words, when an intervention has an effect that is lower in effect than those considered minimally 
important or worthwhile for the patients. When a no effect results is found, researchers need to know 
if this is related to lack of power until an adequate information size is achieved or if the intervention 
do not have the effect as large as the anticipated. The socio-economical resources can be not indeed 
wasted in unnecessary further trials.   
The software can build the ‘futility boundaries’ as a no effect threshold, which were originally 
developed in the interim analysis in RCT. They are calculated using a power function analogous to 
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the alpha-spending function for constructing the superiority and inferiority boundaries with 
application of numerical integration. This leads to early conclusion of no effect of an intervention.  
Below the futility threshold, the likelihood of a statistically significant effect is so low that becomes 
irrelevant. Therefore, the randomisation of new patients is not recommended since the intervention 
does not possess the effect wanted to be detected and further trials might be superfluous. 
 
   
 
Limitation  
Although the TSA is an easy tool to apply and it can be useful in handling the random error, it has its 
limitations. The TSA program it has been increasingly applied on dichotomous outcome however, 
less is its application on continuous outcomes. The reason for that is due to the fact that continuous 
outcomes are more complex to deal with (Guyatt, Thorlund et al. 2013).   
In the presence of different tools for the same continuous outcome, effect measures are expressed in 
standardized mean difference. The TSA program does not comprehend meta-analysis of SMDs. The 
effect size expressed in standard deviation units is not easy and clear to interpret to most of clinicians 
and is therefore prone to produce unrealistic information size requirements. As a consequence, the 
use of effect measures expressed in mean difference is the only acceptable and plausible method in 
the light of the most useful clinical interpretation.  
Another limitation is related to the right setting for type I and II errors, which is always debatable. 
The choice of a more stringent alpha level or a different level of power could vary the scenario and 
release different size of required sample. This is however true not only for the TSA approach but even 
in the process of the sample size calculation in single trials.  
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The dependence of the required information size on estimates of the proportion of events in the control 
group and on the anticipated intervention effect size can be seen limiting. Indeed, a low proportion of 
the event in the control group or small effect size would result in adjusted threshold for statistical 
significance highly conservative or less conservative in presence of larger effect size to detect. 
Moreover, adjusted for heterogeneity might be sometimes a limitation since is difficult to guess and 
estimate its value when only few trials are available.  
One other concern is the challenge of the choice of the adequate anticipated intervention effect, 
worthwhile for the patients. It should be an adequate threshold to balance intervention’s harm and 
benefits. The role of TSA is to help clinicians to create the most plausible, reliable and conservative 
scenario given a clinical question, limiting misleading interpretations. TSA can be trustful as a meta-
analysis might be if only the variables are supported by a rationale: authors should consider if the 
anticipated intervention effect is the most plausible for the patients.  Moreover, minimal anticipated 
intervention effect might be not similar across included trials. Inference on conclusiveness of a meta-
analysis can only be valid and generalized to the patients’ population for which the minimal important 
difference is referred. Therefore, TSA results are just valid under the assumption given by the clinical 
question. 
TSA can handle the random error however, other sources of bias can affect the meta-analysis results. 
Systematic biases are important variables that must be considered when assessing harms and benefits 
of an intervention. The intrinsic risk related to the flown in methodology conduction cannot be 
eliminated so far through he TSA. This analysis can be a valuable tool to prevent false negative or 
false positive results but does not in any way solve the issue of systematic bias. This is however valid 
in each situation where a recommendation has to be taken starting from primary studies.  
 
Alternative methods to the TSA – Examples 
The TSA we have explained so far is just one of the several techniques that exists in literature and 
that can control the risk of random error in the context of sparse data and repeated updates in 
cumulative meta-analysis. I am going to briefly report some examples of alternative techniques. 
However, a consensus about the necessity to use these techniques has not been reached yet: some 
authors claimed that the meta-analysis does not have usually the control of the generation of new 
evidence so that stopping rules and sequential methods are consequently not applicable. Others 
researchers support the view that a meta-analysis is useful to achieve recommendations on benefit 
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and harms of intervention so, sequential methods are instead important as for individual primary 
studies (Higgins, Whitehead et al. 2011).  Methods to avoid the random error beside the frequentistic 
Trial Sequential Analysis include the sequential meta-analysis, the law of the iterated logarithm, and 
Bayesian analyses (i.e. semi-Bayesian analyses; full Bayesian analyses). Nevertheless, consensus on 
which method is the more reliable and adequate has not been reached yet (Bender, Bunce et al. 2008, 
Higgins, Whitehead et al. 2011).   
 
• Law of iterated logarithm 
In this approach, the standardized test statistic is ‘penalized’ with a factor λ to account for the multiple 
testing and for the estimation of heterogeneity between RCTs when applied to a random effect model 
(Hu, Cappelleri et al. 2007). The adjustment factor λ is determined through simulation with the aim 
to control the significance level under different scenarios. The value of λ factor, for example, is equal 
to 1.5 when controlling the overall type I error at the desired level for a maximum of number of 
inspection in a cumulative meta-analysis up to 25. This approach however does not control the type 
II error. As a matter of fact, this method let researchers control the type I error for a broad range of 
situations simultaneously but it may have less power since it is not a method calibrated for a specific 
situation.  
 
• Sequential meta-analysis  
Sequential meta-analysis (SMA) following Whitehead’s boundaries approach (Higgins, Whitehead 
et al. 2011). In a SMA each randomized control trial contributes with two values: z, as the measure 
for the effect size in that RCT and v as the amount of information in the RCT which is proportional 
to the number of patients included. After each RCT, the total amount of information cumulates in 
Z=Ʃz and V= Ʃv. Just as with the alpha-spending and beta spending based boundaries, the sequential 
method for monitoring the amount of information produce superiority, inferiority, and futility 
boundaries. These boundaries are built through a test, called triangular test, to yield the minimum 
possible risk of committing an error (balancing the type I error and II error).  In the context of medical 
research, conventional theory does not support this balance; prevention of alpha error has always been 
considered more important. 
The advantages of this technique are: no prior estimate for total information size is necessary; 
stopping a cumulative meta-analysis for futility is an option; the power can be quantified; point and 
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interval estimates are adjusted for the multiple testing. Nevertheless, this technique does not consider 
the heterogeneity between trial and does not provide an information size.  
 
• Semi- Bayesian procedure  
The semi-Bayesian procedure allows for adding the concept of heterogeneity to the frequentistic 
sequential meta-analysis (SMA). The Bayesian theorem is proposed to make inference about the 
value of the heterogeneity: an informative prior distribution might contribute to produce a realistic 
estimate in the early stages of a sequential meta-analysis. A simulation study showed that a semi-
Bayesian approach can address the underestimation of the heterogeneity in the sequential meta-
analysis, which may lead to smaller confidence intervals (Higgins, Whitehead et al. 2011).  
 
 
• Bayesian approach  
The Bayesian approach is based on a different philosphy: it expresses results in terms of probability 
and incorporates the external evidence. Initial uncertainty is expressed thorugh a prior distribution 
about the quantities of interest. Current data and assumptions concerning how they were generated 
are summarized in the likelihood. The posterior distribution for the quantities of interest can then be 
obtained by combining the prior distribution and the likelihood. The posterior distribution may be 
summarized by point estimates and credible intervals, which look much like classical estimates and 
confidence intervals. The prior distribution may be an expression of subjective belief about the size 
of the effect (it can be based even on information from non randomized studies) whereas the 
likelihood represents both the data from the studies included in the meta-analysis and the analytic 
model (i.e. fixed or random effects) (Higgins JPT and Green S 2011).  
 
In table 1 the comparison of the rationale, advantages and disadvantages of each method.  
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METHOD RATIONALE ADVANTAGES DISADVANTAGES 
Trial Sequential Analysis 
(TSA) 
TSA is a technique that combine the required 
information size (RIS), a conventional threshold for 
a statistically significant treatment effect and the 
alpha-spending monitoring boundaries with 
adjusted statistical thresholds.  
This approach can control both the 
type I and II errors.  
It can provide an information size 
adjusted for the heterogeneity 
between trials. It can declare early 
the ‘futility’ of an intervention.  
Easy-to-use free software 
 
Continuous outcome: impossible deal 
with SMD. Challenge of defining the 
plausible parameters required for 
information size calculation. The 
process must be prospective not 
retrospective. 
 
Law of iterated logarithm The standardized test statistic is ‘penalized’ with a 
factor λ to account for the multiple testing and for 
the estimation of heterogeneity between RCTs 
when applied to a random effect model 
This approach can control the type 
I error for a broad range of 
situations simultaneously.  
This approach does not control the type 
II error: it may have less power since it 
is not a method calibrated for a specific 
situation. Dependency of the value λ on 
the number of inspections 
 
Sequential meta-analysis 
(SMA) 
Each randomized control trial contributes with two 
values: z, as the measure for the effect size in that 
RCT and v as the amount of information in it. The 
sequential method for monitoring the amount of 
information produce superiority, inferiority, and 
futility boundaries. 
 
This approach does not calculate an 
information size but it can quantify 
the power. Balance between type I 
and II errors.  
Conventional theory does not support 
this balance: prevention of alpha error 
has always been considered more 
important. Poor estimation of the 
heterogeneity assumed as in a 
conventional meta-analysis.  
Semi-Bayesian procedure A sequential meta-analysis which incorporates the 
heterogeneity. The Bayesian theorem is used to add 
a priori distribution to the frequentistic sequential 
approach.  
 
Add the concept of updating the 
heterogeneity through the Bayesian 
thinking.  
Not inform about a required 
information size. Challenge in defining 
the priori distribution for 
heterogeneity.  
Bayesian approach The Bayesian approach incorporate multiple prior 
distributions with different anticipated distribution 
of intervention effects (i.e. a skeptical, a realistic 
and an optimistic prior distributions) 
 
Results are communicated as 
probabilities. It can incorporate 
external evidence.  
Challenge of defining a specific 
alternative hypothesis, the variation in 
the prior distributions of the 
intervention effect and the 
heterogeneity. Require deep 
knowledge of statistics. 
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Case analysis 1: TSA in low back pain rehabilitation 
Method 
Case study 
We re-analysed a systematic review published by Saragiotto and colleagues in 2016 on The Cochrane 
Library which addressed the efficacy of motor control exercise as rehabilitative intervention for low 
back pain in adults (Saragiotto, Maher et al. 2016).  Among low back pain rehabilitation interventions, 
exercise has been showed having a moderate effect in reducing low back pain and motor control 
exercise is one of the most common treatment used by clinicians. This intervention consists on 
specific exercises focused on the activation of the deep trunk muscle with the aim to restore the 
control and the coordination of these muscles. The treatment is often 1-1 supervised and the program 
range from 20 days to 12 weeks, with a median of 12 sessions, from one to five per week (Saragiotto, 
Maher et al. 2016).  
Our attention was limited to pain intensity, a continuous outcome, found to be the most reported in 
low back pain clinical trials, followed by disability, range of motion, and quality of life (Castellini, 
Gianola et al. 2015). Therefore, we selected this Cochrane review as pain intensity is the primary 
outcome and effect estimates in its meta-analyses were expressed in mean difference with naïve 95% 
confidence intervals.  The first meta-analysis in the review was selected.  
 
Extraction data  
We extracted the following data from the meta-analysis: type of control intervention, time at follow 
up, population, overall meta-analysed effect and its confidence interval, heterogeneity between the 
results of the trials, and meta-analytic technique used. We searched in the review’s method section 
for the minimal important difference the authors considered as threshold for the clinically judgment 
of findings.  
 
TSA scenarios 
We conducted the analyses using individual trial data from the selected meta-analysis (Saragiotto, 
Maher et al. 2016). We considered as a standard model the Trial Sequential Analysis based on the 
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following parameters: the anticipated intervention effect defined by the authors of the review 
(Saragiotto, Maher et al. 2016);  the standard deviation of the mean difference between intervention 
groups (assumed taking into consideration the pooled meta-analysis estimates of all trials regardless 
the bias risk); an alpha level of 5%, a beta of 20%; the estimated  diversity of the meta-analysis and 
the meta-analytic model (random-effects model) as those used in the original review.  
We aimed to offer four scenarios in which a different value for each of the parameters (anticipated 
intervention effect, alpha level or type I error, beta level or type II error and the heterogeneity) would 
be tested to calculate the DARIS. We changed each parameter at a time until providing the last 
scenario as the most conservative one. Following are the amendments:  
1. The first scenario presented DARIS calculations on the basis of a smaller anticipated 
interventions effect. We chose the upper limit of the confidence interval closer to the null 
effect as the least likely possible effect and so the most conservative one. This conservative 
approach allows to comprehend whether an intervention can produce an effect, or at least, the 
least likely magnitude even though not relevant. If the null effect is included in the TSA-
adjusted confidence interval, there will be very low probability that the assessed intervention 
would have actually an effect.  
2. In the second scenario, the DARIS calculation changed according to the choice of lower alpha 
level of 1%.   
3. The third scenario showed the changes induced if the power was increased to 90%.  
4. The last scenario considered the variation of the diversity (D2) among trials. We hypothesized 
the worst estimated diversity based on the 95% confidence interval of I2 in the meta-analysis.   
 
Results 
Characteristics of the meta-analysis 
The meta-analysis included 13 randomised clinical trials with a total number of patients of 872 
suffering from chronic low back pain (Figure 1). The main intervention was motor control exercise 
while the control intervention included other exercises (i.e., general or conventional exercises, 
stretching, McKenzie). The follow up was at 3 months from randomisation. Pain intensity was 
measured with different tools, however, the review authors converted the measurements into a 
common 0 to 100 scale. Thus, the meta-analysed effect was expressed in mean difference (MD). The 
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meta-analysed effect size was  –7.53 points favoring motor control exercise with a 95% confidence 
interval from –10.54 to –4.52 points. Heterogeneity was moderate, I2 = 43%.  
The authors defined an effect clinically important when “the magnitude of the effect size was at least 
medium (>10% of the scale)”. Accordingly, they concluded that “for the outcome pain, there is low 
quality evidence (downgraded due to risk of bias and publication bias) that there is a small, but not 
clinically important, effect of motor control exercise (MCE) for reducing pain at short term (mean 
difference (MD) –7.53; 95% confidence interval (CI) –10.54 to –4.52; P value < 0.001, 13 trials) 
compared with other exercises”. 
 
 
Figure 1. Meta-analysis on the efficacy of the motor control exercise compared to other exercises on pain 
intensity as outcome.  
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Results of the TSA scenarios  
The first scenario, Figure 2, was obtained imputing the parameters adopted in the review (Saragiotto, 
Maher et al. 2016). The required information size was calculated based on an anticipated intervention 
effect of 10 point on a visual analogue scale (VAS) 0–100 (10% of the scale). The review’ authors 
identified a clinically relevant effect when an effect size >10% of the total points of the VAS tool 
measurement is obtained. Generally, a minimal important change of at least 15 points or 30% on the 
VAS as outcome measure is suggested as a meaningful effect. Nevertheless, a universal consensus 
has not been reached yet since a paper found that an analgesic effect of 10 mm on a 100 mm visual 
analogue scale can represent a ‘minimal effect’(van Tulder, Malmivaara et al. 2007). Actually, 
different clinical settings might reflect different meaningful effect and so different minimal important 
differences (Zanoli 2005). Despite the contrast in the literature, we would select 10 points out of 100 
for our measurements.  
The required information size was 323 patients. The cumulative Z-curve crossed the monitoring 
boundaries during the fourth trial and surpassed the required information size with the fifth trial.  The 
fifth trial ended up with a reliable conclusion that the experimental intervention is able to statistically 
significantly detect a clinical difference of 10 point on a VAS scale compared with the control 
intervention (other exercises). All trials reported after the fifth are unjustified as the required 
information size to detect such a difference has been already reached, along with the statistical 
significance.   
 
• Scenario 1. Anticipated intervention effect  
We set the anticipated intervention effect of 4.52 points as being the lower limit of the 95% confidence 
interval of the overall effect size in the meta-analysis. All the other parameters remained unchanged. 
The RIS increased up to 1580 patients since the effect of the intervention that we would like to observe 
was smaller. The cumulative z-curve crossed the monitoring boundaries for benefit with the fifth 
study: the intervention yielded an effect that is both statistically and clinically significant. From the 
6th to the 13th study the results were confirmed given a narrower confidence interval. Since the 
required information size has not been reached, the CI 95% had to be adjusted for the alpha spending 
function and it ranged from –11.98 to –3.07. Looking at the diversity (49%), we could conclude that 
the intervention does have an effect but there is a moderate level of heterogeneity across studies. 
Further trials are needed in order to amplify the confidence in the results. Figure 3.  
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• Scenario 2. Alpha level 
In figure 4, we run a TSA setting a lower alpha level of 1%. The scenario slightly varied. Graphically, 
the monitoring boundaries for benefit and futility had the contact point on the vertical line of RIS at 
Z=2.58. The required information size increased up to 2352 and the monitoring boundaries for benefit 
were crossed after the tenth trial. The diversity-adjusted confidence interval widened from –13.62 to 
–1.44. The null effect is still excluded therefore it confirmed that the intervention can provide an 
effect at least as the least likely effect of 4.52 points. Nevertheless, further trials are needed to reach 
a conclusion with the 95% of certainty.  
 
• Scenario 3. The beta level  
Using the beta level of 0.10 (corresponding to a 90% of power (1–β)), the diversity adjusted required 
information size increased to 2996 patients. The lower the type II error chosen, the larger is the sample 
size. In this scenario, the monitoring boundaries for benefit were surpassed with the last trial but the 
DARIS has not been reached yet. The diversity-adjusted confidence interval become wider, from –
12.28 to –2.77. Figure 5. 
 
• Scenario 4. The diversity 
In figure 6, we assume a plausible value of D2 of 59%. This percentage was selected observing the 
95% confidence interval of the heterogeneity in the meta-analysis, ranging from 20% to 59% and 
assuming its upper limit as the highest acceptable value of diversity in our analysis. The DARIS now 
became 3685 participants. The cumulative Z-curve touched only the conventional naïve statistical 
threshold but not the monitoring boundaries for benefit. Indeed, the diversity adjusted monitoring 
boundaries included the null effect ranging from –19.81 to 4.76. 
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Figure 2. Trial sequential analysis of motor control exercise versus other exercises. Outcome: pain. Original scenario. Diversity-
adjusted required information size (DARIS): minimal important difference (MID) 10 points; standard deviation of the mean 
difference of 22.77; a 5%, b 20%, and diversity 49.58%.  
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Figure 3. Trial sequential analysis of motor control exercise versus other exercises. Outcome: pain. Scenario 1. Diversity-adjusted 
required information size (DARIS): minimal important difference (MID) 4.52 points; standard deviation of the mean difference of 
22.77; a 5%, b 20%, and diversity of 49.58%. 
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Figure 4. Trial sequential analysis of motor control exercise versus other exercises. Outcome: pain. Scenario 2. Diversity-adjusted 
required information size (DARIS): minimal important difference (MID) 4.52 points; standard deviation of the mean difference of 
22.77; a 1%, b 20%, and diversity of 49.58%. 
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Figure 5. Trial sequential analysis of motor control exercise versus other exercises. Outcome: pain. Scenario 3. Diversity-adjusted 
required information size (DARIS): minimal important difference (MID) 4.52 points; standard deviation of the mean difference of 
22.77; a 1%, b 10%, and diversity of 49.58%. 
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Figure 5. Trial sequential analysis of motor control exercise versus other exercises. Outcome: pain. Scenario 4. Diversity-adjusted 
required information size (DARIS): minimal important difference (MID) 4.52 points; standard deviation of the mean difference of 
22.77; a 1%, b 10%, and diversity of 59%. 
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Discussion  
We examined different TSAs scenarios on continuous outcome and demonstrated how a range 
of possible required information size for a meta-analysis can be yielded according to plausible 
treatment effects, different degrees of heterogeneity of the effect or different levels of type I 
and II errors. The selected meta-analysis found a statistically significant but not clinically 
relevant effect of the experimental intervention. Nevertheless, the TSA performed on the 
review author’ assumption yielded a slightly different interpretation: the evidence achieved is 
enough to accept a statistical and clinical effect of 10% of the pain scale tool.  Review’ authors 
did not take into consideration the range of the 95% confidence interval which included an 
effect size of at least 10 but just the point estimate.  
Overall, the amount of certainty and the size of RIS fluctuate as the range of possible desired 
effect and assumptions changes. The RIS ranged from a number of 323 in the less conservative 
scenario to 3685 patients in the most conservative one. As well, the confidence interval 
widened when the cumulative Z-curve has not reached the RIS until including the null effect 
when a higher amount of diversity is considered. Our first four scenarios all suggested benefit 
of the intervention but for very small and likely irrelevant intervention effects seen form a 
clinical point of view.  
Anticipated a priori all the elements would avoid to fall in misleading results and lead to create 
the best plausible scenario for patient’ needs. Therefore, what it should matter is that all the 
parameters needed to calculate the RIS must be predicted during the process of a systematic 
review protocol. A prospective and a priori application should be more in line with detecting 
false positive or false negative results.  
The choice of the most plausible anticipated intervention effect, worthwhile for the patients, 
might be a challenge for clinicians and researchers since it should represent an adequate 
threshold to balance intervention’s harm and benefits (Guyatt, Oxman et al. 2011). The smaller 
is the size of the anticipated intervention effect to be detect, the higher is the demanded RIS. 
In our example, although a minimal important change of at least 15 points or 30% on the visual 
analogue scale (VAS) is usually suggested as a meaningful effect (Ostelo, Deyo et al. 2008), a 
smaller effect may be beneficial for a population in a chronic painful stage. Our choice of using 
the least likely effect of 4.52 aimed to show whether the intervention can be beneficial even of 
a smaller intervention effect and, if so, if a wider effect can be plausible.  
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Choosing a lower value of statistical threshold as 0.01 allows for a smaller risk of false positive 
results, however a concern has been arisen regarding the problem of multiplicity in systematic 
reviews (Bender, Bunce et al. 2008). As a matter of fact, the statistical threshold is rarely 
adjusted for the number of the primary outcome used, rising concerns in results interpretation. 
Lately, some authors have suggested to address this issue adjusting a priori the statistical 
threshold for the number of primary outcome assessed (Jakobsen, Wetterslev et al. 2014).  
Moreover, increase the level of the power to 90% is recommended in the view of the top of the 
hierarchy of the evidence (Garattini, Jakobsen et al. 2016).  
A degree of heterogeneity has also to be defined. It is natural to expect an additional variation 
in meta-analysis due to the wide span of patients and interventions included compared with a 
single trial. However, confidence interval of a traditional meta-analysis does not point to the 
heterogeneity and its clinical implications. It has been emphasized this concept not only 
through the TSA application but also through a new approach based on predictive confidence 
intervals been introduced recently. This reinforces the need of providing interval that includes 
the heterogeneity, being able to illustrate range of true effects expected in future settings.  
A further concern is represented by the choice of the control group: compare the experimental 
intervention towards other intervention rather than placebo or no treatment might in fact yield 
obfuscating results. Studies should compare the experimental intervention towards placebo or 
no treatment in order to be aware that the effect detected would be actually linked to the 
intervention itself, even though it seems that placebo can have a modest not meaningful effect 
on patient reported outcome as pain (Hrobjartsson and Gotzsche 2010).  The effect on pain 
varied, even among trials with low risk of bias, from negligible to clinically important.  
Other sources of bias can still remain. The systematic error can add uncertainty but results must 
be always interpreted in the view of the quality of primary studies. In rehabilitation field the 
risk of bias is still an important issue. A recent overview of reviews showed that RCTs in stroke 
rehabilitation lack of adequate quality in randomization, allocation concealment and blinding 
(patient, therapist, and assessor), which is often perceived as impossible to obtain (Santaguida, 
Oremus et al. 2012). In all scenarios we disregarded the risk of bias since the majority of the 
included trials presented high risk of bias in order not to add confounders in TSA interpretation. 
However, the intrinsic risk related to the flaws in methodology conduction cannot be eliminated 
so far: TSA can be a valuable tool to prevent false negative or false positive results but does 
not in any way solve the issue of bias. Disregarding the systematic error, our results provided 
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a useful example on how handle the risk of random error through the TSA: this methodology 
is a dynamic process which changes according to the amount of evidence already collected and 
the effect of intervention desired to detect. The scenarios obtained cannot be considered wrong 
or correct but just be different and interpreted in the light of the clinical question, taking into 
consideration the population assessed, the interventions compared and the point of view of the 
patients. Thus, TSA can be so viewed as a ‘moving target’: adding a new trial, a new scenario 
would be created because the heterogeneity between trials can be different. What is more, a 
fluctuation in the scenario is more acceptable if the conclusion would be the most plausible and 
conservative one instead of support conclusion that can be unreliable due to not adequately 
adjusted statistical significance.  
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Case analysis 2: TSA in cardiovascular diseases 
Published as: Comment on: “Cell Therapy for Heart Disease: Trial Sequential Analyses of Two 
Cochrane Reviews”. Castellini G, Nielsen EE, Gluud C. 
Clin Pharmacol Ther. 2017 Jul;102(1):21-24. 
 
A second case analysis was made analysing the use of TSA on cell therapy for heart diseases 
by Fisher and colleagues (Fisher, Doree et al. 2016). The present article discusses the 
usefulness of Trial Sequential Analysis and its dependence on the choice of the parameters for 
calculation of the required information size and the adjacent monitoring boundaries, and 
comments on the approach by Fisher et al..  
 
Comment 
The usefulness of TSA is closely related to the choice of the assumed parameters for the 
calculation of the required information size and the adjacent monitoring boundaries. The 
calculation of the required information size for a dichotomous outcome is comparable to the 
sample size calculation in a single trial and requires assumptions of the expected proportion of 
patients with the outcome in the control group, the assumed risk ratio reduction of the 
experimental intervention, the desired maximum risks of both type I error and type II error, and 
the degree of heterogeneity.  
Fisher et al. conducted Trial Sequential Analysis (TSA) on two Cochrane systematic reviews 
assessing bone marrow-derived cells for patients with acute myocardial infarction or heart 
failure (Fisher, Doree et al. 2016). The review authors highlighted that the effects of cell 
therapy as resulted in their systematic reviews could have been inflated by the underpowered 
meta-analyses (Fisher, Doree et al. 2016). In order to reduce the risk of random errors, Fisher 
et al. applied the TSA method on two dichotomous outcomes: all-cause mortality for both 
conditions; and rehospitalisation of the patients with heart failure.  
We endorse the use of TSA method in systematic reviews, but we have some concerns 
regarding the parameters chosen by Fisher et al.. Below, we discuss each assumed parameter 
used to perform TSA on the outcome all-cause mortality for heart failure patients, but our 
considerations apply to all Fisher et al.’s performed TSAs on dichotomous outcomes. 
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The chosen proportion of death for the control group is 15%. This matches well with the 
observed proportion of deaths in Fisher et al.’s meta-analysis (15.9%; 50/315 patients in the 
control group). Thus, we do not contest their choice.  
Fisher et al. anticipated an intervention effect of 35% risk ratio reduction (RRR) and justified 
this choice providing a reference to an equivalent RRR, associated with percutaneous coronary 
intervention for acute myocardial infarction (Hartwell, Colquitt et al. 2005). However, there 
are mismatches between this publication and the meta-analysis by Fisher et al. in terms of the 
patients and the interventions assessed. Hence, we do not know the real effect of the 
intervention. Therefore, it is important to choose the utmost possible realistic or plausible 
intervention effect in order not to ‘falsely’ lower the required information size which in turn 
may overestimate the ‘proof’ of the observed RRR. It is likely that the vast majority of 
interventions (over 95% of all interventions assessed) do not seem to have any positive 
intervention effects at all (Ioannidis 2005). Hence, a RRR of 10%, 15%, or 20% might have 
been a better choice. A 35% RRR seems unrealistically large and not plausible for the outcome 
death. Furthermore, a RRR of 25%, used by the authors for a sensitivity TSA, also seems 
unrealistic. 
Fisher et al. selected an alpha level of 0.05 (type I error). The choice of a type I error ought to 
reflect the risks of multiplicity in systematic reviews following the number of the primary 
outcomes (Bender, Bunce et al. 2008). The direct consequence of multiplicity due to multiple 
outcomes is erroneous yield of conclusions in favour of tested interventions if any of the 
primary outcomes reaches statistical significance by chance alone. Referring to Fisher et al.’s 
most recent meta-analysis published in 2015, we assumed that only two primary outcomes 
(mortality and rehospitalisation) were considered (Fisher, Doree et al. 2015). This is why, by 
adjusting the threshold for significance according to the defined a priori number of primary 
outcomes, we can deal with multiplicity (Jakobsen, Wetterslev et al. 2014). This approach 
consists of dividing the alpha level for the value half away between 1 (no adjustment) and the 
number of the outcomes. So, for the review in question, this would be 0.05/1.5 resulting in a 
type I error of 0.033. 
The beta level or type II error that Fisher et al. used was 20%, equal to a power of 80%. When 
we are looking at the top of the hierarchy of the evidence (Fisher, Brunskill et al. 2014), a 
power of 90% (or more) seems better in securing an observation of the postulated effect if 
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present. This is a precaution against the risk of discharging a valuable treatment based on too 
little evidence. 
Heterogeneity is another issue which needs to be taken into consideration. Fisher et al. found 
an I2 equal to 0% in their meta-analysis and used this parameter for calculating the 
heterogeneity-adjusted RIS in their TSA. Nevertheless, an I2 estimated among trials in an early 
meta-analysis can be defective (Wetterslev, Thorlund et al. 2009). The I2 estimate might be 
unreliable due to lack of power and precision. Therefore, it can fluctuate over time. This is why 
we suggest assuming a higher heterogeneity in a TSA than the observed. This issue was not 
addressed by Fisher et al. Moreover, diversity (D2) seems a more rational approach as it 
provides more valid results before interventions are turned into treatments (Wetterslev, 
Thorlund et al. 2009).   
We replicated the TSA on all-cause mortality for heart failure patients done by Fisher et al. 
(Fisher, Doree et al. 2016). We calculated the diversity-adjusted required information size 
(DARIS) using a control event proportion of 15%, an anticipated risk relative reduction of 
35%, a type I error of 0.05, a type II error of 0.20, and a D2 of 0%. The DARIS was 1,236 
patients, i.e., much higher than the already accrued number of only 759 patients (Figure 1 – 
Scenario A). The cumulative Z-curve surpassed the traditional monitoring boundary during the 
fifth trial and touched the trial sequential monitoring boundary for benefit at the eleventh trial. 
Fisher et al. concluded that the TSA results showed evidence of a reduction of the risk of 
mortality when cell therapy was administered in heart failure patients.   
We conducted four TSAs scenarios changing one parameter needed to calculate the DARIS at 
a time (anticipated intervention effect, alpha and beta levels, and heterogeneity). We consider 
our values to be more plausible.  
Figure 1, scenario B. Using a risk relative reduction of 20% and with all the other parameters 
unchanged from scenario A, we obtained a DARIS of 4,074 patients. The cumulative Z-curve 
surpassed the conventional statistical threshold at the fifth trial, but the last trial did not cross 
the monitoring boundary for benefit. The RRR is 0.42 and the TSA-adjusted confidence 
interval is between 0.16 and 1.09. The assumption of a smaller RRR alone leads to a conclusion 
less favorable towards cell therapy.  
Figure 1, scenario C. Adjusting the alpha level for multiplicity to 0.033, we obtained a DARIS 
of 4,590 patients. The TSA-adjusted confidence interval widens to 0.07 to 2.34. We do not 
have enough information to provide a reliable conclusion of the effect of the intervention.  
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Figure 1, scenario D. Setting the power to 90%, we obtained a DARIS of 6,048 patients. The 
cumulative Z-curve is far from any monitoring boundary for benefit. 
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Figure 1. Trial Sequential 
Analysis of cell therapy 
versus no cell therapy 
(placebo or no intervention) 
for heart failure on all-cause 
mortality. Scenario A -D. 
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Figure 2. We assumed a plausible value of D2 of 31%. This percentage was selected, observing 
the 95% confidence interval of the heterogeneity in the meta-analysis, ranging from 0% to 31% 
and assuming its upper limit as value in our analysis. We obtained a DARIS of 8,765 
participants. The cumulative Z-curve crossed the conventional statistical threshold, but it was 
far from the monitoring boundaries for benefit, futility, and harm. The RRR of 0.42 does not 
change and the TSA-adjusted confidence interval remains wide, from 0.07 to 2.34.   
 
 
Figure 2. Trial Sequential Analysis of cell therapy versus no cell therapy (placebo or no 
intervention) for heart failure on all-cause mortality. The diversity adjusted information size 
(DARIS) was calculated based on a control event propotion of 15%, a relative risk reduction 
(RRR) of 20% an alpha (a) of 0.033, a beta (b) of 0.10, and diversity (D) of 31%. 
 
In addition, Fisher et al. declared that “no adjustment for risk of bias” was performed. We 
should underline that TSA cannot adjust for risk of bias at all; it can only offer a method to 
control the risks of random errors. When the individual trials are at high risk of bias, the 
influence of systematic errors should be considered when interpreting the results. This makes 
the conclusions drawn by Fisher et al. on their TSA even less plausible.   
In conclusion, the TSA is a powerful method which can inform readers and researches whether 
a sufficient amount of information has been accrued for a conclusion to be made, and it can 
roughly estimate how much more information is needed to accept or discard an intervention 
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effect (Kulinskaya and Wood 2014). TSA is not able to wash away systematic errors. 
Moreover, to provide the most realistic scenario for clinicians and patients, we strongly 
recommend deciding the assumptions and parameters for the calculation of the DARIS and its 
adjacent monitoring boundaries a priori. We did not do so in the present analyses, and critics 
may argue that the parameters we chose were too conservative. However, due to both risks of 
random errors and systematic errors in the conducted randomised clinical trials on stem cells 
for patients with heart failure, we need further randomised clinical trials conducted in 
accordance with the SPIRIT Statement.  
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General conclusion 
Trial Sequential Analysis (TSA) is a statistical technique developed to control the risks of 
random errors and prevent premature conclusions of statistical superiority, no effect, or 
inferiority of experimental interventions in meta-analyses (Thorlund K, Wetterslev J et al. 
2011). The TSA is a powerful technique which can inform readers and researches if a relevant 
amount of information has been accrued to make a conclusion. It can estimate how much more 
information is needed to accept or discard an intervention effect but cautiousness in defining 
the parameters should be taken (Kulinskaya and Wood 2014). Indeed, the usefulness of TSA 
is closely related to the choice of the assumed parameters for calculation of the DARIS and its 
adjacent monitoring boundaries. Therefore, to provide the most realistic scenario for clinicians 
and patients, deciding the assumptions and parameters of the TSA a priori is strongly 
recommended. What is to remember, however, is that TSA is not able to wash away systematic 
errors.  
For each meta-analysis answered a clinical question, there should be parameters which best fit 
for it: this chapter offers a more didactic way to figure out how specific parameters can change 
the interpretation of findings according to what we want to detect. TSA can be trustful as a 
meta-analysis might be if only the variables are supported by a rational, given a clinical 
question: authors should consider if the anticipated intervention effect is the most plausible for 
the patients assessed and which is the degree of certainty one wants to detect.  
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Chapter 2. Precision of results: a focus on the GRADE system  
 
Introduction 
Since 2008, the GRADE approach (Grading of Recommendations Assessment, Development and 
Evaluation) has gained its momentum as an international standard to assess the strength of body of 
the evidence, informing transparently and explicitly the confidence that researchers have on the 
results. (Balshem, Helfand et al. 2011).   
GRADE is a method for rating the quality of evidence in systematic reviews and grading strength of 
recommendations in guidelines. The m can be applied to several clinical questions ranging from 
diagnosis, prevention, therapy and to public health and health system questions. The add value of this 
system is that it offers a transparent and structured process for developing and presenting evidence 
summaries for systematic reviews and guidelines in health care and for carrying out the steps involved 
in developing recommendations.  
The GRADE introduces the concept of the “quality of the evidence” which is a judgment about the 
extent to which we can be confident that the estimates of the effect are correct. Using the GRADE 
system, this judgment is carried out for each critical or important outcome for a patient and are based 
on: the study design (randomized trial vs observational study), the risk of bias, the precision of the 
overall estimate across studies, the consistency of the results across studies, the indirectness of results 
and the publication bias.  
The GRADE approach is based on two steps:  
1. Assessment of the body of the evidence, i.e. systematic reviews;  
2. Formulation of recommendations. 
Following, the schematic view of the GRADE process of grading the quality of the evidence and the 
strength of recommendations (Guyatt, Oxman et al. 2011): 
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Once systematic review or guideline authors decide the questions in terms of population, outcome, 
comparison and intervention (PICO), the process needs to define the critical or important outcomes 
for the patients. Then, the data from the eligible studies are used to generate the best estimate of the 
effect on each patient important outcome.  
 
GRADE approach in systematic reviews 
GRADE’s approach begins with the study design. The randomized controlled trial design starts as 
high quality evidence whereas the observational study as low quality evidence.  
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The GRADE working group has selected five factors that might lower the quality of the evidence and 
three factors that might increase the quality. GRADE’s approach to rating confidence in effect 
estimates (quality of evidence) is shown in the following figure:  
 
In the process of the quality of the evidence’ assessment, authors use this approach to rate the quality 
for each outcome across studies in a systematic review.  GRADE is “outcome centric”, this means 
that each single important outcome is rated for quality and the quality might be different form one 
outcome to another. Before assessing the quality of the evidence, systematic reviewers and guideline 
developers should identify all potential patient important outcomes, including benefits, harms, and 
costs. Reviewers will then assess the quality of evidence for each important outcome.  
As we can see in the figure above, the GRADE approach results in an assessment of the quality of a 
body of evidence as high, moderate, low, or very low which have the following meanings (Balshem, 
Helfand et al. 2011):  
- High: we are very confident that the true effect lies close to that of estimate of the effect  
- Moderate: we are moderately confident in the effect estimate. The true effect is likely to be 
close to the estimate of the effect but there is possibility that it is substantially different.  
- Low:  our confidence in the effect estimate is limited. The true effect may be substantially 
different from the estimate of the effect 
- Very low: We have very little confidence in the effect estimate. The true effect is likely to be 
substantially different from the estimate of the effect.  
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The 5 domains which can lower the quality  
1. Risk of bias  
This domain concerns with the internal validity of study results. Risk of bias refers to systematic 
deviation of the results which is caused by the way the study is designed or conducted. In clinical 
trial, results can be inflated by particular source of bias and vary in direction: bias due to a particular 
design flaw (e.g. lack of blinding) may underestimate an effect in one study but overestimate it in 
another study.  Systematic bias in randomized trials include allocation concealment, blinding 
(participants, personnel or outcome assessor), loss to follow-up and intention to-treat principle in 
results analyses. Moreover, limitations might include stopping early for apparent benefit and selective 
reporting of outcomes according to the results. Regarding observational studies, results might be 
inflated due to inappropriate controls and or inadequate adjustment for prognostic imbalance (Guyatt, 
Oxman et al. 2011).  
2. Inconsistency  
Inconsistency refers to differences of the magnitude of intervention effects across studies. In 
systematic reviews, authors should investigate the reason of these differences: explanations can lie in 
the population (e.g, age, severity of disease), interventions (e.g. frequency, doses), outcomes (e.g. in 
follow up) or study methods (e.g. risk of bias). If one or more categories provide an explanation, 
different estimates should be discussed across patients, outcomes or interventions. If large variability 
(often referred to as heterogeneity) in magnitude of effect remains unexplained, the quality of 
evidence decreases. Judgment of the extent of heterogeneity is based on similarity of point estimates, 
extent of overlap of confidence intervals, and statistical criteria including tests of heterogeneity and 
I2 (Guyatt, Oxman et al. 2011). 
3. Indirectness - Directness of Evidence generalizability, transferability, applicability 
Direct evidence is when research directly compares the interventions in which we are interested on 
the population in which we are interested and measures the outcomes important to patients. When 
population, interventions, outcomes are different from those we are interested in we have indirectness 
(Guyatt, Oxman et al. 2011).  
Indirectness can be about:  
1. populations/patients (e.g. interested in children found adults population) 
2. interventions (e.g. interested in high dosage, found low dosage, interested in long treatment, 
found short) 
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3. outcomes (e.g hip fracture vs bone density; interested in long term but found short term 
results). 
4. interventions that have not been tested in head-to-head comparisons.  
4. Imprecision  
In a systematic review, imprecision refers to the confidence in the estimates of effect, whose extent 
is mostly captured by the confidence interval. Conceptually, the confidence interval (typically 95%) 
is the range in which the truth probably lies. In other words, it is the range of results which would 
include the true underlying value if an experiment is repeated numerous times and the confidence 
interval recalculated for each experiment.  
When the confidence interval around the estimate of treatment effect is not sufficiently narrow, the 
quality of the evidence is rated down by one level whereas if the confidence interval is very wide, 
rated down by two levels. However, the confidence interval alone is not sufficient to judge 
imprecision because trials with small numbers of events may get the results fragile. Therefore, other 
two elements are to consider: (1) a clinical threshold of benefit or harm; (2) the calculation of the 
optimal information size. GRADE working group authors suggest: “if the total number of patients 
included in a systematic review is less than the number of patients generated by a conventional sample 
size calculation for a single adequately powered trial, consider the rating down for imprecision.” To 
calculate the optimal information size, Guyatt et al. suggest to use online calculators (i.e. 
http://www.stat.ubc.ca/|rollin/stats/ssize/b2.html.) or, as an alternative, they provide a figure 
(reported on the right) to consult in order to determine the optimal information size for risk relative 
reductions of 20%, 25% and 30% across varying control event rates. 
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Generally, this is the rule suggested in Guyatt et al. (Guyatt, Oxman et al. 2011) for dichotomous 
outcomes:  
- If the optimal information size criterion is not met, rate down for imprecision, unless the 
sample size is very large (at least 200, and perhaps 4000 patients).  
- If the optimal information size criterion is met and the 95% confidence interval excludes no 
effect (i.e. confidence interval around risk ratio excludes 1.0) precision is adequate.  
- If the optimal information size criterion is met, and confidence interval overlaps no effect (i.e. 
confidence interval includes risk ratio of 1.0), rate down if confidence interval fails to exclude 
important benefit or important harm. 
 
5. Publication bias  
Studies suggesting a beneficial intervention effect or a larger effect size might have a higher chance 
to be published, while negative intervention effects might remain unpublished. In this situation, a 
systematic review of the published studies could identify a spurious beneficial intervention effect, or 
miss an important adverse effect of an intervention. Publication bias refers to the possibility that 
results are inflated by only positive studies, industrial sponsored trials or early studies which can 
overestimate effects when ‘‘negative’’ studies face delayed publication. Usually, publication bias is 
assessed through a funnel plot showing asymmetry of the included studies: smaller studies might be 
not symmetrically distributed around either the point estimate (dominated by the larger trials) or the 
results of the larger trials themselves (Guyatt, Oxman et al. 2011).  
 
The three domains which can raise the quality in observational studies are: 
1. Large magnitude of effect (RRR 50%/RR 2) 
2. Dose response relation 
3. Residual confounding  
 
The endpoint of the GRADE approach: Evidence Profile and Summary of Findings Table  
The Evidence Profile table and the Summary of Findings table are two approaches through which the 
GRADE working group intends to present the quality of the available evidence and the judgments 
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related to the quality rating.  These two approaches have different purposes and are directed to 
difference audiences: 
Evidence profile table is a summary of the evidence for a given question with a detailed quality 
assessment and an explicit judgment of each factor which determines the quality. It is always used by 
guideline producers to agree about the judgments underling the quality assessment.  
Summary of Findings (SoF) tables presents, for each relevant comparison of alternative management 
strategies, the quality rating for each outcome, the best estimate of the magnitude of effect in relative 
terms, and the absolute effect that one might see across subgroups of patients with varying baseline 
or control group risks. The SoF does not include the detailed judgment and it is prepared within a 
systematic review.  
 
GRADE and TSA in systematic reviews and meta-analysis 
A recent publication by Jakobsen and colleagues suggest to include the TSA as a supplement of 
imprecision assessment of the GRADE approach (Jakobsen, Wetterslev et al. 2014).  Both TSA and 
GRADE take into consideration the imprecision domain in systematic reviews. Consequently, to 
investigate how TSA can yield a different interpretation of this domain in meta-analysis results 
compared with those obtained by the GRADE approach could captivating.  
Imprecision, along with risk of bias, are the most common domains associated with GRADE 
downgrading of overall evidence quality or certainty (Pandis, Fleming et al. 2015). Systematic 
reviews employ multiple parameters to evaluate imprecision: accrued sample size, required or optimal 
information size (OIS) (meta-analytic ‘sample size’), alpha, beta, confidence intervals of the overall 
effect, and specified critical margins of ‘no effect’, ‘important benefit’ or ‘important harm’ (Guyatt, 
Oxman et al. 2011). GRADE combines all components in a simple rule: “If the optimal information 
size criterion is not met, rate down for imprecision, unless the sample size is very large (at least 2000, 
and perhaps 4000 patients); if the optimal information size criterion is met and the 95% confidence 
interval (CI) excludes no effect, do not rate down for imprecision; if the optimal information size 
criterion is met, and the 95% CI overlaps no effect, rate down for imprecision if the CI fails to exclude 
important benefit or important harm.” (Schünemann H 2013, Schunemann 2016) 
The GRADE rules of thumb are based on broad assumptions and generalities across medical fields. 
The most relevant advantage is facilitating the trustworthiness of recommendations, enabling users 
to reflect on the sample as a basis for recommendations. However, rating imprecision in isolation, 
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without a formal evaluation of accrued sample and magnitude of effects (e.g. benefits or harms), 
would be hazardous (Anttila, Persson et al. 2016, Schunemann 2016). Because random errors are a 
frequent cause of erroneous estimation of treatment effect, often in small meta-analyses (Imberger, 
Thorlund et al. 2016), several authors have highlighted the need to adjust the statistical threshold and 
calculate a required information size in meta-analyses to increase the validity and reliability of its 
conclusions (Thorlund, Imberger et al. 2011, Jakobsen, Wetterslev et al. 2014).  Among the 
techniques that can control for the risk of random error in the context of sparse data (Higgins, 
Whitehead et al. 2011), Trial Sequential Analysis (TSA) is often used to control for spurious findings 
(Simmonds, Salanti et al. 2017, Wetterslev, Jakobsen et al. 2017) and is currently suggested as a 
potential supplement for a more throughout assessment of imprecision when using the GRADE 
system (Jakobsen, Gluud et al. 2014).  
The abstract was presented as oral communication at the 8th International Conference of EBHC 
Teachers & Developers hosted by GIMBE Foundation in October 2017 in Taormina (Italy) and at the 
25th Cochrane Colloquium in Edinburgh (UK) in September 2018. 
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Imprecision Assessment: A Comparison between the GRADE System and the 
Trial Sequential Analysis 
Published as: Castellini G, Bruschettini M, Gianola S, Gluud C, Moja L. Assessing imprecision in 
Cochrane systematic reviews: a comparison of GRADE and Trial Sequential Analysis.  
Syst Rev. 2018;7(1):110. Published 2018 Jul 28. doi:10.1186/s13643-018-0770-1 
Abstract  
Background The evaluation of imprecision is a key dimension of the grading of the confidence in 
the estimate. GRADE gives recommendations on how to downgrade evidence for imprecision, but 
authors vary in their use. Trial Sequential Analysis (TSA) has been advocated for a more reliable 
assessment of imprecision. We aimed to evaluate reporting of and adherence to GRADE and to 
compare the assessment of imprecision of intervention effects assessed by GRADE and TSA in 
Cochrane systematic reviews. 
Methods Cross-sectional study. We included 100 Cochrane reviews irrespective of type of 
intervention with a key dichotomous outcome meta-analyzed and assessed by GRADE. Methods and 
results sections of each review were assessed for adequacy of imprecision evaluation. We reanalysed 
imprecision following the GRADE Handbook and the TSA Manual.   
Results Overall, only 13.0% of reviews stated the criteria they applied to assess imprecision. The 
most common dimensions were the 95% width of the confidence intervals and the optimal 
information size. Review authors downgraded 48.0% of key outcomes due to imprecision. When 
imprecision was reanalysed following the GRADE Handbook, 64% of outcomes were downgraded. 
Agreement between review authors’ assessment and assessment by the authors of this study was 
moderate (kappa 0.43, 95% confidence interval [CI] 0.23 to 0.58). TSA downgraded 69.0% outcomes 
due to imprecision. Agreement between review authors’ GRADE assessment and TSA, irrespective 
of downgrading levels, was moderate (kappa 0.43, 95% CI 0.21 to 0.57). Agreement between our 
GRADE assessment following the Handbook and TSA was substantial (kappa 0.66, 95% CI 0.49 to 
0.79).  
Conclusions In a sample of Cochrane reviews, methods for assessing imprecision were rarely 
reported. GRADE according to Handbook guidelines and TSA led to more severe judgement of 
imprecision rather than GRADE adopted by reviews’ authors. Cochrane initiatives to improve 
adherence to GRADE Handbook are warranted. TSA may transparently assist in such development. 
Keywords: Review, Meta-analysis, Bias, Confidence Intervals, Epidemiologic methods 
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Aim 
We conducted an empirical assessment of a sample of Cochrane systematic reviews (SRs) in which 
the focus was imprecision as a threat to validity. We investigated the reporting of and the adherence 
to GRADE in assessing imprecision, the expected and observed downgrading of evidence, and the 
reasons for downgrading. Moreover, after having estimated the Cochrane authors’ handling of 
GRADE and imprecision, we applied ourselves GRADE assessment of imprecision following the 
GRADE Handbook guidelines (Schünemann H 2013) and TSA following the TSA Manual (Thorlund 
K, Wetterslev J et al. 2011) to independently replicate the assessments of imprecision. 
 
Methods 
Search strategy 
For this cross-sectional study, Cochrane systematic reviews were sampled from the Cochrane 
Database of Systematic Reviews (Cochrane). We purposively retrieved 100 reviews in reverse 
chronological order starting at the time of our search, 23 February 2017. The most current reviews, 
i.e. the latest published,  were selected to ensure inclusion of the most recent publications following 
the introduction of GRADE (Guyatt, Oxman et al. 2008) and its detailed guidance (Guyatt, Oxman 
et al. 2011, Guyatt, Oxman et al. 2011, Schünemann H 2013, Schunemann 2016). The nature of this 
study was explorative and no sample size was calculated.  
 
Eligibility criteria and study selection 
Titles and abstracts were screened for eligibility in their chronological order of publication. Full texts 
were retrieved and evaluated against our inclusion criteria by one investigator. A second investigator 
checked all eligible records, and a final list was agreed. Cochrane systematic reviews were considered 
eligible for inclusion if: (1) they were reviews of interventions; (2) they meta-analyzed at least two 
randomized controlled trials for a dichotomous outcome; 3) the dichotomous outcome was listed in 
the summary of findings (SoF) table.  
We excluded diagnosis/prognosis reviews, studies on health service organisation, overviews of 
systematic reviews and network meta-analyses, and meta-analyses with only uninformative trials (i.e. 
with no events). The unit of analysis was one outcome for each review: either the primary outcome 
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or the first outcome meta-analyzed and listed in the SoF. We reasoned a priori that this outcome 
would most likely provide the basis for calculating sample size and orient clinical decision-making. 
 
Data collection 
General characteristics and reporting of GRADE in Cochrane reviews 
Two investigators independently extracted data from all selected reviews. A third investigator 
resolved disagreements. We used a standardized ad hoc data collection form that we piloted on the 
first 5 Cochrane reviews and then revised according to problems identified. For each review we 
sought general information (e.g. author, contact author country, Cochrane review group name, new 
or updated review, type of intervention - pharmacological or non-pharmacological).  
 
We evaluated what authors reported in the review methods section for assessment of imprecision. In 
particular, we wanted to determine whether the authors stated they had assessed imprecision and how 
(e.g. required or optimal information size, benefit/harm thresholds, width of 95% confidence intervals 
(CI), use of TSA) and in what way they planned to use imprecision assessment (e.g. evidence is 
downgraded when the required or optimal information size is not reached). We then recorded the 
grading of imprecision of the outcome selected from the SoF table and the reasons for downgrading. 
In some cases, we searched other sections of the full-text article for additional information. 
 
Adherence to GRADE  
We judged whether the review authors adhered to GRADE guidance for downgrading or non-
downgrading evidence for imprecision. To determine whether the imprecision evaluation was 
appropriate (e.g. expected and observed downgrading of evidence), we consulted the instructions for 
downgrading for imprecision and re-assessed the optimal information size as suggested by the 
GRADE Handbook guidelines (Chapter 5.2.4.2 Imprecision in in systematic reviews in Schünemann 
H). For each review, we calculated the optimal information size in which we assumed an alpha of 
0.05, a beta of 0.20, an a priori anticipated intervention effect – e.g., risk ratio reduction (RRR) or 
improvement – defined using the clinically relevant threshold reported by the review authors or, when 
not stated, the RRR suggested by GRADE authors, as a default threshold of 25% (Guyatt, Oxman et 
al. 2011), and the control event proportion of the meta-analysis. We used the normogram for events 
proposed by Guyatt et al. to determine the expected optimal information size (Guyatt, Oxman et al. 
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2011). Finally, we determined whether the reviewers incorporated and reported the imprecision 
assessment in their evaluation of evidence quality.  
 
Agreement between GRADE assessment of imprecision and TSA 
We evaluated agreement between downgrading of evidence as proposed in the original reviews and 
those performed by the authors of this article, and that resulting from TSA. For each review, we 
performed overarching TSAs: for each outcome, we re-analysed all trials that had been originally 
included in the meta-analysis. Data were synthesized using the same effect size with its 95% 
confidence interval (CI) and the same meta-analytic technique (i.e., random effects or fixed effect 
models), applying the reported statistical heterogeneity (I2 value). Each trial was sequentially added 
in the TSA by publication year; this created a series of time points that formed the basis of the 
cumulative analysis. All TSAs were performed using TSA software (v 0.9.5.5 Beta) (2011). For each 
review, we calculated the diversity-adjusted required information size (DARIS) using, again, an alpha 
of 0.05, a beta of 0.20, a RRR as defined by the review authors or the default threshold of 25%, and 
the control event proportion. When a random effects model was chosen, between-trial variability was 
taken into account by adjusting the required information size with the diversity (D2) originating from 
the meta-analysis of trials (Wetterslev, Thorlund et al. 2009). The Lan-DeMets trial sequential 
monitoring boundaries based on O’Brien-Fleming α-spending function was used (Wetterslev, 
Thorlund et al. 2008, Wetterslev, Jakobsen et al. 2017). The cumulative Z-curve (the series of Z-
statistics after each consecutive trial) was calculated and plotted against these monitoring boundaries.  
In our primary analysis, we assumed for TSA minimal important or realistic anticipated intervention 
effects for all outcomes. If, following TSA methods (Jakobsen, Wetterslev et al. 2014), none of the 
sequential boundaries for benefit, harm or futility were crossed, imprecision was downgraded by two 
levels (Additional file 1 reports TSA judgement).  
 
Data analysis  
The data were summarized with descriptive statistics. Absolute and relative frequencies for 
categorical items and median and interquartile range (IQR) for continuous items were used. We 
reported adherence to GRADE through figures and agreement between the assessments involving the 
use of GRADE and TSA in contingency tables, with calculation of Cohen’s kappa (Watson and Petrie 
2010).  
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Agreement between GRADE imprecision assessment performed by the review authors and TSA was 
rated on the ordinal scale as: 0, not downgraded; 1, downgrade by 1 level; 2, downgrade by 2 levels. 
Moreover, we dichotomized the ordinal scale into ‘downgraded’ and ‘not downgraded’ for 
imprecision to evaluate the agreement irrespective of level of downgrading.  Interpretation of 
agreement strength (k-values) was made according to the scale devised by Landis and Koch: <0.00 
poor, 0–0.20 slight, 0.21-0.40 fair, 0.41-0.60 moderate, 0.61-0.80 substantial, 0.81-1.00 almost 
perfect (Landis and Koch 1977). 
Univariable logistic regression was performed to investigate the impact of variables on downgrading 
for imprecision (dependent variable): Cochrane Group, the country of the contact author, type of 
intervention, number of patients included in the meta-analysis, heterogeneity among trials, and meta-
analysis technique (random effects or fixed effect models). Each method, GRADE assessment of 
imprecision by the review authors, GRADE performed by the authors of this article, and TSA, was 
separately assessed and one variable evaluated at a time. The impact of these three variables on the 
agreement between the methods was then tested.  
For hypothesis testing, a probability value of <.05 was considered statistically significant. All 
statistical tests were 2-sided. Stata statistical software was used for all statistical analyses 
(StataCorp.2003.). 
 
Sensitivity analysis  
TSAs were replicated using RRRs of (A) 20% and (B) 30%, keeping all other assumptions the same. 
The concordance between the GRADE judgement on imprecision by the review authors and the TSA 
assessment was calculated irrespective of the levels of downgrading to determine whether the choice 
of the anticipated intervention effect affected the agreement.  
 
Results  
Characteristics of Cochrane reviews 
We included 100 out of 216 potentially eligible Cochrane systematic reviews published in 2017 
(issues 1 and 2) and 2016 (issues 12 and 11) of The Cochrane Library (Fig. 1), involving 36 (67.9%) 
out of 53 different Cochrane groups. Figure 1 shows the flow chart of reviews’ selection with reasons 
for exclusion. Additional file 2 reports included reviews and their main characteristics. 
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The three most active review groups were Pregnancy and Childbirth (n = 13 reviews), Neonatal (n = 
11 reviews), and Heart (n = 8 reviews). The corresponding authors were based in the United Kingdom 
(n = 28 reviews), Australia (n = 15 reviews), or Canada (n=11 reviews). Sixty-one Cochrane reviews 
were updates of previous reviews. Table 1 presents the general characteristics of the reviews.  
 
 
Figure 1. Flow chart of systematic review. 
 
96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. General characteristics of the 100 Cochrane systematic reviews.  
 
Overall, meta-analyses on the selected outcome were performed with a median of 5 randomized 
clinical trials (RCTs) (IQR, 2 to 9 RCTs; range, 2 to 30 RCTs). Most meta-analyses (81.0%) reported 
an effect measure expressed as risk ratio, 17.0% used the odds ratio, and only 2.0% reported the risk 
difference. Half of the SRs (51.0%) achieved statistically significant results according to the naïve 
95% CI. The median heterogeneity of the meta-analyses was 12.0% (IQR, 0.0% to 49.0%; range, 
0.0% to 98.0%). 
 
Reporting of GRADE in Cochrane reviews 
Nearly all (96.0%) of the reviews referred to GRADE in their methods section (Table 2). Of the four 
reviews that did not mention GRADE but performed it, two presented some information in the 
discussion. Very few (13.0%) of the reviews that graded the evidence reported the criteria they 
applied to assess imprecision. The most common imprecision components were width of 95% CI 
Characteristics Value (no. of 
reviews) 
No. of countries (no. total) 22 
Top five countries 
- United Kingdom 28 
- Australia 15 
- Canada 11 
- China 7 
- Italy 6 
No. of Cochrane groups (no. total) 36 
Top five Cochrane groups 
- Cochrane Pregnancy and Childbirth Group 13 
- Cochrane Neonatal Group 11 
- Cochrane Heart Group 8 
- Cochrane Airways Group 6 
- Cochrane Gynecology and Fertility Group 6 
Status of systematic reviews (no./out of 100) 
- Updated 61 
- New 39 
Type of intervention (no./out of 100) 
- Pharmacological 54 
- Non-pharmacological 46 
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(8.0%) and optimal information size referred to participants (4.0%). Ten reviews combined at least 
two criteria to assess imprecision. Only two reviews reported a comprehensive list of reasons behind 
imprecision judgment, thus allowing for full replication. Two other reviews planned and conducted 
a TSA. Neither the publisher Cochrane Group nor the country of the contact author influenced the 
reporting of imprecision assessment (univariable logistic regressions, respectively: Cochrane Group, 
p= 0.716; country of contact author, p= 0.782). 
 
 
Reported  
(no. of reviews out of 100)  
Methods section  
 
Reviewers carried out GRADE assessment  96 
Criteria considered for assessing imprecision?   13 
- Width of 95% confidence interval  8 
- Optimal information size – no. of participants  4 
- Optimal information size – no. of events  1 
- Threshold for benefit or harm  1 
- Trial Sequential Analysis 2 
  
Results section  
 
Optimal information size – no. of events  2 
Optimal information size – no. of participants 8 
Thresholds for benefit or harm 15 
Trial Sequential Analysis  2 
Table 2 Summary of approaches to imprecision and formal quantitative analyses related to 
imprecision in Cochrane systematic reviews. Values are numbers. 
 
The quality of the meta-analyzed dichotomous outcomes was often graded as low (41.0%), with few 
outcomes reaching high quality (9.0%). Few reviews clearly stated on which criteria their assessment 
of imprecision were based. However, lack of details on how imprecision was assessed did not prevent 
the systematic reviewers to evaluate it, completing the SoF. Overall, almost half of the outcomes 
(48.0%) were downgraded for imprecision, with only six reviews downgrading imprecision by two 
levels. The most frequent reasons for downgrading due to imprecision were low number of events or 
small sample size (26.0%) and wide 95% CIs (25.0%). Six outcomes were downgraded due to 
imprecision, but no reason was reported in the SoF tables or full-text.  
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Adherence to GRADE Handbook instructions 
When the authors of this article followed the GRADE Handbook instructions on how to replicate 
assessment and evaluate adherence, 64 outcomes were downgraded due to imprecision. Sixty-six did 
not meet the OIS for events. Overall, in 30.0% of reviews, judgment of outcomes differed between 
the review authors and the authors of this article who followed the GRADE Handbook (Figs.  2 and 
3). Cohen’s kappa coefficient between the grading of imprecision as proposed by the original authors 
and as reanalyzed by us following the GRADE Handbook was 0.43 (95% CI 0.23 to 0.58), which 
expressed moderate strength of agreement.  
 
Figure 2. Primary outcomes that met the OIS – number of events: comparing GRADE assessment of 
imprecision carried out by review authors with GRADE carried out by the authors of this article 
following GRADE Handbook guidelines. 
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Figure 3. Primary outcomes that did not meet the OIS – number of events: comparing GRADE 
assessment of imprecision carried out by review authors with GRADE carried out by the authors of 
this article following GRADE Handbook guidelines. 
 
Imprecision by TSA 
The anticipated intervention effect was reported only by 12 reviews. For the other reviews, we 
adopted a 25% RRR to calculate the required information size. Overall, 69 outcomes were 
downgraded due to imprecision by applying TSA (downgrading by 2 levels since the anticipated 
intervention effect was assumed as being realistic). Indeed, five more outcomes were downgraded for 
imprecision by applying TSA as compared to using the GRADE Handbook instructions. The required 
information size was reached by 17 meta-analyses (17.0%). In the remaining 83.0%, the median 
number of participants needed to reach the required information size was 4 187 (IQR, 1 467 to 11 
104 participants).  
 
Agreement between GRADE by review authors and TSA 
Weighted Cohen’s kappa coefficient showing agreement between GRADE performed by review 
authors and TSA was 0.20 (95% CI 0.11 to 0.30). The coefficient expressed slight agreement (Table 
3).  
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Table 3. Concordance in downgrading due to imprecision by 1 and 2 levels between GRADE carried 
out by review authors and TSA. 
 
Considering only the outcomes downgraded or not downgraded due to imprecision, irrespective of 
levels, unweighted Cohen’s kappa coefficient was 0.43 (95% CI 0.21 to 0.57), expressing moderate 
strength of agreement (Table 4).   
 
Agreement between GRADE by authors of this article and TSA 
The imprecision evaluated by the authors of this article following the GRADE Handbook guidelines 
and by TSA was similar: unweighted Cohen’s kappa coefficient was 0.66 (95% CI 0.49 to 0.79), 
expressing substantial agreement (Table 4).  
 
 TSA 
Not downgraded Downgraded Total 
GRADE by review authors 
Not downgraded  27 25 52 
Downgraded  4 44 48 
Total  31 69 100 
GRADE by the authors of this article 
Not downgraded  26 10 36 
Downgraded  5 59 64 
Total  31 69 100 
Table 4. Concordance in downgrading due to imprecision between GRADE carried out by the review 
authors and by the authors of this article and with TSA. 
 
 TSA 
Not downgraded 
Downgraded by 
1 level 
Downgraded 
by 2 levels 
Total 
GRADE by review authors  
Not downgraded 27 0 25 52 
Downgraded 
by 1 level 
3 0 39 42 
Downgraded 
by 2 levels 
1 0 5 6 
Total 31 0 69 100 
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Results of logistic regression analyses  
In the univariable logistic regression analysis, the type of the intervention (GRADE by review 
authors: p= 0.65; TSA: p=0.78), the number of patients included in the meta-analysis (GRADE by 
the review authors: p=0.08; TSA: p=0.07), the heterogeneity (GRADE by review authors: p=0.12; 
TSA: p=0.38), and the meta-analysis technique (random effects or fixed effect models) (GRADE by 
review authors: p=0.86; TSA: p=0.29) were not associated with downgrading due to imprecision. 
When GRADE assessment of imprecision carried out by the review authors was compared to TSA 
assessment and GRADE replicated by the authors of this article according to the Handbook 
guidelines, it seemed that the meta-analytic model (random or fixed effect) might influence the 
agreement in both cases (p=0.04 and p=0.09, respectively), whereas the number of patients might 
influence only agreement between GRADE by the authors of this article and TSA (p=0.01).  
 
Sensitivity analysis 
TSAs with an anticipated intervention effect of 30% RRR revealed 60.0% of the SRs downgraded 
due to imprecision. When the anticipated intervention effect was lowered to 20% RRR, the percentage 
of SRs downgraded due to imprecision increased to 73.0%. Cohen’s kappa coefficients, expressing 
downgrading or not due to imprecision, irrespectively of the downgrading levels (by 1 or 2), did not 
change much: coefficients 0.43 (95% CI, 0.22 to 0.58) and 0.43 (95% CI, 0.20 to 0.56), respectively. 
 
Discussion 
Given the implications of imprecision evaluation for recommending health care interventions as 
standard of care or cautionary noting that additional randomised clinical trials are warranted, it is 
expected that imprecision be transparently evaluated and reported. There remains ample room for 
improvement, however. Almost half of the outcomes were downgraded due to imprecision, but only 
about 1 in 10 reviews reported the criteria to downgrade imprecision. The width of 95% of confidence 
intervals and the number of study participants were the most common criteria to infer downgrading 
due to imprecision. One-third of the conclusions that did not downgrade the evidence for imprecision 
would have been contradicted based on GRADE assessment of imprecision following the GRADE 
Handbook or TSA if these methods had been applied. This was mainly because GRADE evaluation 
by the review authors was more lenient and also because the number of patients included in the meta-
analyses was often insufficient to make any definitive conclusion.  
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The GRADE approach and TSA have different connotations that might influence the judgment 
process. While GRADE is defined as ”a semi quantitative approach that encompasses imprecision 
besides the other certainty domains” and has intrinsic subjectivity (Schunemann 2016), TSA can be 
viewed as a purely quantitative and objective approach (Jakobsen, Wetterslev et al. 2014). Despite 
their differences, the agreement between the two approaches was substantial. Nonetheless, the two 
methods give different weight to the extent of imprecision. TSA tended toward more severe judgment, 
while GRADE seemed to be more easily applied by the review authors, resulting in overestimation 
of the certainty of evidence. When imprecision is rated as negligible (i.e. the true effect plausibly lies 
within the 95% CI), it is more likely that the effect estimates can be trusted and evidence quality rated 
highly. TSA will allow the reader to gauge the extent of confidence on imprecision of primary results 
of meta-analyses, though it might also be perceived as too radical by some. With a GRADE approach, 
reviewers’ decisions on downgrading are more open to subjective decisions. To guide such decisions, 
further research is warranted on optimal information size and of different types of interventions under 
different circumstances.  
 
Strengths and weaknesses of the study 
This study has several limitations. We included only Cochrane reviews of health care interventions, 
a fairly homogeneous but partial sample of systematic reviews published in the medical literature. 
Reviews published in other medical journals might provide different results. However, since 
Cochrane strongly encourages use of the GRADE approach, including imprecision, it seems 
implausible that other journals would perform better. Our analyses are valid for pooled results and 
restricted to dichotomous outcomes, limiting the generalizability of our results. However, in the 
medical literature two third of primary outcomes reported by systematic reviews are dichotomous 
(Page, Shamseer et al. 2016). Besides, calculation and definition of a clinical threshold for continuous 
outcomes, i.e., the minimal important differences or minimal detectable changes, remain ambiguous 
and unclear (Copay, Subach et al. 2007, Armijo-Olivo, Warren et al. 2011). Furthermore, our logistic 
regression results may be under-powered to detect any significant factor, due to the limited number 
of studies included in the analysis. 
While our analysis was protected against confounding by disease area and type of intervention 
because it is based on a sample of meta-analyses irrespective of interventions, it may still have been 
confounded by other meta-analysis characteristics. Given the wide diversity of the studies included, 
the quantitative results are suggestive and might change in the future when GRADE and Cochrane 
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propose methods and policies that strengthen imprecision assessment. Furthermore, imprecision 
assessment may vary between research areas (i.e. type of interventions), becoming speculative in 
fields where trials and reviews are too small to permit exploration of imprecision. 
When we evaluated the conclusiveness of evidence by TSA in studies where the anticipated effect 
treatment effect was not reported, we could not directly assess the authors’ assumptions on relevant 
intervention effects. We chose one arbitrary hypothesis when we recalculated the required 
information size based on a 25% relative risk reduction or improvement, which might be unrealistic 
for some outcomes. Nevertheless, the proportion of primary outcomes downgraded for imprecision 
did not change substantially when we applied different thresholds for benefits in our sensitivity 
analyses. Moreover, we only used a two level downgrading approach when our TSA did not show 
benefit, harm or futility. By e.g. employing Trial Sequential Analysis-adjusted confidence intervals, 
this simple approach could have been refined.  
As well, our results are based on our subjective application of the GRADE approach following the 
GRADE Handbook, which, would then influence the assessments we made between the methods. 
Despite these limitations, this project aspires to be a step towards optimized assessment and 
interpretation of the certainty of evidence regarding imprecision. Recently, evidence synthesis has 
evolved into a dynamic process. A new concept of systematic reviews, living systematic reviews, has 
been introduced (Elliott, Synnot et al. 2017). In this context, TSA has been suggested as a valid 
method to assess constantly updated evidence (Simmonds, Salanti et al. 2017) since it can offer 
constantly updating of optimal information size as new trials are added. This dynamicity could affect 
the imprecision domain, with assessment more closely related to what has been reached for a specific 
condition, outcome, and intervention at a certain time point.  
 
Implications for systematic reviewers  
As part of their mandate to identify potentially effective interventions, systematic reviewers should 
include precision as a key dimension to evaluate, particularly in situations where uncertainty about 
the ratio between benefits and harms is high and where new trial data may influence the summary 
judgment of the review (Riva, Puljak et al. 2017). More detailed guidance from PRISMA and 
PRISMA-P could facilitate the analysis and reporting of imprecision (Moher, Liberati et al. 2009, 
Moher, Shamseer et al. 2015). There is room for better standardisation of approaches and inclusion 
of quantitative methods, such as TSA, to formally evaluate imprecision. 
104 
 
Implications for clinicians 
Imprecision assessment seems to be based on GRADEing criteria that vary considerably in meaning, 
value, or boundaries depending on context or conditions. Incomplete or vague imprecision assessment 
supports the natural tendency to simplify a review’s findings about an intervention as positive or 
negative and to over-rely on P-values (Pocock and Stone 2016). Instead, clinicians using evidence to 
orient their practice should interpret imprecision as a dynamic and often uncertain dimension that 
requires thorough examination of all of the evidence, including size of the trials, number of 
participants with outcomes and heterogeneity (diversity) across trials. TSA offers the means to model 
heterogeneity and estimate optimal information size based on different heterogeneity thresholds.  
 
Future research 
Further research is needed to determine whether accurate assessment of imprecision might change 
the clinicians’ perception about the definitive effectiveness of interventions. It would be beneficial to 
develop an international database of prospectively updated TSAs for all health interventions, where 
people can easily consult the progress of research. This might also help to diminish “the butterfly 
behavior of researchers” from moving onto the next research question before the previous quest has 
been fully exploited (Liberati 2004).  
 
Conclusions 
A significant lack of reporting of and adherence to GRADE was observed in Cochrane systematic 
reviews. Stricter adherence to GRADE Handbook guidelines and/or adoption of TSA would have led 
to more frequent downgrading of the quality of evidence. Our findings reiterate the need for a more 
reliable application of GRADE in Cochrane and non-Cochrane reviews for the assessment of 
imprecision. The reasons for downgrading should be defined following a more structured reporting 
system. Initiatives to improve adherence to GRADE indications are warranted to ensure high-quality 
systematic reviews. Cochrane groups, peer reviewers, and editors need to be more supportive during 
the GRADE assessment process as it is still difficult to apply and requires a structured reporting 
policy to ensure transparency and intelligibility in the process. 
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General conclusion 
In an era in which clinicians, researcher and stakeholders need to be constantly updated with the 
evidence, it has been progressively important to reliably provide the extent of the confidence (the 
uncertainty) of the benefit or harm of the effect of an intervention. The effect estimate from the meta-
analysis and its precision (or confidence interval) is one of the deciding factors in grading the existing 
evidence. Through this section, we showed how TSA and GRADE approach are integrated in the 
evidence synthesis in order to consider precision and trustworthiness of meta-analysis findings.  
TSA has been recently introduced as statistical method to assist a modern version of the systematic 
review: the living systematic review, which might be particularly useful as basis for the creation of 
‘living guidelines’ (Elliott, Synnot et al. 2017, Simmonds, Salanti et al. 2017). Indeed, TSA might 
help in controlling the statistical precision of the summary effects when continually or frequently 
update of meta-analyses for this living study design. When a living systematic review is being used 
to make decisions, then it is preferable to consider approaches to avoid inadvertent type I and II errors.  
The GRADE approach has been more and more essential in the developing of guidelines and 
recommendations thanks to its comprehensive method to balance the certainty and magnitude of the 
evidence with benefits/harms and feasibility of interventions.  
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SECTION 3 
 Is it possible to simultaneously compare multiple 
interventions in a systematic review? 
 
Background  
A key limitation of a meta-analysis is that it can compare only two treatments at a time, yielding 
only partially information that clinicians, patients and policy-makers need. Since usually more than 
two treatment options are available in a real clinical setting for certain conditions, a meta-analysis 
can offer just a part of the whole picture and might be not supportive for an optimal clinical decision 
making.  
In the last decade, a new meta-analytic technique called network meta-analysis (NMA) has been 
developed to assess the effectiveness of several interventions and offer the synthesis of the evidence 
across a network of randomized trials. The interest for this technique has been increased across 
researchers and over the time. Indeed, the PRISMA Statement for Reporting of Systematic Reviews 
published an extension incorporating the guideline for reporting Network Meta-analyses of Health 
Care Interventions (Hutton, Salanti et al. 2015).  
In order to acquire the basis of this methodology, I attended a course at the Winter epidemiology 
school organized by the University of Bern in January 2017. Lectures were given by Prof. Georgia 
Salanti and Julian Higgins, the main experts of the network meta-analysis. Thereafter, a protocol 
has been developed to apply this methodology in low back pain field: a multi interventions 
comparison among rehabilitative treatment to reduce pain and disability in patients affected by acute 
low back pain will be performed.  
Following, I have briefly reported the basis of NMA methodology.  
 
What is a network meta-analysis? 
A network meta-analysis, in the context of a systematic review, is a meta-analysis in which multiple 
treatments (i.e. more than two) are compared using both direct comparisons and indirect 
comparisons of interventions. The direct evidence comes from RCTs, i.e. A vs C and B vs C, while 
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the indirect evidence comes from studies comparing treatment of interests with a common 
comparator, i.e. A vs B. The combination of the direct and indirect sources of the evidence builds 
the network meta-analysis, even called mixed-treatment comparison . 
The NMA enables the rank of the interventions and the estimation of the probability that each 
intervention is the best for each outcome. The ranking presentation or the probabilities are very 
useful for clinical purpose since they are straightforward to understand and easy to read by 
clinicians who usually want to know the preferential order of treatments that could be prescribed to 
an average patient.  
A systematic review with a network meta-analysis is generally more complex to conduct and mostly 
to interpret it. To present the resulting evidence, reviews with a NMA commonly include a graph 
of the network to summarize the numbers of studies that compared the different treatments and the 
numbers of patients who have been studied for each treatment:  
 
 
 
 This network graph shows:  
• nodes: points representing the competing interventions;  
• edges: adjoining lines between the nodes that show which interventions have been 
compared among the included studies.  
The sizes of the nodes and the thicknesses of the edges typically represent the amounts of the 
existing evidence for specific nodes and comparisons.  A network meta-analysis can include an 
unlimited number of treatments, trials and patients. However, in order to conduct a standard network 
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meta-analysis, the treatments should form a connected network, i.e. a path from each treatment to 
every other treatment in the network should exist.  
 
The validity of a network meta-analyses is dependent upon the assumption of transitivity and 
consistency, topics which are discussed below.  
 
Indirect comparison: what it is?  
When there is information on three or more competing interventions in a systematic review, it is 
possible to perform an indirect comparison. Suppose that there are “head-to-head” trials comparing 
direct evidence of interventions A versus B in one trial and in the other interventions A versus C. 
No trial, however, compares the interventions B versus C. We can extract an indirect comparison of 
the relative effect of B versus C by combining the summary estimates of AvsB and AvsC. This is 
possible considering each comparison as a vector that identifies the direction of the intervention 
effect. Therefore, the indirect comparison of B versus C may result as following:  
Indirect MD(BvsC) = direct MD(BvsA) + direct MD(AvsC) 
 
And graphically:  
 
 
 
 
Using the relative intervention effects from each group of trial preserves the within trial 
randomization. Basically, the direct comparison is more precise and strong since it provides more 
information per randomized participant than the indirect comparison.   
 
Transitivity  
Clinical and methodological differences, “effect modifiers” (i.e. age, sex) are inevitable across 
studies in a systematic review. An important assumption which should be underlined in order to 
B A
 
C
 
Direct estimate BvsA Direct estimate AvsC 
Indirect estimate BvsC 
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allow an indirect comparison is that the common comparator A allows a transitive relationship 
between AB and AC effects. In other words, we can compare C and B via A. In order to do that, 
the comparator A should be similar in studies AB and AC. Transitivity requires similarity which is 
that the sets of studies used to obtain the indirect comparison are sufficiently similar in 
characteristics that moderate the intervention effect. Therefore, to undertake an indirect comparison 
is necessary to analyse and measure whether such differences are sufficiently large to cause 
intransitivity. In practice, the transitivity can be assessed by comparing the distribution of the effect 
modifiers across the different comparisons: if there is imbalance, the plausibility of a transitive 
relationship and so the validity of an indirect comparison would be threaten. The transitivity 
requires that all the competing intervention are “jointly randomizable” as if all the interventions 
can be compared simultaneously in a single multi-arm trial.  
 
Mixed estimates 
When both direct and indirect intervention effects are available, these can be combined into a single 
summary estimate of the intervention effect called mixed estimate. A mixed estimate is an inverse 
variance weighted average of the direct and indirect evidence.  
 
Consistency  
The network meta-analysis is subject to another assumption other than transitivity, the consistency. 
While the transitivity refers to clinical and methodological discrepancies across the different 
comparison, the consistency is the statistical manifestation of the transitivity. In other words, the 
consistency is the amount of agreement between direct and indirect intervention effects. The 
consistency is mathematically shown as following:  
“true” indirect MD(BvsC) = “true” direct MD(AvsC) - “true” direct MD(AvsB) 
We can consider the transitivity and the consistency as the clinical/methodological and statistical 
heterogeneity respectively in standard meta-analysis.  
 
The graphical representation: network diagrams 
The graphical representation of a network meta-analysis is called network diagram.  Following 
there is an example extracted from a systematic review on the efficacy of exercise for lower limb 
osteoarthritis (Uthman, van der Windt et al. 2014).  
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In  
In the figure above, the nodes are representing the competing interventions while the lines are 
showing the available direct evidence between pairs of interventions. Closed loops reveal the 
presence of a multi arm study.  
It is important to underline that the assumption of transitivity and consistency should be hold in each 
single loop otherwise the validity of the results is vulnerable.  
 
Ranking of the intervention effects 
The network meta-analysis has the advantage to present the ranking of the competing interventions, 
using the ranking probabilities, which are the probabilities that an intervention is at a specific rank 
when compared to other interventions in the network for the selected outcome. These probabilities 
can be represented in several way, using for examples table or rankograms. For instance, it is 
possible to represent the rank through the area under the cumulative rankogram (SUCRA) which is 
a value between 0 and 1 and can be re-expressed as percentage. The larger the SUCRA, the higher 
the treatment in the hierarchy according to the outcome. 
 
 
 
 
1. No intervention  control 
2. Flexibility (F) 
3. Strenghtening (S) 
4. Aerobic (A) 
5. Flexibility + strenghtening 
6. Flexibility + aerobic 
7. Strenghtening + Aerobic 
8. Combined (F+S+A) 
9. Acquatic strenghtening 
10. Acquatic flexibilty + 
strenghtening 
11. Acquatic combined 
(F+S+A) 
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Case example of NMA: effectiveness of treatments for LBP interventions  
 
Published as: Effectiveness of treatments for acute and sub-acute mechanical non-specific low back pain: 
protocol for a systematic review and network meta-analysis. Gianola S, Castellini G, Andreano A, Corbetta 
D, Frigerio P; Pecoraro V, Redaelli V, Tettamanti A, Turolla A, Moja L, Valsecchi MG 
Systematic Reviews; 8; 196. July 2019.  
 
The development and conduction of a network meta-analysis is challenging and the load of 
randomized controlled trials to analyse is remarkable therefore, a collaboration with other health 
professionals is fundamental to successfully develop it. For this reason, the project was in 
collaboration with other physiotherapists and researchers: this was a unique opportunity not only to 
develop a complex study design but even to develop ability to do networking and to share knowledge 
and have intellectual exchanges.  
 
Methods 
A systematic review protocol has been developed and registered on PROSPERO database 
(CRD42018102527, available at: http://www.crd.york.ac.uk/). This review protocol was prepared 
using the Preferred Reporting Items for Systematic Review and Meta-Analyses Protocol (PRISMA-
P) guidelines and their recommendations (Moher, Shamseer et al. 2015, Moher, Stewart et al. 2016). 
Sections specific to NMA have been considered according to Chaimani et al.(Chaimani, Caldwell et 
al. 2017). We used the PRISMA-NMA extension statement to structure the contents of the actual 
systematic review and network meta-analysis (Hutton, Salanti et al. 2015). 
 
Eligibility criteria  
Types of studies  
We only included randomized controlled trials (RCTs). RCTs were considered if authors explicitly 
stated that it is randomised (Higgins, Altman et al. 2011). Quasi-randomised trials and cross-over 
trials were excluded.  
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Participants 
We included trials that involve participants older than 18 years, both males and females, experiencing 
pain for up to 12 weeks of non-specific LBP. We classified the population based on pain duration: 
acute (less than six weeks) or subacute (six to 12 weeks) (van Tulder, Becker et al. 2006). 
Accordingly, we selected trials for pain duration, regardless of the population definition reported for 
a study (e.g., chronic patients with pain for less than 12 weeks). When the duration of pain exceeds, 
for few weeks, the standard definition of subacute pain (i.e., recruitment from 8 to 16 weeks), we 
contacted the authors to obtain the data for our population of interest only, otherwise the study would 
be excluded. According to the definition of aspecific LBP, we excluded studies focusing on specific 
pathological entities (e.g., spondylolisthesis) and subgroups of patients (e.g., pregnant women). There 
was no restriction on the severity or stage of the symptoms. Studies focusing on both neck and back 
pain in which the two subgroups of patients could not be identified, or patients presenting with both 
conditions, were excluded. 
 
Interventions 
We considered all conservative rehabilitation or pharmacological treatments provided by health 
professionals, such as general medical practitioners or physiotherapists, aimed at relieving pain and/or 
reducing physical disability. We considered any modality (e.g. physical, pharmacological), treatment 
extent, frequency or intensity. We excluded RCTs or arms of RCTs including non-conservative 
treatments (e.g., surgical approaches), herbal medicine, homeopathy and all alternative treatments. 
We included acupuncture and dry needling. We set the following classification of interventions for 
potential nodes: 
1. exercise (e.g., cognitive, back school) 
2. manual therapy (e.g., spinal manipulation, mobilization, trigger point/myofascial therapy) 
3. acupuncture (e.g., dry needling and acupuncture) 
4. any physical therapy (e.g., low-laser therapy, diathermy, Transcutaneous Electrical Nerve 
Stimulation, ultrasound therapy, heat wrap) 
5. taping (such as kinesiotaping) 
6. usual care defined as treatment suggested by general medicine (minimal intervention: 
advice to stay active or to take drugs as needed; education) 
7. paracetamol 
8. non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 inhibitors  
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9. muscle relaxant drugs 
10. opioid drugs 
11. steroids  
12. antidepressant drugs 
13. inert treatment (e.g., placebo drug, sham therapy) 
14. no treatment (no treatment, waiting list control) 
 
Outcomes and study time-points  
Primary outcomes were pain intensity (e.g., measured by numeric rating scale, visual analogue scale, 
McGill Pain Questionnaire or, box scale, other validated quantitative measures) and back-specific 
functional status (e.g., measured by the Oswestry disability questionnaire, Roland-Morris disability 
scale or other validated quantitative measures). If a trial reported more than one measure of pain 
intensity in different conditions (e.g., “night” or “at rest” or “at movement”), we would select “pain 
at rest” as a measure of generic pain. The secondary outcome was any adverse event. 
All time points were abstracted. However, in the analyses we planned to summarize the immediate-
term (closest to 1 week), short-term (closest to 1 month assessment), intermediate (closest to 3–6 
months) and long-term effects (closest to 12 months).  
 
Information sources 
We searched the following electronic databases since the inception date up to November 30 2017: 
MEDLINE (PubMed), CENTRAL, EMBASE (Elsevier, EMBASE.com) using the appropriate 
Thesaurus and free-text terms. We contacted investigators and relevant trial authors, seeking 
information on unpublished data, if necessary. 
We checked the reference lists of all the studies identified, and we examined the references of any 
systematic review or meta-analysis identified during the search process. 
No restriction on language or publication period were applied. Non-English studies for which a 
translation cannot be obtained were classed as potentially eligible but were not be considered in the 
full review. A full electronic search strategy for Pubmed/Medline is presented in Appendix 1.   
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Study selection 
Two of the authors of the present protocol independently screened the abstracts of all the publications 
obtained by the search strategy. These authors then independently assessed the full text of the 
potentially relevant studies for inclusion. We discarded all studies that did not fulfil the above 
inclusion criteria. We then obtained the full text of the remaining articles. We resolved disagreements 
through discussion and consult a third author if disagreements persist. Covidence software 
(COEVIDENCE) was used to manage the study selection phase. 
 
Data extraction 
We used a specifically designed and piloted data collection form using an Excel sheet (Microsoft 
Inc.). Two authors independently extracted characteristics and outcome data from the included 
studies. Disagreements were resolved through discussion or with assistance from a third author if 
necessary. 
From each study included we extracted: name of the first author, year of publication, setting, number 
of centers, population definition (acute/subacute); number, gender and age of participants, dropouts; 
the interventions compared with their primary and secondary outcomes, time point follow-up, and 
duration of whole treatment.  
All relevant arm-level data were extracted. We considered post-treatment assessments. When these 
were lacking, the post-treatment data were extrapolated by the difference between the baseline and 
mean change values and SDs were imputed using the average of the available SD for the same 
instrument. If any data from the baseline and post treatment were not available, the mean change and 
SD values were adopted as a last option (Higgins, Deeks et al. 2011).  
We assumed that any patient meeting the inclusion criteria is, in principle, equally likely to be 
randomized to any of the eligible low back pain interventions.  
 
Geometry of the network 
We explicitly described the process leading to node grouping (James, Yavchitz et al. 2018, James, 
Yavchitz et al. 2018). The network of treatments was judged based on the characteristics of the 
available studies, presented and evaluated graphically. We evaluated: if the network was 
disconnected, if there was a sufficient number of comparisons in the network with available direct 
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data; if there was a high number of comparisons based on a single study; if any key treatment was 
missing. Next, the feasibility of a network meta-analysis was assessed.  
All RCTs reporting only two arm comparisons between the same kind of intervention (e.g., exercise 
versus exercise) were excluded, whereas if they presented at least one third arm comparator, they 
would be included (e.g., exercise versus NSAIDs). We included both multi-arm trials comparing three 
or more interventions, and those comparing different dosages or regimens of an intervention to a 
different one. Intervention arms of different dosages and regimens of the same intervention across 
the RCTs were merged together for the global analysis of all outcomes. We did not consider all the 
comparisons in which an intervention presents multiple co-interventions for the experimental group 
(e.g., mixed treatment: laser therapy plus manipulation plus exercise versus waiting list controls) or 
for the control group (e.g., usual care: education, some physical exercise plus drugs taken as needed) 
to avoid inconsistencies across trials.  
 
Risk of bias within individual studies 
Two review authors independently assessed the risk of bias in the included studies. Disagreements 
was resolved through discussion or arbitration with a third review author when consensus cannot be 
reached. We assessed the risk of bias for each included study using the ’Risk of bias’ (RoB) 
assessment tool recommended by The Cochrane Collaboration (Higgins, Altman et al. 2011). 
Specifically, we evaluated the following criteria: random sequence generation, allocation 
concealment, blinding of participants, providers and outcome assessment, incomplete outcome data, 
and selective outcome reporting. Each item was scored as ‘high’, ‘low’, or ‘unclear’ RoB if no 
sufficient information was reported. To summarize the overall RoB for a study, allocation 
concealment, blinding of outcome assessment, and incomplete outcome data were carefully 
considered in order to classify each study as: 'low risk of bias' when all three criteria are met; 'high 
risk of bias' when at least one criterion is unmet; and 'moderate risk of bias' in the remaining cases. 
Allocation concealment, blinding of outcome assessment, and incomplete outcome were chosen since 
expected to be of importance across the pain intensity outcomes in altering results.. 
 
Measures of treatment effect  
Relative treatment effects 
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Through pairwise meta-analyses, we estimated the primary outcomes as continuous outcomes, using 
the mean difference (MD) or standardized mean difference (SMD) when different outcome 
measurements had been reported for each trial. The uncertainty of all estimates was expressed with 
its 95% confidence interval (CI).  
 
Data summary 
Methods for direct treatment comparisons 
We performed conventional pairwise meta-analyses for each primary outcome using a random-effects 
model for each treatment comparison with at least two studies (DerSimonian and Laird 1986) using 
Stata software v. 15 and the command metan (Stata-IC 2017). 
 
Methods for multiple comparisons  
We performed the network meta-analyses within a frequentist setting, assuming equal heterogeneity 
across all treatment comparisons, and accounting for correlations induced by multi-arm studies 
(Salanti 2012, Miladinovic, Hozo et al. 2014). We used a multivariate normal model with random-
effects (Higgins, Jackson et al. 2012, White, Barrett et al. 2012). We first fitted a design by treatment 
interaction model to assess the presence of inconsistency (global χ2 test). If the null hypothesis of all 
inconsistency parameters being equal zero was not rejected, we fitted a consistency model. If a global 
significant inconsistency was found, we tried to interpret the significant inconsistency parameters, 
split nodes to possibly remove the problem, and try to model the inconsistency using meta-regression.   
 
Relative treatment ranking 
We estimated all ranking probabilities and cumulative ranking probabilities for each treatment and 
outcome. We then calculated the median rank with their 95% credible intervals, to assess the 
robustness of the finding. To determine a treatment hierarchy with a single number, we will calculate 
the surface under the cumulative ranking curve (SUCRA) and express it as a percentage (Salanti, 
Ades et al. 2011).  
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We performed network meta-analyses in Stata 15 (Stata-IC 2017) using the ‘network’ command and 
the ’mvmeta’ command ((MTM). , White 2011, Higgins, Jackson et al. 2012, Chaimani, Higgins et 
al. 2013). 
 
Assessment of statistical heterogeneity 
In the standard pairwise comparisons, we assessed the statistical heterogeneity within each pairwise 
comparison using the I² statistic, where an I² value of 25% to 49% indicates a low degree of 
heterogeneity, 50% to 75% a moderate degree of heterogeneity, and more than 75% indicates a high 
degree of heterogeneity (Higgins, Thompson et al. 2003). 
In the network meta-analyses, we assumed that the standard heterogeneity is constant across the 
different treatment comparisons. We estimated it including a random effect in the multivariate normal 
model, assuming a multivariate normal distribution with mean 0 and a variance-covariance matrix 
with diagonal elements τ2 and off-diagonal elements equal to τ2/2, and discuss the magnitude of the 
estimated variance parameter. 
 
Assessment of transitivity and statistical consistency in network meta-analyses  
We assessed the assumption of transitivity (or similarity) by comparing the distribution of the 
potential effect modifiers across the various pairwise comparisons. If there were no multi-arm trials, 
we evaluated the inconsistency assumption in each closed loop of the network separately as the 
difference between direct and indirect estimates for a specific comparison (inconsistency factor). The 
magnitude of the inconsistency factors and their 95% CIs will be used to make an inference about the 
presence of inconsistency in each loop.  
If multi-arm trials were present, as it is problematical to identify loop inconsistencies, we used the 
node-splitting approach to evaluate existing differences between direct and indirect estimates for each 
node (Dias, Welton et al. 2010).  
To check the assumption of consistency in the entire network, we used the design-by-treatment model 
as described by Higgins (Higgins, Jackson et al. 2012). This method accounts both for loop and design 
(i.e. different sets of treatments compared in a trial) inconsistencies in multi-arm trials. Using this 
approach, we made an inference about the presence of inconsistency from any source in the entire 
network based on an χ² test. Inconsistency and heterogeneity are interwoven: to distinguish between 
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these two sources of variability, we will employ the I² statistic for inconsistency, as it measures the 
percentage of variability that cannot be attributed to random error or heterogeneity (within 
comparison variability). 
 
Preliminary Results: back pain and specific functional status at 1 week of follow up   
Study selection  
After removing duplicates, the whole search strategy retrieved 6964 records. Reviewing the titles and 
abstracts, we discarded 6419 irrelevant citations. We examined the full text of the remaining 549 
records of which 517 did not meet the inclusion criteria. Within this group, 249 records included a 
different population (e.g, chronic pain), 145 different interventions (e.g., mixed treatments) or 
comparisons (e.g., exercise versus exercise), 20 different outcomes (e.g., cost-effectiveness related to 
pain), 66 a study design different from RCT, 14 were further duplicates and 23 studies not in English 
or Italian that are still in awaiting assessment. In total, 22 authors were contacted, and 2 of the 5 who 
responded provided data usable for analysis. Finally, 36 studies were included (citations in Appendix 
2). For a further description of screening process, see the study flow diagram in Figure 1.  
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Figure 1. Flow Chart of study selection. 
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General Characteristics 
A total of 7787 participants were included in 36 trials. The sample size varied between 92 and 227 
participants (InterQuartile range -IQR) with a median of 126 participants. The majority of studies 
involved acute patients (n=19 trials). The median year of publication of the trials was 2004 (IQR 
2000-2010). Table 1 summarizes these general characteristics. Average age ranged from 38 to 44 
and a median percentage male ranged from 41% to 53%.  
General characteristics are summarized in Appendix 3 including all studies and participants 
characteristics. No important concerns were raised regarding the violation of the transitivity 
assumption when the following variables were considered as potential effect modifiers: stage of LBP, 
length of treatment, age, sex. Similarity of trials characteristics was guaranteed in terms of clinical 
and methodological features.  
We presented the NMA results for pain and disability compared with inert treatment (control 
treatment), and the SUCRA values at immediate term, 1 week of follow up. Therefore, we showed 
quantitative analysis for 27 RCTs included.   
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*the tot number of interventions is higher due to multi-arms trials  
Table 1. General characteristics 
 
  
Study Characteristic  No. (%) of RCTs (N = 36) 
 
Year of publication   
1971-1980  1 (2.8) 
1981-1990  3 (8.3) 
1991-2000  6 (16.7) 
2001-2010  18 (50.0) 
2011-2018  8 (22.2) 
Interventions*   
Exercise  18 (50.0) 
Manual therapy  7 (19.4) 
Acupuncture  2 (5.6) 
Usual care   17 (47.2) 
Inert treatment  12 (33.3) 
Heat wrap  3 (8.3) 
Paracetamol  4 (11.1) 
NSAIDs  8 (22.2) 
Muscle relaxant drugs  9 (25.0) 
Opioids  2 (5.6) 
Length of treatment   
< 7days  15 (41.7) 
> 7 days  16 (44.4) 
Not reported  5 (13.9) 
Stage of LBP   
         Acute LBP  19 (52.8) 
         Subacute LBP  9 (25.0) 
         Acute and Subacute 
LBP 
 8 (22.2) 
Setting of center   
Multi-center  19 (52.8) 
Single-center  17 (47.2) 
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Risk of bias assessment  
Figure 2 and 3 summarized the RoB assessments. Regarding the overall RoB across studies (n=36), 
only 8 trials were at low RoB (22%). We categorized 56% of the studies as at unclear RoB (n=20) 
and 22% at high RoB (n=8).  
 
 
Figure 2. Risk of bias graph.  
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Figure 3. Risk of bias summary.   
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Effect of interventions on pain and disability at short term FU (1 week) 
Pain was investigated by 20 studies at 1 week of FU: 16 out of 20 studies (N = 3760) provided data 
on 16 direct comparisons between 10 different treatment nodes (Figure 4a). Figure 5a shows the 
network according to level of bias in included trials.  
Disability was investigated by 13 studies at 1 week of FU. The NMA on disability at 1 week (11 out 
of 13 studies [N =4266] provided data on 13 direct comparisons between 9 different treatment nodes, 
Figure 4b. Figure 5b shows the network according to level of bias in included trials.  
 
 
A: pain  B: disability  
Figure 4. Network plot for pain and disability outcomes at short term of 1 week FU. 
 
 
 
A: pain  B: disability  
Figure 5. Network plot by risk of bias for pain and disability outcomes at short term of 1 week FU. 
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Pairwise comparisons 
Treatment effects in pairwise meta-analyses are shown in Figures 6a for pain and 6b for disability. 
A 
 
B 
 
Figure 6a and 6b. Pairwise comparison for pain (A) and disability (B).  
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Inconsistency assessment 
We tested inconsistency using the design-by-treatment interaction model (White 2011) approach. We 
first tested it globally and we found no evidence of inconsistency for both pain and disability (pain: 
p=0.7639, χ2=3.35 on 6 df; disability: p=0.92, χ2=0.96 on 4 df ). We then examined inconsistency 
for each loop in each outcome analysis.  
• Pain   
We found 7 triangular and 2 quadratic loops. Three out of 9 loops were inconsistent since the 95% 
CI exclude the 0 that is, the direct estimate of the summary effect differs statistically from the indirect 
estimate (Figure 7a). However, we also examined all of the indirect sources of the evidence at once 
in order to compare direct with the indirect evidence from the whole of the rest of network, making 
use of all (indirect) loops that connect two interventions in the comparison, using the network sidesplit 
STATA command. Direct evidence estimates were consistent with indirect evidence in every 
comparison. We could not identify any important variable that differed across comparisons in those 
loops, but the number of included studies was very small in the inconsistent loops. 
 
Figure 7a. Inconsistency plot for pain outcome.  
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• Disability  
We found 5 triangular (Figure 7b). Two loops were inconsistent since the 95% CI exclude the 0 that 
is, the direct estimate of the summary effect differs statistically from the indirect estimate. As for pain 
outcome, we run the network sidespilt command with the results that direct evidence estimates were 
consistent with indirect evidence in every comparison. We could not identify any important variable 
that differed across comparisons in those loops, but the number of included studies was very small in 
the inconsistent loops. 
 
Figure 7b. Inconsistency plot for disability outcome.  
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Network meta-analysis results  
NMA for pain showed that manual therapy (-1.45; 95%CI -2.60, -0.30) and muscle relaxants (-0.98; 
95% CI -1.35, -0.42) significantly decreased pain compared to the inert treatment (Figure 8a).  
NMA for disability showed that muscle relaxant drugs (-2.55; 95%CI -3.76, -1.33) is the only 
treatment that significantly decreased disability compared to the inert treatment (Figure 8b). 
A 
 
B 
 
Figure 8a and 8b. NMA estimates and prediction intervals. Forest plots for pain (A) and disability 
(B), in acute and subacute LBP at immediate term vs inert treat.  
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Following, comparisons between treatments are presented in netleague tables. Results should be read 
from left to right and the estimate is in the cell in common between the column defining treatment 
and the row defining treatment.  
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Ranking of treatments  
 
• Pain outcome 
Rank probability indicating the possibility of each intervention being the best (1) and then the worst 
(0) for pain are presented in table 2. In terms of efficacy, the most effective treatment was manual 
therapy (95.4%) and the last was the heat wrap (4.7%).  Figure 10 shows the cumulative probability 
rank of the greatest likelihood of being the efficacious treatment for acute LBP. 
Treatment SUCRA Probability of being best 
Manual therapy 95.4 78.1 
Muscle relaxants 86.3 14.2 
Opioid  71.6 3.7 
Acupuncture 66.8 3.1 
Paracetamol 42.0 0.0 
Inert treatment 41.3 0.0 
NSAIDs 34.6 0.0 
Exercise 33.1 0.7 
Usual care 24.2 0.3 
Heat wrap 4.7 0.0 
Table 2. SUCRA for pain outcome.  
 
Figure 10. Cumulative SUCRA for pain.  
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• Disability  
Rank probability indicating the possibility of each intervention being the best (1) and then the worst 
(0) for disability are presented in table 3. In terms of efficacy, the most effective treatment was muscle 
relaxant drugs (97.3%) and the less was the usual care (28.3%).  Figure 11 shows the cumulative 
probability rank of the greatest likelihood of being the efficacious treatment for acute LBP. 
 
Treatment SUCRA Probability of being best 
Muscle relaxant 97.3 83.5 
Acupuncture 74.0 8.3 
Exercise 46.5 4.0 
NSAIDs 45.9 0.1 
Manual therapy 45.8 3.0 
Heat wrap 45.5 0.3 
Inert treatment 33.9 0.0 
Paracetamol 32.8 0.1 
Usual care 28.3 0.7 
Table 3. Disability SUCRA. 
 
Figure 11. Cumulative SUCRA for disability.  
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Discussion  
Our results showed that muscle relaxant and manual therapy are effective rehabilitative treatments in 
reducing pain at 1 week of follow up. These results are consistent with those published in literature 
by a recent systematic review where, for people with acute LBP, muscle relaxants provide clinically 
significant short-term pain relief (Abdel Shaheed, Maher et al. 2017). As well, international 
guidelines recommend muscle relaxants drugs as pharmacological treatment for acute low back pain 
even though with different strength of recommendations (van Tulder, Becker et al. 2006, Qaseem, 
Wilt et al. 2017, VA/DoD 2017). On the contrary, the NICE guideline recommend the use of NSAIDs 
for acute low back pain but our results are discordant (2016).  This disagreement can be due to our 
stringent inclusion criteria of clinical trials: we selected only RCTs assessing “pure” treatments in 
patients with non-specific acute and sub-acute LBP (e.g., no sciatica), excluding all co-interventions 
(e.g., exercise plus NSAIDs), in order to be more conservative about the best available evidence 
preventing clinical and methodological intransitivity.  We need, anyway, to be cautious in interpreting 
results on the efficacy of muscle relaxants drugs since, for example, thiocolchicoside has been lately 
advocated as dangerous with potential for genetic toxicity by the Italian Medicines Agency.  
Several systematic reviews investigated the effect of manual therapy but we cannot compare manual 
therapy results with those published in these reviews since they investigated specific types of manual 
therapy techniques alone, i.e spinal manipulations or chiropractic treatments. In contrast, our results 
comprehend a wide range of manual therapy interventions: indeed, in real clinical practice, a health 
professional does not limit his intervention to a single manual therapy technique. Besides, integrating 
all treatments into one category, the statistical power of the manual therapy node was amplified.  
Manual therapy resulted effective also in reducing disability. In agreement with our findings, the 
NICE guideline recommend “manual therapy (spinal manipulation, mobilisation or soft tissue 
techniques such as massage) for managing low back pain with or without sciatica, but only as part of 
a treatment package including exercise, with or without psychological therapy”(2016).  
Overall, the loops in NMA analyses were generally represented by studies with unclear risk of bias. 
The next step will be to apply the GRADE assessment onto our results: the application of GRADE is 
more complex in systematic reviews with network meta-analysis than in the traditional systematic 
reviews with meta-analysis. The quality of a specific trial can affect more estimates in the network in 
both direct or indirect comparisons (Brignardello-Petersen, Bonner et al. 2018).  
Our results derived from several small trials. In general, the NMA, combining indirect and direct 
evidence, might increase the power and precision of treatment effect estimates. Despite this, some 
authors suggest to cautiously interpret this analysis because even a network meta analyses may be of 
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low power and might influence estimates of the effect and the SUCRA values. Clinicians can be 
mistakenly endorse higher ranked treatments when no clinical relevant differences actually exist: 
disparities between clinical implications among treatments can be due to “play of chance” rather than 
real differences (Faltinsen, Storebo et al. 2018). The risk of random errors is a concept currently 
omnipresent and to which attention has been more and more paid in the evidence synthesis process 
mostly because of the introduction of the “living systematic reviews” and the “living guidelines” 
where the evidence is updated as soon as new relevant data emerge (Akl, Meerpohl et al. 2017, Elliott, 
Synnot et al. 2017). For instance, Faltinsen et al. recently suggested to assess the usefulness of Trial 
Sequential Analysis for network meta analyses and they called for future research on it (Faltinsen, 
Storebo et al. 2018).  
 
Conclusion 
The NMA is a powerful tool for evidence synthesis generation and appear to be of great promises but 
it can also be dangerous if not adequately performed and interpreted. Indeed, clinical and 
methodological assumption and nodes of the intervention network should be clearly defined in a 
protocol stage in order to not fall into bias besides being observed and controlled throughout all the 
NMA analysis process. An adequate and appropriate reporting should be also required in the context 
of evidence quality, statistical power, random errors and treatment rankings. In conclusion, we 
realized that NMA is resource expensive: it usually involves a lot of studies at each step of the 
systematic review from screening phase to data extraction, more than a conventional systematic 
review. 
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CONCLUSIONS 
 
Despite the use of meta-analysis has been internationally widespread for 40 years by now, signs of a 
“midlife crisis” have been shown (Gurevitch, Koricheva et al. 2018).  This project reflects the endless 
need in medicine to find and provide the best and the most reliable available evidence for supporting 
clinical decision making process and health care planning.  It has enlightened limitations and threats 
in scientific process that surrounds evidence synthesis, encompassing both the unit of analysis of 
meta-analysis, the primary studies, and the next hierarchical level, the meta-analysis itself.  
Our studies point out that inadequate reporting of primary studies, underpowered meta-analysis and 
lack of head-to-head comparisons can have negative influence on clinical-decision making. However, 
there are innovative methods that can mitigate these problems.. 
 
Reporting issues in RCTs and systematic reviews 
Evidence syntheses are not immune to shortcoming in primary studies: one of the most common 
threats is inadequate reporting. The diffusion of meta-analyses to evaluate primary studies was 
associated with an increasing consciousness of the relevance of reporting. When a clinical trial fails 
to report essential elements, as we showed in chapter 1, its results should be interpreted with caution. 
Reporting shortcomings in primary studies focused on a common rehabilitation clinical problem – 
back pain - are highly frequent. We found that reporting issues are also spread across publication 
types, and meta-analyses and systematic reviews, including Cochrane reviews, are not immune. 
Therefore, inadequate reporting is likely to afflict to some extent all kind of publications at each level 
of hierarchy, possibly extending to tertiary publication types such as guidelines. 
Even though many reporting guidance documents and checklists have been developed during the last 
20 years, adhere to them seems to be slow and, at best, partial (Jin, Sanger et al. 2018). Our studies 
show that a deep gap is still present: these checklists seem to have scarce appeal on who should adhere 
to them. Despite partial failure in changing reporting, reporting checklists and tools have been 
increasing in terms of number and types of publication coverage, extending to very specific types of 
publications (e.g. CONSORT for cluster-RCTs) or publication sub-section (e.g. PRISMA-diagnostic 
test accuracy for abstracts checklist). It is difficult to imagine how all these checklists will make a 
difference given that the ancestor checklists, such as CONSORT and PRISMA did improve reporting 
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to a limited extend. Authors of scientific article are required to follow reporting guidelines: editors 
and journals emphasise the importance of adhering to checklists, and this often is a pre-requisite to 
publish research articles. However, a real control of it and how checklists are used  seems to not being 
fully implemented: reporting is a “nice to have” detail that easily gets lost in the publication process. 
Journals should not just require the submission of a complete guideline checklist with author’s 
manuscript but they should be stricter in asking to reviewers and editors to check for the real 
adherence of these tools in order to allow for a significant and real reporting improvement.  
For both clinical trials and systematic reviews, registering in advance study design protocol can limit 
reporting bias. Indeed, the advanced registration is linked to higher methodological quality (Ge, Tian 
et al. 2018).  
A direct factor on which to invest efforts and resources to improve reporting and research conduction 
is education on high quality research methods. Researchers, medical doctors and professional health 
practitioners are exposed to light statistical and critical appraisal courses for analysing and 
interpreting evidence and conduct adequate study design. Until quantitative methods and clinical 
epidemiology do not become part of academic curricula, at least of those professionals who intend to 
do research as part of their activities, research reporting and methods will likely to not improve much. 
As some authors suggested, training in research methods and interpretation of findings should be part 
of the basic training for higher-degree in medical fields, including research post-graduates, medical 
doctors and other professional science practitioners (Gurevitch, Koricheva et al. 2018).  
 
Precision, sample size and heterogeneity from RCTs to systematic reviews 
The pooled estimate of the effect of an intervention will always have some degree of uncertainty: 
what is desirable is to find a process to standardise (making replicable) the measurement of precision 
of estimates. Systematic reviews often include small studies that report greater and more variable 
effects than those reported by larger studies. Small studies are, indeed, more affected by random noise 
and publication bias: it has been demonstrated that sample size is associated with methodological 
quality, with small studies on average having more methodological threats (Kjaergard, Villumsen et 
al. 2001).  
On one hand, our study shows how small studies often do not include a sample size calculation as 
part of their methods. On the other hand, meta-analyses do not differ, as they seem to have the same 
problem with low numbers of events or participants, few studies, to achieve a conclusive, reliable and 
more precise result. It is interesting how the issue of sample size crosses different steps of research 
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production: its inadequacy can affect precision of results of primary studies and be reflected on the 
classic meta-analysis results or the network meta-analysis findings altering the assessment of the 
overall certainty of the evidence at GRADE level.  
The concept of sample size and power are of paramount relevance, matching the importance of 
another methodological concept of systematic review science: the heterogeneity. We have shown how  
important it is to integrate the statistical manifestation of heterogeneity into an optimal information 
size calculated for a meta-analysis, as the Trial Sequential Analysis allows. Whereas, the clinical 
manifestation should be critically explored to avoid imbalance in the distribution of effect modifiers 
between primary studies. Define the heterogeneity is one of the key assumption in the network meta-
analysis conduction.  
The GRADE approach is the best attempt that the research community has developed in order to 
obtain a comprehensive assessment of the certainty of the evidence. In fact, imprecision, sample size 
and heterogeneity are all considered into the grading of the evidence.  
Further efforts are needed to offer a friendlier presentation of certainty of results and increase 
education: the gap that still exists between research and clinical practice is enlarge by the inability of 
clinicians and other stakeholders to understand the implications of sample size or heterogeneity 
limiting factors.  
 
Conclusions  
Advances in evidence synthesis have been stimulated by many factors: the need for more precise and 
reliable results, the need for more standard and transparent methods to assess the body of the evidence, 
the need for innovative software for cumulative analysis and for multiple comparisons instead of pair-
wise comparisons. 
Over the years, we have shown how it has been achieved a remarkable level of knowledge in methods 
to synthetize the evidence with the attempt to offer more reliable interpretation of meta-analysis 
findings, creating the pre-condition to optimally inform the clinical decision making. Evidence 
syntheses, systematic reviews and meta-analyses are a unique transparent and accurate tool to offer 
the best available evidence to clinicians and stakeholders. It is important to remember that a balanced 
clinical decision should not only take into consideration the best available accurate and reliable 
evidence but must integrate it with the clinical expertise and the patient’s values reflecting the 
evidence-based medicine model.  
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Appendix 
Appendix 1 
Search strategy PubMed  
"Adult"[Mesh] OR adult*[Title/Abstract] 
AND  
back pain[Mesh] OR “acute low back pain” [Title/Abstract] OR “acute back pain”[Title/Abstract] OR 
backache [Title/Abstract] OR lumbago [Title/Abstract] OR “back disorder”[Title/Abstract] 
AND  
Randomized Controlled Trial[ptyp] OR Controlled Clinical Trial[ptyp] OR RCT [Title/Abstract] OR 
“Randomized Controlled Trial” [Title/Abstract] OR random* [Title/Abstract] OR trial[Title/Abstract]  
AND 
“Exercise”[Mesh] OR “Exercise therapy”[Mesh] OR Exercis* [Title/Abstract] OR training[Title/Abstract] 
OR “motor control” [Title/Abstract]  OR “back school” [Title/Abstract] OR Manipulation, Chiropractic 
[Mesh] OR Manipulation, Orthopedic[Mesh]  OR Manipulation, Osteopathic [Mesh] OR Manipulation, 
Spinal [Mesh] OR Musculoskeletal Manipulations [Mesh] OR Chiropractic [Title/Abstract] OR 
manipulation [Title/Abstract] OR manipulate[Title/Abstract] OR “Spinal Manipulation” [Title/Abstract] OR 
“Lumbar Manipulation” [Title/Abstract] OR thrust [Title/Abstract] OR manual therap* [Title/Abstract] OR 
mobilization [Title/Abstract] OR ACUPUNCTURE [Mesh] OR ACUPUNCTURE THERAPY [Mesh] OR 
acupuncture [Title/Abstract] OR electro-acupuncture [Title/Abstract] OR acupressure [Title/Abstract] OR 
dry-needling [Title/Abstract] OR Massage[Mesh]  OR massage [Title/Abstract] OR  “myofascial release” 
[Title/Abstract]  OR Trigger Points [Mesh] OR “Trigger Points” [Title/Abstract] OR Health Education 
[Mesh] OR “Physical Education and Training”[Mesh]  OR patient education [Mesh] OR "Patient-Centered 
Care"[Mesh] OR “information booklet” [Title/Abstract] OR book* [Title/Abstract]  OR pamphlet* 
[Title/Abstract] OR leaflet* [Title/Abstract]  OR poster* [Title/Abstract] OR education* [Title/Abstract] OR 
information* [Title/Abstract] OR Diathermy[Mesh]  OR Diatherm* [Title/Abstract] OR  
tecar[Title/Abstract] OR Transcutaneous Electrical Nerve Stimulation [Mesh] OR TENS [Title/Abstract] OR 
“Electric Nerve Stimulation” [Title/Abstract] OR “Electrical Stimulation therapy” [Title/Abstract] OR 
Electrostimulation [Title/Abstract] OR “electric stimulation therapy” [Title/Abstract] OR electroanalgesia 
[Title/Abstract] OR electroacupuncture [Title/Abstract] OR electromagnetic [Title/Abstract]  OR 
electrotherapy*[Title/Abstract] OR taping [Title/Abstract]  OR tape*[Title/Abstract]  OR 
Kinesio[Title/Abstract]  OR strap*[Title/Abstract]   OR sound [Mesh] OR Ultrasonic Therapy [Mesh]  
OR Ultrasonics [Mesh] OR Ultrasonography [Mesh] OR Ultrasonic Waves [Mesh] OR Ultrasonic* 
[Title/Abstract] OR ultrasound [Title/Abstract] OR Low-Level Light Therapy [Mesh] OR laser 
[Title/Abstract] OR infrared [Title/Abstract] OR ultraviolet [Title/Abstract] OR monochromatic 
[Title/Abstract] OR drug therapy [Title/Abstract] OR  NSAIDS[Title/Abstract] OR "Cyclooxygenase 
Inhibitors" [Pharmacological Action]  OR cyclooxygenase [Title/Abstract]  OR cyclo-oxygenase 
[Title/Abstract] OR Anti-Inflammatory Agents, Non-Steroidal [Pharmacological Action] OR Anti-
Inflammatory Agents, Non-Steroidal [Mesh] OR aspirin [Title/Abstract] OR acetylsalicyl* [Title/Abstract] 
OR Salicylic Acid [Title/Abstract] OR carbasalate calcium [Title/Abstract] OR Diflunisal[Title/Abstract] OR 
aceclofenac [Title/Abstract] OR alclofenac [Title/Abstract] OR Diclofenac [Title/Abstract] OR Indomethacin 
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[Title/Abstract] OR Sulindac [Title/Abstract] OR meloxicam [Title/Abstract] OR Piroxicam [Title/Abstract] 
OR dexibuprofen [Title/Abstract] OR dexketoprofen [Title/Abstract] OR Fenoprofen [Title/Abstract] OR 
Flurbiprofen [Title/Abstract] OR ibuprofen [Title/Abstract] OR ketoprofen [Title/Abstract] OR  
Naproxen[Title/Abstract] OR metamizol [Title/Abstract] OR Dipyrone[Title/Abstract] OR phenylbutazone 
[Title/Abstract] OR phenazone [Title/Abstract] OR Antipyrine[Title/Abstract] OR propyphenazone 
[Title/Abstract] OR celecoxib[Title/Abstract] OR  etoricoxib [Title/Abstract] OR nabumeton[Title/Abstract] 
OR parecoxib[Title/Abstract] OR rofecoxib [Title/Abstract] OR celecoxib [Title/Abstract] OR valdecoxib 
[Title/Abstract] OR lumiracoxib[Title/Abstract] OR etoricoxib [Title/Abstract] OR parecoxib 
[Title/Abstract] OR vioxx[Title/Abstract] OR celebrex[Title/Abstract] OR bextra[Title/Abstract] OR 
prexige[Title/Abstract] OR  arcoxia [Title/Abstract] OR  etodolac [Title/Abstract] OR 
floctafenine[Title/Abstract] OR Meclofenamic Acid[Title/Abstract] OR meclofenamate [Title/Abstract] OR 
meloxicam[Title/Abstract] OR  oxaprozin[Title/Abstract] OR piroxicam[Title/Abstract] OR 
tenoxicam[Title/Abstract] OR tolmetin[Title/Abstract] OR paracetamol[Title/Abstract] OR 
Acetaminophen[Mesh] OR “Analgesics, Opioid”[Pharmacological Action] OR M03$ [Title/Abstract] OR 
muscle relax*[Title/Abstract] OR anti-spasm* [Title/Abstract] OR calmative[Title/Abstract]  OR 
carisoprodol[Title/Abstract]  OR cyclobenzaprine[Title/Abstract] OR flexeril[Title/Abstract]  OR 
metaxalone[Title/Abstract]  OR methocarbamol[Title/Abstract]  OR baclofen[Title/Abstract]  OR 
orphenadrine[Title/Abstract]  OR tizanidine[Title/Abstract]  OR Zanaflex[Title/Abstract]  OR 
dantrolene[Title/Abstract] OR Dantrium[Title/Abstract]   OR Quinine[Title/Abstract]  OR 
chlorzoxazone[Title/Abstract] OR norflex[Title/Abstract]  OR norgesic[Title/Abstract] OR  
alprazolam[Title/Abstract]  OR xanax[Title/Abstract]  OR  Triazolam[Title/Abstract]  OR  
Brotizolam[Title/Abstract]  OR  Oxazepam[Title/Abstract] OR Loprazolam[Title/Abstract]  OR  
Lormetazepam[Title/Abstract]  OR  Lorazepam[Title/Abstract]  OR Ativan[Title/Abstract]  OR 
Temazepam[Title/Abstract]  OR Normison[Title/Abstract]  OR Temaz*[Title/Abstract]  OR 
Estazolam[Title/Abstract]  OR  Bromazepam[Title/Abstract]  OR Chlordiazepoxide[Title/Abstract]  OR  
Clobazam[Title/Abstract] OR Nimetazepam[Title/Abstract]  OR Flunitrazepam[Title/Abstract]  OR  
Nitrazepam[Title/Abstract]  OR Clonazepam[Title/Abstract]  OR Quazepam[Title/Abstract]  OR 
Diazepam[Title/Abstract]  OR Valium[Title/Abstract] OR  Phenazepam[Title/Abstract]  OR 
Medazepam[Title/Abstract] OR  Prazepam [Title/Abstract]  OR  Flurazepam[Title/Abstract]  OR  
Clorazepate[Title/Abstract] OR Nordazepam[Title/Abstract] OR NO2A*[Title/Abstract]   OR opioid 
[Title/Abstract]   OR analges*[Title/Abstract]   OR narcotic*[Title/Abstract]  OR morphine[Title/Abstract]  
OR ordine [Title/Abstract]  OR hydromorphone [Title/Abstract]  OR dilaudid[Title/Abstract]   OR 
oxycodone[Title/Abstract]   OR endone[Title/Abstract]   OR targin[Title/Abstract]   OR 
oxymorphone[Title/Abstract]   OR OPANA*[Title/Abstract]  OR codeine[Title/Abstract]  OR 
dihydrocodeine[Title/Abstract]   OR ketobemidone[Title/Abstract]   OR pethidine[Title/Abstract]   OR 
Fentanyl[Title/Abstract]  OR durogesic[Title/Abstract]   OR diphenylpropylamine[Title/Abstract]   OR 
dextromoramide[Title/Abstract]   OR piritramide[Title/Abstract]   OR dextropropoxyphene[Title/Abstract] 
OR bezitramide[Title/Abstract]   OR methadone[Title/Abstract]   OR physeptone[Title/Abstract]   OR 
pentazocine[Title/Abstract]   OR phenazocine[Title/Abstract]   OR buprenorphine[Title/Abstract]   OR 
norspan[Title/Abstract]   OR suboxone[Title/Abstract]   OR subutex[Title/Abstract]   OR 
etorphine[Title/Abstract]   OR tilidine[Title/Abstract]  OR trama*[Title/Abstract]  OR 
tramadol[Title/Abstract]  OR dezocine[Title/Abstract]   OR tapentadol[Title/Abstract]   OR 
meptazinol[Title/Abstract] OR “benzodiazepines”[Mesh] 
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Appendix 3.  
Study and Patient characteristics (n=36) for transitivity assessment.  
ID Author Year Setting 
 
Stage of LBP Length of 
treatment   
Outcomes  Week of 
FU  
Sample 
size 
Treatments Age 
mean 
Age 
varianc
e (SD) 
% of 
male 
1 Berry 1988 Single 
center 
Acute LBP (less 
than 6 weeks) 
1 week Pain 1 week 113 1.Tizanidine  
2.placebo  
44 
38 
13 
13 
51 
51 
2 Casale 1988 Single 
center 
Acute LBP (less 
than 6 weeks) 
1 week Pain 1 week 20 1.Dantrolene sodium 
2.placebo 
46,70  
47,10  
2,3 
2,2 
70 
80 
3 Dreiser 2003 Multi-
center 
Acute LBP (less 
than 6 weeks) 
1 week Pain; 
disability 
Day 3; 
day 8  
369 1.Diclofenac NSAIDs 
2. Ibuprofen  
3. placebo 
40,9 
40,6 
41 
10,9
  
11,6
  
11,3
  
48,4 
52,2 
47,2 
4 Eken 2014 Single 
center 
Acute LBP (less 
than 6 weeks) 
 1 day Pain 1 day 137 1. Morphine  
2.paracetamol 
3. Dexketoprofen  
31,5 
 
9,5
  
60,6 
5 Hagen 2010 Single 
center 
Subcute LBP (6-
12 weeks) 
8 weeks Pain; 
disability 
6 
months; 
12 
months 
246 1. exercise  
2.minimal 
intervention  
 
40,7 
41,6 
10,5 
11 
48 
50 
6 Hasegawa 2014 Single 
center 
Acute LBP (less 
than 6 weeks) 
1 week Pain; 
disability 
1 week; 1 
month 
80 1. acupuncture  
2. sham acupuncture  
 
47 
43,9 
9,8 
10,9 
37,5 
35 
7 Hindle  1972 Single 
center 
Acute LBP (less 
than 6 weeks) 
not 
reported 
Pain; 
disability 
1 week 48 1. cariprosodol  
2. butabarbital 
3. placebo  
 
37 
34,6 
43,5 
NA 
NA 
NA 
56 
50 
62 
8 Hsieh 2002 Single 
center 
Mixed (acute and 
subacute) 
3  weeks Pain; 
disability 
3 weeks 148 1.manipulation 
2.myofascial therapy 
3.exercise 
47,4 
49 
47,9 
14 
14,8 
13,7 
67,3 
66,7 
60,4 
142 
 
9 Jallama 2005 Multi-
center 
Mixed LBP (less 
than 12 weeks) 
1 week  Pain; 
disability 
6, 13, 26, 
52 weeks 
314 1.minimal 
intervention strategy 
as behavioural 
therapy 
2.usual care 
43,2 
42 
11,1 
12 
52 
53 
10 Ketenci 2005 Single 
center 
Acute LBP (less 
than 6 weeks) 
1 week  Pain 1 week  97 1.thiocolchicoside 
2. tizanidine  
3.placebo  
37 
37 
40 
NA 
NA 
NA 
58 
37 
48 
11 Li 2008 Multi-
center 
Subacute LBP (6-
12 weeks) 
1 week Pain 1 week 220 1. flupirtine  
2.tramadol 
46 
46,5 
15,1 
15,7 
35 
46 
12 Linstrom 1992 Single 
center 
Mixed LBP (less 
than 12 weeks) 
not 
reported 
Pain; 
disability 
12 
months 
103 1.cognitive 
behavioural therapy 
2.usual care 
39,4 
42,4 
10,7 
10,9 
76,5 
64 
13 Linton 2000 Single 
center 
Subacute LBP (6-
12 weeks) 
not 
reported 
Pain; 
disability 
12 
months 
243 1.cognitive- 
behavioural therapy 
2phamphlet-
education 
3.infopack-education 
44 
45 
44 
 
NA 
NA 
NA 
 
30 
29 
26 
14 Little  2001 Multi-
center 
Subacute LBP (6-
12 weeks) 
3 weeks Pain; 
disability 
1 week; 
1month 
234 1.no treatment 
2 booklet-education 
3.exercise 
47 
42 
47 
17 
14 
14 
43 
43 
43 
15 Machado  2010 Multi-
center 
Acute LBP (less 
than 6 weeks) 
3 weeks Pain; 
disability 
1 week; 3 
weeks 
146 1.first line-usual care 
2.McKenzie exercise 
45,9 
47,5 
14,9 
14,4 
52 
48 
16 Malmivaar
a 
1995 Multi-
center 
Acute LBP (less 
than 6 weeks) 
Not 
reported  
Pain; 
disability 
3 weeks; 
12 weeks 
119 1.exercise 
2.usual care 
3. bad rest 
40,8 
41,1 
NA 
NA 
NA 
NA 
40 
29 
NA 
17 Mayer  2005 Multi-
center 
Mixed (acute and 
subacute) 
5 days  Pain; 
disability 
2-4 day; 
1 week 
76 1.heat wrap 
2.exercise 
3.education 
29,3 
32,6 
31,3 
9,9 
10,3 
10,9 
NA 
NA 
NA 
18 Moffett 1999 Multi-
center 
Subacute LBP (6-
12 weeks) 
4 weeks Pain; 
disability 
6 weeks; 
6 
months; 
12 
months 
187 1.behavioural 
exercise 
2.usual care 
41,1 
42,6 
9,21 
8,62 
43 
44 
143 
 
19 Nadler  2002 Multi-
center 
Subacute LBP (6-
12 weeks) 
 2 days Pain; 
disability 
4 days 371  1. paracetamol ** 
2. ibuprofen ** 
3. heat wrap 
4. unheated wrap 
5. oral placebo 
35,82 
34,90 
36,61 
36,79 
38,00 
10,54 
11,29 
10,4 
9,32 
9,07 
41,6 
43,4 
40,6 
42,1 
40 
20 Nadler 2003 Multi-
center 
Subacute LBP (6-
12 weeks) 
3 days  Pain; 
disability 
5 days 191 1.heat wrap** 
2.placebo ** 
3.unheated wrap 
4.(ibuprofen) 
NSAIDs ** 
35,55 
36,73  
36,25 
34,88 
11,57 
10,82 
11,56 
11,32 
45,7 
45,7 
45,7 
45,7 
21 Postacchin
i 
1988 Multi-
center 
Acute LBP (less 
than 6 weeks) 
2 weeks Pain 3 weeks; 
3 months 
61 1.bad rest 
2.manipulation -
manual therapy 
3. (diclofenac) 
NSAIDs 
4.placebo 
36,3 NA 55 
22 Pozo-Cruz  2012 Multi-
center 
Subacute LBP (6-
12 weeks) 
36 weeks Pain; 
disability 
12 
months 
90 1.occupational 
exercise 
2. education 
46,83 
45,50 
9,13 
7,02 
15,2 
11,4 
23 Rabin 2014 Multi-
center 
Mixed (acute and 
subacute) 
7weeks Pain; 
disability 
8 weeks 105 1.exercise 
2.manual therapy 
38,3 
35,5 
 
10,5 
9,1 
47,9 
45,6 
24 Ralph 2008 Multi-
center 
Acute LBP (less 
than 6 weeks) 
1 days Pain; 
disability 
3 days 562 1.cariprosodol  
2.placebo 
39,3 
41,5 
11,82 
11,7 
51,3 
45 
25 Schneider 2015 Single 
center 
Mixed (acute and 
subacute) 
4 weeks Pain; 
disability 
4 weeks; 
3 
months; 
6 months 
112 1.manual 
manipulation 
2.mechanical assisted 
manipulation 
3.usual care 
40,4 
41,4 
40,3 
15,9 
15,3 
11,6 
40 
32,4 
40 
26 Seferlis  1998 Multi-
center 
Acute LBP (less 
than 6 weeks) 
8 weeks Pain; 
disability 
1 
months; 
3 
months; 
12 
months 
180 1.exercise 
2.general practitioner 
program-usual care 
3. intensive training 
program mixed 
39 
 
19-64 
range 
52,8 
27 Serfer 2010 Single 
center 
Acute LBP (less 
than 6 weeks) 
1 week Pain; 
disability 
1 week 806 1.carisoprodol 250 
mg (myorelaxant) 
40,9 
40,5 
40,7 
11,7 
12,4 
13,1 
47,7 
44,3 
39,4 
144 
 
2. carisoprodol 350 
mg (myorelaxant) 
3.placebo 
28 Shin  2013 Multi-
center 
Acute LBP (less 
than 6 weeks) 
1 week Pain; 
disability 
2 weeks; 
4 weeks; 
24 weeks 
58 1.acupuncture 
2.diclofenac 
37,93 
38,69 
7,37 
8,64 
66 
52 
29 Staal  2004 Single 
center 
Mixed LBP (less 
than 12 weeks) 
12 weeks Pain; 
disability 
3 
months; 
6 months 
134 1.behavioural graded 
activity 
2. usual care 
39 
37 
9 
8 
95,5 
95,5 
30 Storheim  2003 Single 
center 
Subacute LBP (6-
12 weeks) 
15 weeks Pain; 
disability 
18 weeks 93 1.behavioural 
exercise 
2. exercise 
3. control-usual care 
42,3 
41,3 
38,9 
9,2 
9,4 
11,9 
46,7 
52,9 
44,8 
31 Szpalski 1994 Single 
center 
Acute LBP (less 
than 6 weeks) 
2 weeks Pain 1 week; 2 
weeks 
73 1.tenoxicam 
2.placebo 
37,5 
38,9 
9,2 
10,4 
62,2 
66,7 
32 Takamoto 2015 Multi-
center 
Acute LBP (less 
than 6 weeks) 
2 weeks Pain; 
disability 
1 week; 1 
month 
63  1.manual therapy 
2.placebo  
3.effleurage massage  
38 
38,1 
Na 
3 
3,8 
3 
45,4 
47,1 
37,5 
33 Tuzun 2005 Multi-
center 
Acute LBP (less 
than 6 weeks) 
 5 days Pain 5 days 143 1.thiocolchicoside 
2.placebo 
40,7 
41 
10,3 
11 
50 
42 
34 Wand 2004 Single 
center 
Acute LBP (less 
than 6 weeks) 
6 weeks Pain; 
disability 
6 weeks; 
3 
months; 
6 months 
102 1.exercise 
2. usual care 
34 
35 
9 
7,9 
55,8 
45,09 
35 Whitfill 2010 Single 
center 
Mixed LBP (less 
than 12 weeks) 
10 weeks Pain 12 
months 
102 1.cognitive 
behavioural therapy 
2.usual care 
42,3 
37,6 
Na 
Na 
 
50 
43,2 
36 Williams 2014 Multi-
center 
Acute LBP (less 
than 6 weeks) 
 4 weeks  Pain; 
disability 
1week; 1 
month; 3 
month;  
1641  1.paracetamol 
2.paracetamol as 
needed 
3.placebo 
44,1 
45,5 
45,4 
14,8 
16,7 
15,9 
52 
53 
55 
**arms dropped 
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